Pyrazolopyridazinone compound, and pharmaceutical composition and use thereof

ABSTRACT

Provided in the present application are a compound represented by formula (I), a pharmaceutical composition containing the compound, and the use thereof. The compound represented by formula (I) of the present application has a good effect in terms of inhibiting the activity of HPK1.

CROSS REFERENCE TO RELATED APPLICATIONS

This application is the U.S. national phase of International Patent Application No. PCT/CN2021/128460, filed on Nov. 3, 2021, which claims priority to Chinese Patent Application No. 202011209391.X, filed on Nov. 3, 2020, the disclosures of which are incorporated herein by reference in their entirety.

TECHNICAL FIELD

The present application relates to a pyrazolopyridazinone compound, particularly a pyrazolopyridazinone derivative with HPK1 inhibitory activity.

BACKGROUND ART

Hematopoietic progenitor kinase 1 (HPK1), belonging to the mitogen-activated protein kinase kinase kinase kinase-4 (MAP4K) family, is a serine/threonine kinase originally cloned from hematopoietic progenitor cells (Hu, M. C. et al., Genes Dev. 1996; 10: 2251-2264; Keifer, F. et al, The EMBO Journal 1996; 15: 7013-7025). HPK1 is mainly distributed in lymphoid organs and lymphoid tissues, such as bone marrow, lymph nodes, thymus, etc., and is expressed predominantly in immune cells (T cells, B cells, dendritic cells, macrophages, etc.) (Hu, M. C. et al., Genes Dev. 1996; 10:2251-2264). This has drawn attention to the immunomodulatory role of HPK1.

Studies have shown that HPK1 is a negative regulator of the T cell receptor (TCR) signaling pathway. TCR signaling causes the activation of HPK1, and subsequently binding to SLP-76 protein (Lasserre, R. et al., J Cell Biol. 2011; 195: 839-853; Shui, J. et al., Nature Immuno. 2007; 8: 84-91). Activated HPK1 phosphorylates the Ser376 residue of SLP-76, promoting the binding of SLP-76 to 14-3-3 protein (Di Bartolo, V. et al., J. Exp. Med. 2007; 204: 681-691; Shui, J. et al, Nature Immuno. 2007; 8: 84-91). The SLP-76/14-3-3 interaction downregulates ERK signaling and calcium flux, and triggers the ubiquitination of SLP-76. The degradation of the SLP-76 complex blocks the TCR activation pathway consequently, thereby inhibiting T cell function (Lasserre, R. et al, J. Cell Biol. 2011; 195: 839-853).

In in vivo experiments, HPK1 knockout mice showed enhanced T cell function under antigen stimulation and produced more cytokines, such as IL-2 and IFN-γ (Shui, J. et al., Nature Immuno. 2007; 8: 84-91; Alzabin, S. et al, J. Immunol. 2009; 182: 6187-6194; Alzabin, S. et al, Cancer Immunol. Immunother. 2010; 59: 419-429). Further studies demonstrated that the kinase activity of HPK1 plays a key role in the negative regulation of immune cells. Compared with wild-type mice, mice with blockade of the kinase activity of HPK1 showed enhanced CD8+ T cell function, faster clearance of chronic lymphocytic meningitis virus, and better inhibition of tumor growth (Hernandez, S. et al., Cell Reports 2018; 25: 80-94). In Lewis lung cancer (LLC) model, mice transfected with HPK1^(−/−) T cells exhibited stronger antitumor immune responses than wild-type (Sawasdikosol, S. et al., Immunol. Res. 2012; 54: 262-265). Similar studies revealed that the immunosuppressive effects of HPK1 on B cells (Sauer, K. et al., J. Biol. Chem. 2001; 276: 45207-45216; Tsuji, S. et al., J. Exp. Med. 2001; 194: 529-539; Wang, X. et al, J. Biol. Chem. 2012; 287: 34091-34100; Königsberger, S. et al, PLos One, 2010; 5: e12468), dendritic cells (Alzabin, S. et al, J. Immunol. 2009; 182: 6187-6194), NK cells and Treg cells are also derived from its kinase activity (Liu, J. et al., PLos One, 2019; 14: e0212670).

Clinical studies have found that, comparing with health controls, the HPK1 levels were significantly downregulated in tissues from patients of systemic lupus erythematosus (Zhang, Q. et al, J. Autoimmun., 2011; 37: 180-189) and psoriatic arthritis (Stoeckman, A. K. et al, Genes Immun 2006; 7: 583-591; Baltiwalla, F. M. et al., Mol. Med. 2005; 11: 21-29), suggesting that HPK1 downregulation contributes to the enhancement of autoimmune responses. On the other hand, upregulation of HPK1 levels has been observed in various cancers, such as acute myeloid leukemia (Chen-Deutsch, X. et al., Leuk. Res. 2012; 36: 884-888; Chen-Deutsch, X. et al., Cell Cycle 2012; 11: 1364-1373), bladder urothelial carcinoma (Wang. Y et al, Mol. Med. Rep. 2012; 5: 260-265), extramammary Paget's disease (Qian, Y et al, Am J. Dermatopathol. 2011; 33: 681-686) and colon cancer (Yang, H. S. et al., Mol. Cell Biol. 2006; 26: 1297-1306).

Therefore, HPK1 is a potential target for the treatment of tumors and viral diseases. The development of small-molecule inhibitors of HPK1 kinase holds important clinical promise.

Although some patent applications for small molecule HPK1 inhibitors have been published, such as WO2018049191, WO2018049200, WO2018102366, WO2018183964, WO2019090198, WO2019206049, WO2019238067 and WO2020092528, no drug targeting HPK1 has been approved yet. Therefore, the development of novel small-molecule HPK1 inhibitors with good activity is still an urgent need.

SUMMARY

A main purpose of this application is to provide a compound of formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, active metabolite, polymorph, isotope labeled compound, isomer or prodrug thereof,

-   -   wherein, R¹ is selected from:     -   1) hydrogen, halogen, cyano, —C(═O)NR^(a)R^(b), —OR^(a) and         —NR^(a)R^(b);     -   2) C₁₋₆ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₃₋₆ cycloalkyl and         3- to 8-membered aliphatic heterocyclyl, unsubstituted or         optionally substituted with 1, 2, 3 or 4 substituents         independently selected from R¹¹;     -   R^(a) and R^(b) are each independently selected from:     -   1) hydrogen;     -   2) C₁₋₆ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₃₋₆ monocyclic         cycloalkyl, and 3- to 6-membered aliphatic monocyclic         heterocyclyl, unsubstituted or optionally substituted with 1, 2,         or 3 substituents independently selected from R¹¹; or R^(a) and         R^(b) attached to the same nitrogen atom, together with the         nitrogen atom, form a 3-6 membered aliphatic monocyclic         heterocyclyl unsubstituted or optionally substituted with 1, 2         or 3 substituents independently selected from R¹¹;     -   R¹¹ is selected from fluorine, chlorine, C₁₋₃ alkyl and         hydroxyl;     -   Cy^(A) is selected from 6- to 10-membered aryl or 5- to         10-membered heteroaryl, unsubstituted or optionally substituted         with 1, 2, 3, 4 or 5 substituents independently selected from         R¹²;     -   R¹² is selected from:     -   1) oxo, halogen, cyano, —C(═O)R^(a2), —C(═O)OR^(a2),         —C(═O)NR^(a2)R^(b2), —C(═NR²)NR^(a2)R^(b2), —OR^(a2),         —OC(═O)R^(a2), —OC(═O)OR^(c2), —OC(═O)NR^(a2)R^(b2), —SR^(a2),         —S(═O)R^(c2), —S(═O)₂R^(c2), sulfonic acid group,         —S(═O)NR^(a2)R^(b2), —S(═O)₂NR^(d2)R^(c2),         —S(═O)(═NR^(d2))R^(c2), —NR^(a2)R^(b2), —NR^(a2)C(═O)R^(b2),         —NR^(a2)C(═O)OR^(c2), —NR^(e2)C(═O)NR^(a2)R^(b2),         —NR^(e2)C(═NR^(d2))NR^(a2)R^(b2), —NR^(a2)S(═O)₂R^(c2),         —NR^(e2)S(═O)₂NR^(a2)R^(b2) nitro, —PR^(c2)R^(f2),         —P(═O)R^(c2)R^(f2) and phosphonic acid group;     -   2) C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, 6- to 10-membered         aryl, 5- to 10-membered heteroaryl, C₃₋₁₂ cycloalkyl and 3- to         12-membered aliphatic heterocyclyl, unsubstituted or optionally         substituted with 1, 2, 3, 4, 5 or 6 substituents independently         selected from R²²;     -   3) the two R¹² substituents attached to two adjacent         ring-forming atoms on the aryl or heteroaryl group of Cy^(A)         respectively, together with the two said ring-forming atoms,         form a C₅₋₁₂ alicyclyl or a 5- to 12-membered aliphatic         heterocyclyl, unsubstituted or optionally substituted by 1, 2,         3, 4, 5 or 6 substituents independently selected from R²²;     -   R^(a2), R^(b2) and R^(e2) are each independently selected from:     -   1) hydrogen;     -   2) C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, phenyl, 5-6 membered         heteroaryl, C₃₋₁₂ cycloalkyl and 3-12 membered aliphatic         heterocyclyl, unsubstituted or optionally substituted with 1, 2,         3, 4, 5 or 6 substituents independently selected from R²²;     -   or,     -   R^(a2) and R^(b2) attached to the same nitrogen atom, together         with the nitrogen, form a 3-12 membered aliphatic heterocyclyl,         unsubstituted or optionally substituted with 1, 2, 3, 4 or 5         substituents independently selected from R²²;     -   R^(c2) and R^(b2) are each independently selected from the group         consisting of C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, phenyl,         5-6 membered heteroaryl, C₃₋₁₂ cycloalkyl and 3-12 membered         aliphatic heterocyclyl, unsubstituted or optionally substituted         with 1, 2, 3, 4 or 5 substituents independently selected from         R²²;     -   or,     -   R^(c2) and R^(f2) attached to the same phosphorous atom,         together with the phosphorous, form a 3-12 membered aliphatic         heterocyclyl, unsubstituted or optionally substituted with 1, 2,         3, 4 or 5 substituents independently selected from R²²;     -   R^(d2) is selected from:     -   1) hydrogen, cyano, nitro and —S(═O)₂R^(G);     -   2) C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, phenyl, 5-6 membered         heteroaryl, C₃₋₁₂ cycloalkyl and 3-12 membered aliphatic         heterocyclyl, unsubstituted or optionally selected from 1, 2, 3,         4 or 5 substituents independently selected from R²²;     -   R²² is selected from:     -   1) oxo, halogen, cyano, —C(═O)R^(a4), —C(═O)OR^(a4),         —C(═O)NR^(a4)R^(b4), —C(═NR^(d4))NR^(a4)R^(b4), —OR^(a4),         —OC(═O)R^(a4), —OC(═O)OR^(c4), —OC(═O)NR^(a4)R^(b4), —SR^(a4),         —S(═O)R^(c4), —S(═O)₂R^(c4), sulphonic acid group,         —S(═O)NR^(a4)R^(b4), —S(═O)₂NR^(a4)R^(b4),         —S(═O)(═NR^(d4))R^(c4), —NR^(a4)R^(b4),         —NR^(a4)C(═O)R^(b4,)—NR^(a4)C(═O)OR^(c4),         —NR^(e4)C(═O)NR^(a4)R^(b4), —NR^(e4)C(═NR^(d4))NR^(a4)R^(b4),         —NR^(a4)S(═O)₂R^(c4), —NR^(e4)S(═O)₂NR^(a4)R^(b4) nitro,         —PR^(c4)R^(f4), —P(═O)R^(c4)R^(f4), phosphonic acid group and         imino group (═N—R^(d4)).     -   2) C₁₋₆ alkyl, C₁₋₆ alkylene, C₂₋₆ alkenyl, C₂₋₆ alkynyl,         phenyl, 5-6 membered heteroaryl, C₃₋₁₀ cycloalkyl and 3-10         membered aliphatic heterocyclyl, unsubstituted or optionally         substituted with 1, 2, 3, 4 or 5 substituents independently         selected from R³²;     -   R^(a4), R^(b4) and R^(e4) are each independently selected from:     -   1) hydrogen;     -   2) C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, phenyl, 5-6 membered         heteroaryl, C₃₋₁₀ cycloalkyl and 3-10 membered aliphatic         heterocyclyl, unsubstituted or optionally substituted with 1, 2,         3, 4 or 5 substituents independently selected from R³²;     -   or,     -   R^(a4) and R^(b4) attached to the same nitrogen atom, together         with the nitrogen, form a 3-10 membered aliphatic heterocyclyl,         unsubstituted or optionally substituted with 1, 2, 3, 4 or 5         substituents independently selected from R³²;     -   R^(c4) and R^(f4) are each independently selected from C₁₋₄         alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, phenyl, 5-6 membered         heteroaryl, C₃₋₁₀ cycloalkyl and 3-10 membered aliphatic         heterocyclyl, unsubstituted or optionally substituted with 1, 2,         3, 4 or 5 substituents independently selected from R³²;     -   or,     -   R^(c4) and R^(f4) attached to the same phosphorous atom,         together with the phosphorous, form a 3-10 membered aliphatic         heterocyclyl, unsubstituted or optionally substituted with 1, 2,         3, 4 or 5 substituents independently selected from R³²; R^(d4)         is selected from:     -   1) hydrogen, cyano, nitro and —S(═O)₂R^(G);     -   2) C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, phenyl, 5-6 membered         heteroaryl, C₃₋₁₀ cycloalkyl and 3-10 membered aliphatic         heterocyclyl, unsubstituted or optionally substituted with 1, 2,         3, 4 or 5 substituents independently selected from R³²;     -   R³² is selected from:     -   1) oxo, halogen, cyano, —C(═O)R^(a6), —C(═O)OR^(a6),         —C(═O)NR^(a6)R^(b6), —C(═NR^(d6))NR^(a6)R^(b6), —OR^(a6),         —OC(═O)R^(a6), —OC(═O)OR^(c6), —OC(═O)NR^(a6)R^(b6), —SR^(a6),         —S(═O)R^(c6), —S(═O)₂R^(c6), sulphonic acid group,         —S(═O)NR^(a6)R^(b6), —S(═O)₂NR^(a6)R^(b6),         —S(═O)(═NR^(d6))R^(c6), —NR^(a6)R^(b6), —NR^(a6)C(═O)R^(b6),         —NR^(a6)C(═O)OR^(c6), —NR^(e6)C(═O)NR^(a6)R^(b6),         —NR^(e6)C(═NR^(d6))NR^(a6)R^(b6), —NR^(a6)S(═O)₂R^(c6),         —NR^(e6)S(═O)₂NR^(a6)R^(b6), nitro, —PR^(c6)R^(f6),         —P(═O)R^(c6)R^(f6), phosphonic acid group and imino group         (═N—R^(d6));     -   2) C₁₋₄ alkyl, C₁₋₄ alkylene, C₂₋₄ alkenyl, C₂₋₄ alkynyl,         phenyl, 5-6 membered heteroaryl, C₃-8 cycloalkyl and 3-8         membered aliphatic heterocyclyl, unsubstituted or optionally         substituted with 1, 2, 3 or 4 substituents independently         selected from R^(G);     -   R^(a6), R^(b6) and R^(e6) are each independently selected from:     -   1) hydrogen;     -   2) C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, phenyl, 5-6 membered         heteroaryl, C₃₋₈ cycloalkyl and 3-8 membered aliphatic         heterocyclyl, unsubstituted or optionally substituted with 1, 2,         3 or 4 substituents independently selected from R^(G);     -   or,     -   R^(a6) and R^(b6) attached to the same nitrogen atom, together         with the nitrogen, form a 3-8 membered aliphatic heterocyclyl,         unsubstituted or optionally substituted with 1, 2, 3 or 4         substituents independently selected from R^(G);     -   R^(c6) and R^(f6) are each independently selected from C₁₋₄         alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, phenyl, 5-6 membered         heteroaryl, C₃₋₈ cycloalkyl and 3-8 membered aliphatic         heterocyclyl, unsubstituted or optionally substituted with 1, 2,         3 or 4 substituents independently selected from R^(G);     -   or,     -   R^(c6) and R^(f6) attached to the same phosphorous atom,         together with the phosphorous, form a 3-8 membered aliphatic         heterocyclyl, unsubstituted or optionally substituted with 1, 2,         3 or 4 substituents independently selected from R^(G);     -   R^(d6) is selected from:     -   1) hydrogen, cyano, nitro and —S(═O)₂R^(G);     -   2) C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, phenyl, 5-6 membered         heteroaryl, C₃₋₈ cycloalkyl, 3-8 membered aliphatic         heterocyclyl, unsubstituted or optionally substituted with 1, 2,         3 or 4 substituents independently selected from R^(G);     -   Cy^(B) is selected from 6-10 membered aryl or 5-10 membered         heteroaryl, unsubstituted or optionally substituted with 1, 2,         3, 4 or 5 substituents independently selected from R¹³;     -   R¹³ is selected from:     -   1) oxo, halogen, cyano, —C(═O)R^(a3), —C(═O)OR^(a3),         —C(═O)NR^(a3)R^(b3), C(═NR^(d3))NR^(a3)R^(b3), —OR^(a3),         —OC(═O)R^(a3), —OC(═O)OR^(c3), —OC(═O)NR^(a3)R^(b3), —SR^(a3),         —S(═O)R^(c3), —S(═O)₂R^(c3), sulphonic acid group,         —S(═O)NR^(a3)R^(b3), —S(═O)₂NR^(a3)R^(b3),         —S(═O)(═NR^(d3))R^(c3), —NR^(a3)R^(b3), —NR^(a3)C(═O)R^(b3),         —NR^(a3)C(═)OR^(c3), —NR^(e3)C(═O)NR^(a3)R^(b3),         —NR^(e3)C(═NR^(d3))NR^(a3)R^(b3), —NR^(a3)S(═O)₂R^(c3),         —NR^(e3)S(═O)₂NR^(a3)R^(b3), nitro, —PR^(c3)R^(f3),         —P(═O)R^(c3)R^(f3) and phosphonic acid group; 2) C₁₋₆ alkyl,         C₂₋₆ alkenyl, C₂₋₆ alkynyl, 6-10 membered aryl, 5-10 membered         heteroaryl, C₃-12 cycloalkyl and 3-12 membered aliphatic         heterocyclyl, unsubstituted or optionally substituted with 1, 2,         3, 4, 5 or 6 substituents independently selected from R²³;     -   3) two R¹³ attached to two adjacent ring-forming atoms on the         aryl or heteroaryl group of Cy^(B) respectively, together with         the two said ring-forming atoms form a C₅₋₁₂ alicyclyl ring or a         5-12 membered aliphatic heterocyclyl, unsubstituted or         optionally substituted with 1, 2, 3, 4 or 5 substituents         independently selected from R²³;     -   R^(a3), R^(b3) and R^(e3) are each independently selected from:     -   1) hydrogen;     -   2) C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, phenyl, 5-6 membered         heteroaryl, C₃₋₁₂ cycloalkyl and 3-12 membered aliphatic         heterocyclyl, unsubstituted or optionally substituted with 1, 2,         3, 4, 5 or 6 substituents independently selected from R²³;     -   or,     -   R^(a3) and R^(b3) attached to the same nitrogen atom, together         with the nitrogen, form a 3-12 membered aliphatic heterocyclyl,         unsubstituted or optionally substituted with 1, 2, 3, 4 or 5         substituents independently selected from R²³;     -   R^(c3) and R^(f3) are each independently selected from C₁₋₄         alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, phenyl, 5-6 membered         heteroaryl, C₃₋₁₂ cycloalkyl and 3-12 membered aliphatic         heterocyclyl, unsubstituted or optionally substituted with 1, 2,         3, 4 or 5 substituents independently selected from R²³;     -   or,     -   R^(c3) and R^(f3) attached to the same phosphorous atom,         together with the phosphorous atom, form a 3-12 membered         aliphatic heterocyclyl, unsubstituted or optionally substituted         with 1, 2, 3, 4 or 5 substituents independently selected from         R²³;     -   R^(d3) selected from:     -   1) hydrogen, cyano, nitro and S(═O)₂R^(G);     -   2) C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, phenyl, 5-6 membered         heteroaryl, C₃₋₁₂ cycloalkyl and 3-12 membered aliphatic         heterocyclyl, unsubstituted or optionally substituted with 1, 2,         3, 4 or 5 substituents independently selected from R²³;     -   R²³ is selected from:     -   1) oxo, halogen, cyano, —C(═O)R^(a5), —C(═O)OR^(a5),         —C(═O)NR^(a5)R^(b5), C(═NR^(d5))NR^(a5)R^(b5), —OR^(a5),         —OC(═O)R^(a5), —OC(═O)OR^(c5), —OC(═O)NR^(a5)R^(b5), —SR^(a5),         —S(═O)R^(c5), —S(═O)₂R^(c5), sulphonic acid group,         —S(═O)NR^(a5)R^(b5), —S(═O)₂NR^(a5)R^(b5),         —S(═O)(═NR^(d5))R^(c5), —NR^(a5)R^(b5), —NR^(a5)C(═O)R^(b5),         —NR^(a5)C(═O)OR^(c5), —NR^(e5)C(═O)NR^(a5)R^(b5),         NR^(e5)C(═NR^(d5))NR^(a5)R^(b5), —NR^(a5)S(═O)₂R^(b5),         —NR^(e5)S(═O)₂NR^(a5)R^(b5) nitro, —PR^(c5)R^(f5),         —P(═O)R^(c5)R^(f5), phosphonic acid group and imino group         (═N—R^(d5)).     -   2) C₁₋₆ alkyl, C₁₋₆ alkylene, C₂₋₆ alkenyl, C₂₋₆ alkynyl,         phenyl, 5-6 membered heteroaryl, C₃₋₁₀ cycloalkyl and 3-10         membered aliphatic heterocyclyl, unsubstituted or optionally         substituted with 1, 2, 3, 4 or 5 substituents independently         selected from R³³;     -   R^(a5), R^(b5) and R^(e5) are each independently selected from:     -   1) hydrogen;     -   2) C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, phenyl, 5-6 membered         heteroaryl, C₃₋₁₀ cycloalkyl and 3-10 membered aliphatic         heterocyclyl, unsubstituted or optionally substituted with 1, 2,         3, 4 or 5 substituents independently selected from R³³;     -   or,     -   R^(a5) and R^(b5) attached to the same nitrogen atom, together         with the nitrogen atom, form a 3-10 membered aliphatic         heterocyclyl, unsubstituted or optionally substituted with 1, 2,         3, 4 or 5 substituents independently selected from R³³;     -   R^(c5) and R^(f5) are each independently selected from C₁₋₄         alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, phenyl, 5-6 membered         heteroaryl, C₃₋₁₀ cycloalkyl and 3-10 membered aliphatic         heterocyclyl, unsubstituted or optionally substituted with 1, 2,         3, 4 or 5 substituents independently selected from R³³;     -   or,     -   R^(c5) and R^(f5) attached to the same phosphorous atom,         together with the phosphorous atom, form a 3-10 membered         aliphatic heterocyclyl, unsubstituted or optionally substituted         with 1, 2, 3, 4 or 5 substituents independently selected from         R³³;     -   R^(d5) is selected from:     -   1) hydrogen, cyano, nitro and —S(═O)₂R^(G);     -   2) C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, phenyl, 5-6 membered         heteroaryl, C₃₋₁₀ cycloalkyl and 3-10 membered aliphatic         heterocyclyl, unsubstituted or optionally substituted with 1, 2,         3, 4 or 5 substituents independently selected from R³³;     -   R³³ selected from:     -   1) oxo, halogen, cyano, —C(═O)R^(a7), —C(═O)OR^(a7),         —C(═O)NR^(a7)R^(b7), —C(═NR^(d7))NR^(a7)R^(b7), —OR^(a7),         —OC(═O)R^(a7), —OC(═O)OR^(c7), —OC(═O)NR^(a7)R^(b7), —SR^(a7),         —S(═O)R^(c7), —S(═O)₂R^(c7), sulphonic acid group,         —S(═O)NR^(a7)R^(b7), —S(═O)₂NR^(a7)R^(b7),         —S(═O)(═NR^(d7))R^(c7), —NR^(a7)R^(b7), —NR^(a7)C(═O)R^(b7),         —NR^(a7)C(═O)OR^(c7), —NR^(e7)C(═O)NR^(a7)R^(b7),         —NR^(e7)C(═NR^(d7))NR^(a7)R^(b7), —NR^(a7)S(═O)₂R^(c7),         —NR^(e7)S(═O)₂NR^(a7)R^(b7,)nitro, —PR^(c7)R^(f7),         —P(═O)R^(c7)R^(f7), phosphonic acid group and imino group         (═N—R^(d7));     -   2) C₁₋₄ alkyl, C₁₋₄ alkylene, C₂₋₄ alkenyl, C₂₋₄ alkynyl,         phenyl, 5-6 membered heteroaryl, C₃-8 cycloalkyl and 3-8         membered aliphatic heterocyclyl, unsubstituted or optionally         substituted with 1, 2, 3 or 4 substituents independently         selected from R^(G);     -   R^(a7), R^(b7) and R⁷ are each independently selected from:     -   1) hydrogen;     -   2) C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, phenyl, 5-6 membered         heteroaryl, C₃₋₈ cycloalkyl and 3-8 membered aliphatic         heterocyclyl, unsubstituted or optionally substituted with 1, 2,         3 or 4 substituents independently selected from R^(G);     -   or,     -   R^(a7) and R^(b7) attached to the same nitrogen atom, together         with the nitrogen atom, form a 3-8 membered aliphatic         heterocyclyl, unsubstituted or optionally substituted with 1, 2,         3 or 4 substituents independently selected from R^(G);     -   R^(c7) and R^(f7) are each independently selected from C₁₋₄         alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, phenyl, 5-6 membered         heteroaryl, C₃₋₈ cycloalkyl and 3-8 membered aliphatic         heterocyclyl, unsubstituted or optionally substituted with 1, 2,         3 or 4 substituents independently selected from R^(G);     -   or,     -   R^(c7) and R^(f7) attached to the same phosphorous atom,         together with the phosphorous atom, form a 3-8 membered         aliphatic heterocyclyl, unsubstituted or optionally substituted         with 1, 2, 3 or 4 substituents independently selected from         R^(G);     -   R^(d7) is selected from:     -   1) hydrogen, cyano, nitro and —S(═O)₂R^(G);     -   2) C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, phenyl, 5-6 membered         heteroaryl, C₃₋₈ cycloalkyl and 3-8 membered aliphatic         heterocyclyl, unsubstituted or optionally substituted with 1, 2,         3 or 4 substituents independently selected from R^(G);     -   R^(G) is selected from:     -   1) halogen, oxo, cyano, carboxyl, hydroxyl, C₁₋₄ alkoxy, amino,         C₁₋₄ alkylamino, nitro, C₁₋₄ alkylthio, sulphonic acid group,         C₁₋₄ alkyl sulfinyl, C₁₋₄ alkyl sulfonyl, C₁₋₄         alkylaminosulfinyl and C₁₋₄ alkylaminosulfonyl;     -   2) C₁₋₄ alkyl, C₁₋₄ alkylene, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₃₋₆         cycloalkyl and 3-8 membered aliphatic heterocyclyl,         unsubstituted or optionally substituted with 1, 2, 3 or 4         substituents independently selected from oxo, halogen, hydroxyl,         hydroxymethyl, carboxyl, cyano, C₁₋₃ alkoxy, amino, C₁₋₄         alkylamino, nitro and sulphonic acid group.

In some embodiments, in formula (I), R¹ is selected from hydrogen, fluorine, cyano, methyl and methoxy.

In some embodiments, in formula (I), Cy^(A) is phenyl, pyridyl, pyrimidyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, or a bicyclyl represented by

where a phenyl is fused with a 5-7 membered saturated aliphatic heterocyclyl, wherein Z represents 1-3 heteroatoms optionally selected from nitrogen and oxygen; when Z═N, said N is optionally linked to Ry; Ro is selected from oxo, F, amino, C₁₋₃ alkyl (optionally substituted with F, hydroxyl, amino and C₁₋₃ alkoxy); said aliphatic heterocyclyl may be fused with another 5-6 membered nitrogen-containing saturated aliphatic heterocyclyl to form fused ring; said phenyl, pyridyl, pyrimidyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, or bicyclyl represented by

is unsubstituted or optionally substituted with 1, 2 or 3 substituents independently selected from R¹², wherein 1) when Cy^(A) contains one R¹², the R¹² is selected from one of the followings:

-   -   Wherein R^(x) is selected from —OH, C₁₋₆ alkyl (e.g., methyl),         C₁₋₆ alkoxy (e.g., methoxy), —NH₂, C₁₋₆ alkylamino (e.g., amino,         dimethylamino)

-   -   2) when Cy^(A) contains more than one R¹², other R¹² are each         independently selected from fluorine, C₁₋₆ alkyl (e.g., methyl),         C₁₋₆ alkoxy (e.g., methoxy), (C₁₋₆ alkylamino)methyl (e.g.,         (dimethylamino)methyl, (methylamino)methyl);     -   Cy^(B) is selected from one of the followings:

-   -   R^(a3) and R^(b3) are each independently selected from hydrogen,         C₁₋₆ alkyl, and C₃₋₆ cycloalkyl, or R^(a3) and R^(b3) together         with N atom to which they are attached form a 4-6 membered         saturated aliphatic heterocyclyl; said C₁₋₆ alkyl, C₃₋₆         cycloalkyl, and 4-6 membered saturated aliphatic heterocyclyl is         unsubstituted or optionally substituted with substituent(s)         selected from hydroxyl, C₁₋₆ alkyl, and fluoro-substituted C₁₋₆         alkyl;     -   R^(y) is selected from H, C₁₋₆ alkyl (e.g., methyl), C₁₋₆ alkyl         substituted with hydroxyl or halogen (e.g., hydroxyethyl,         hydroxypropyl, difluoroethyl), C₃₋₆ cycloalkyl (e.g.,         cyclobutanyl, cyclobutanyl substituted with amino), 4-6 membered         N-containing saturated aliphatic heterocyclyl, 5-6 membered         O-containing saturated aliphatic heterocyclyl, and —C(═O)Rs, Rs         is selected from C₁₋₆ alkyl optionally substituted with         hydroxyl, amino, and 5-6 membered N-containing aliphatic         heterocyclyl.

In some embodiments, In formula (I), Cy^(A) is selected from phenyl, pyridyl, pyrimidyl, thiazolyl or a bicyclyl represented by

where a phenyl is fused with a 5-7 membered saturated aliphatic heterocyclyl, wherein Z represents 1-3 heteroatoms optionally selected from nitrogen and oxygen; when Z═N, Z is optionally substituted with Ry; Ro is selected from oxo, F, amino, C₁₋₃ alkyl (optionally substituted with F, hydroxyl, amino, and C₁₋₃ alkoxy); said aliphatic heterocyclyl may form fused ring with another 5-6 membered nitrogen-containing saturated aliphatic heterocyclyl heteroatom; When Cy^(A) is selected from phenyl, pyridyl, pyrimidyl, or thiazolyl, R¹² is selected from

wherein Rz is selected from hydrogen, C₁₋₆ alkyl (substituted with cyano, or methoxy), 4-6 membered oxygen-containing aliphatic heterocyclyl, or —S(═O)₂—C₁₋₆ alkyl; Rp, single or multiple substituent(s), are each optionally selected from hydrogen, C₁₋₆ alkyl (optionally substituted with F, hydroxyl, and amino); Rq is selected from hydroxyl, amino, C₁₋₃ alkyl (optionally substituted with 5-6 membered nitrogen-containing aliphatic heterocyclyl, or 5-6 membered nitrogen-containing heteroaryl), spiro heterocyclyl composed of two 4-5 membered nitrogen- and/or oxygen-containing rings, 5-6 membered aliphatic heterocyclyl containing one or two heteroatoms selected from nitrogen and oxygen; said aliphatic heterocyclyl is optionally substituted with F or C₁₋₃ alkyl.

In some embodiments, in formula (I), Cy^(A) is selected from phenyl, R¹² is selected from

wherein Rz is selected from hydrogen, C₁₋₆ alkyl (substituted with cyano, or methoxy), 4-6 membered oxygen-containing aliphatic heterocyclyl, or —S(═O)₂—C₁₋₆ alkyl; Rp, single or multiple substituent(s), are each optionally selected from hydrogen, C₁₋₆ alkyl (optionally substituted with F, hydroxyl, or amino); Rq is selected from hydroxyl, amino, C₁₋₃ alkyl (optionally substituted with 5-6 membered nitrogen-containing aliphatic heterocyclyl, or 5-6 membered nitrogen-containing heteroaryl), spiro heterocyclyl composed of two 4-5 membered nitrogen- and/or oxygen-containing aliphatic heterocyclyl, 5-6 membered aliphatic heterocyclyl containing one or two heteroatoms selected from nitrogen and oxygen; wherein said aliphatic heterocyclyl is optionally substituted with F or C₁₋₃ alkyl.

In some embodiments, in formula (I), Cy^(A) is selected from the followings:

-   -   Wherein W₁ is selected from CH₂ or oxygen;     -   R^(T) is selected from hydrogen or methyl;     -   R^(V) is selected from fluorine or methyl, the amount of R^(V)         is 0, 1 or 2.

In some embodiments, in formula (I), Cy^(B) is selected from phenyl, optionally substituted with H, F, —CN, C₁₋₃ alkyl (substituted with F, and amino), C₁₋₃ alkoxy (substituted with F), C₃₋₆ cycloalkoxy, and —C(═O)NR^(a3)R^(b3), wherein R^(a3) and R^(b3) are each independently selected from hydrogen, C₁₋₆ alkyl, C₃₋₆ cycloalkyl (substituted with C₁₋₃ alkyl optionally substituted with F), or R^(a3) and R^(b3) together with the N atom to which they are attached form a 4-5 membered aliphatic heterocyclyl (optionally substituted with hydroxyl and C₁₋₃ alkyl).

In some embodiments, in formula (I), Cy^(B) is selected from:

In some embodiments, in formula (I), when Cy^(A) is phenyl, and R¹² is an aliphatic heterocyclyl, R¹² is linked to the meta- or para-position of said phenyl.

In some embodiments, the compounds of formula (I) include isotope labeled compounds wherein ¹H is deuterated.

In an aspect, the application provides a pharmaceutical composition including the compound of formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, active metabolite, polymorph, isotope labeled compound, isomer or prodrug thereof, and a pharmaceutically acceptable carrier.

In an aspect, the application provides the compound of formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, active metabolite, polymorph, isotope labeled compound, isomer or prodrug thereof, or a pharmaceutical composition thereof, for the prevention or treatment of a disease mediated with HPK1.

In an aspect, the application provides use of the compound of formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, active metabolite, polymorph, isotope labeled compound, isomer or prodrug thereof, or a pharmaceutical composition thereof, in the preparation of a medicament for the prevention or treatment of a disease mediated with HPK1.

In some embodiments, the application provides use of the compound of formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, active metabolite, polymorph, isotope labeled compound, isomer or prodrug thereof, or a pharmaceutical composition thereof, for the treatment or amelioration of one or more diseases selected from the group consisting of benign or malignant tumors, myelodysplastic syndromes and diseases caused by viruses.

In an aspect, the application provides a method for inhibiting the activity of HPK1 including administering the compound of formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, active metabolite, polymorph, isotope labeled compound, isomer or prodrug thereof to a subject.

In some embodiments, the application provides a method for treating a disease or disorder mediated with HPK1 in a patient, including administering therapeutically effective amount of the compound of formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, active metabolite, polymorph, isotope labeled compound, isomer or prodrug thereof to the patient.

In some embodiments, the compounds of formula (I) has the activity of inhibiting HPK1.

In some embodiments, the disease includes one or more diseases selected from the group consisting of benign or malignant tumors, myelodysplastic syndromes and diseases caused by viruses.

EMBODIMENTS

Typical embodiments embodying the features and advantages of the present application will be described in detail in the following description. It should be understood that the present application may have various variations in different embodiments, none of which is departing from the scope of the present application, and the description therein is essentially for illustrative purposes and not for the purpose of limiting the scope of the application.

In some embodiments, R¹ is selected from:

-   -   1) hydrogen, halogen, cyano, acetylenyl, —OR^(a) and         —NR^(a)R^(b);     -   2) C₁₋₄ alkyl, C₃₋₅ monocyclic cycloalkyl, and 4-7 membered         aliphatic heterocyclyl, unsubstituted or optionally substituted         with one, two, three or four substituents independently selected         from R¹¹.

In some embodiments, R¹ is selected from hydrogen, fluorine, chlorine, bromine, cyano, C₁₋₄ alkyl, C₃₋₄ cycloalkyl, 3-4 membered aliphatic heterocyclyl and —OR^(a).

In some embodiments, R¹ is selected from hydrogen, fluorine, cyano, methyl, ethyl, 1-propyl, isopropyl, cyclopropyl, methoxy, ethoxy and cyclopropoxy.

In some embodiments, R¹ is hydrogen.

In some embodiments, R^(a) and R^(b) are each independently selected from hydrogen, C₁₋₃ alkyl, C₃₋₄ cycloalkyl and 3-4 membered aliphatic heterocyclyl;

-   -   or, R^(a) and R^(b) attached to same nitrogen atom, together         with the nitrogen atom, form an unsubstituted 3-6 membered         aliphatic heterocyclyl.

In some embodiments, R^(a) and R^(b) are each independently selected from hydrogen, methyl, ethyl and cyclopropyl.

In some embodiments, Cy^(A) is phenyl, naphthyl, or 5, 6, 7, 8, 9 or 10 membered heteroaryl containing 1, 2 or 3 ring-forming heteroatoms selected from N, O, and S, said phenyl, naphthyl and 5, 6, 7, 8, 9 or 10 membered heteroaryl is unsubstituted or optionally substituted with 1, 2, 3 or 4 substituents independently selected from R¹².

In some embodiments, the aryl or heteroaryl of Cy^(A) contains one R¹² selected from a cyclic group, wherein the cyclic group is selected from 6-10 membered aryl, 5-10 membered heteroaryl, C₃₋₇ cycloalkyl, and 3-7 membered aliphatic heterocyclylaliphatic containing 1 or 2 ring-forming heteroatoms optionally selected from N, O, and S, wherein said 6-10 membered aryl, 5-10 membered heteroaryl, C₃₋₇ cycloalkyl, and 3-7 membered aliphatic heterocyclyl is unsubstituted or optionally substituted with 1, 2 or 3 substituents independently selected from R²²; or, the aryl or heteroaryl of Cy^(A) contains 2, 3 or 4 of R¹², wherein one of the R¹² is the above mentioned cyclic group, and other R¹² are each independently selected from C₁₋₆ alkyl, halogen, cyano, —OR^(a2) and —NR^(a2)R^(b2).

In some embodiments, the aryl or heteroaryl of Cy^(A) contains one R¹² which is a cyclic group selected from phenyl, 5-6 membered heteroaryl, C₃₋₆ cycloalkyl, and 4, 5, 6, and 7 membered aliphatic heterocyclylaliphatic containing 1 or 2 of ring-forming heteroatoms selected from N, O, and S, wherein said phenyl, 5-6 membered heteroaryl, C₃₋₆ cycloalkyl, and 4, 5, 6, and 7 membered aliphatic heterocyclyl is unsubstituted or optionally substituted with 1, 2 or 3 substituents independently selected from R²²;

-   -   or,     -   the aryl or heteroaryl of Cy^(A) contains 2 or 3 of R¹², wherein         one of the R¹² is the above mentioned cyclic group, and other         R¹² are each independently selected from C₁₋₆ alkyl, halogen,         cyano, —OR^(a2) and —NR^(a2)R^(b2).

In some embodiments, Cy^(A) is phenyl or 5-6 membered heteroaryl, optionally substituted with 1, 2, 3 or 4 substituents independently selected from R¹².

In some embodiments, Cy^(A) is phenyl or 5-6 membered heteroaryl, optionally substituted with 1, 2, 3 or 4 substituents independently selected from R¹², wherein two R¹², together with two adjacent ring-forming atoms of the phenyl or heteroaryl to which they are attached respectively, form C₅, C₆, C₇ aliphatic monocyclyl or 5, 6, 7 membered aliphatic monocyclic heterocyclyl, said C₅, C₆, C₇ aliphatic monocyclyl or 5, 6, 7 membered aliphatic monocyclic heterocyclyl is unsubstituted or optionally substituted with 1, 2, 3 or 4 substituents independently selected from R²².

In some embodiments, Cy^(A) is phenyl, 5 membered or 6 membered heteroaryl containing one or two heteroatoms selected from N and S, for example, one nitrogen atom, two nitrogen atoms, or one nitrogen atom and one sulfur atom, said phenyl, 5 membered or 6 membered heteroaryl is optionally substituted with 1, 2 or 3 substituents independently selected from R¹².

In some embodiments, Cy^(A) is phenyl, pyridyl, pyrimidyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl or isoxazolyl, which is optionally substituted with 1, 2 or 3 substituents independently selected from R¹².

In some embodiments, Cy^(A) is phenyl, pyridyl, pyrazolyl, imidazolyl or thiazolyl, which is optionally substituted with 1, 2 or 3 substituents independently selected from R¹².

In some embodiments, the aryl or heteroaryl of Cy^(A) contains two, three or four of R¹² wherein two R¹², together with two adjacent ring-forming atoms of the aryl or heteroaryl to which they are attached respectively, form C₅₋₆ aliphatic cyclyl (alicycly) or 5-8 membered aliphatic heterocyclyl containing 1, 2 or 3 ring-forming heteroatoms selected from N, O, and S, wherein said C₅₋₈ aliphatic cyclyl (alicycly) or 5-8 membered aliphatic heterocyclyl is unsubstituted or optionally substituted with 1, 2 or 3 substituents independently selected from R²²; other not-ring-forming R¹² are each independently selected from C₁₋₆ alkyl, halogen, cyano, —OR^(a2) and —NR^(a2)R^(b2).

In some embodiments, the aryl or heteroaryl of Cy^(A) contains two, three or four of R¹² wherein two R¹², together with two adjacent ring-forming atoms of the aryl or heteroaryl to which they are attached respectively, form 5, 6, 7 membered aliphatic monoheterocyclyl containing 1 or 2 ring-forming heteroatoms selected from N and O, wherein said aliphatic monocyclic heterocyclyl is unsubstituted or optionally substituted with 1, 2 or 3 substituents independently selected from oxo, R^(H), —(CH₂)₀₋₂—OH, —(CH₂)₀₋₂—OR^(H), —(CH₂)₀₋₂—NH₂, —(CH₂)₀₋₂—NR^(H) and —(CH₂)₀₋₂—N(R^(H))₂; other not-ring-forming R¹² are each independently selected from C₁₋₆ alkyl, halogen, cyano, —OR^(a2) and —NR^(a2)R^(b2); R^(H) is selected from methyl, ethyl, isopropyl, cyclopropyl and 3-oxetanebutyl.

In some embodiments, each R¹² is independently selected from:

-   -   1) oxo, halogen, cyano, —C(═O)R^(a), —C(═O)OR^(a),         —C(═O)NR^(a2)R^(b2), —C(═NR^(d2))NR^(a2)R^(b2), —OR^(a2),         —OC(═O)R^(a2), —OC(═O)OR^(c2), —OC(═O)NR^(a2)R^(b2), —SR^(a2),         —S(═O)R^(c2), —S(═O)₂R^(c2), sulphonic acid group,         —S(═O)NR^(a2)R^(b2), —S(═O)₂NR^(a2)R^(b2),         —S(═O)(═NR^(d2))R^(c2)—NR^(a2)R^(b2), —NR^(a2)C(═O)R^(b2),         —NR^(a2)C(═O)OR^(c2), —NR^(e2)C(═O)NR^(a2)R^(b2),         —NR^(e2)C(═N^(d2))NR^(a2)R^(b2), —NR^(a2)S(═O)₂R^(c2),         —NR^(e2)S(═O)₂NR^(a2)R^(b2) and nitro;     -   2) C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, 6-10 membered aryl,         5-10 membered heteroaryl, C₃-12 cycloalkyl and 3-12 membered         aliphatic heterocyclyl, unsubstituted or optionally substituted         with 1, 2, 3, 4, 5 or 6 substituents independently selected from         R²²;     -   3) two R¹², together with two adjacent ring-forming atoms         ring-forming atoms of the aryl or heteroaryl in Cy^(A) to which         they are attached respectively, form C₅₋₁₂ aliphatic cyclyl or         5-12 membered aliphatic heterocyclyl, unsubstituted or         optionally substituted with 1, 2, 3, 4, 5 or 6 substituents         independently selected from R²².

In some embodiments, each R¹² is independently selected from:

-   -   1) oxo, halogen, cyano, —C(═O)R^(a2), —C(═O)OR^(a2),         —C(═O)NR^(a2)R^(b2), —C(═NR^(d2))NR^(a2)R^(b2), —OR^(a2),         —OC(═O)R^(a2), —OC(═O)OR^(c2), —OC(═O)NR^(a2)R^(b2),         —NR^(a2)R^(b2), —NR^(a2)C(═O)R^(b2), —NR^(a2)C(═O)OR^(c2),         —NR^(e2)C(═O)NR^(a2)R^(b2), —NR^(e2)C(═N^(d2))NR^(a2)R^(b2),         —NR^(a2)S(═O)₂R², —NR^(e2)S(═O)₂NR^(a2)R^(b2) and nitro;     -   2) C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, 6-10 membered aryl,         5-10 membered heteroaryl, C₃₋₁₀ cycloalkyl and 3-10 membered         aliphatic heterocyclyl, unsubstituted or optionally substituted         with 1, 2, 3, 4, 5 or 6 substituents independently selected from         R²²;     -   3) two R¹², together with two adjacent ring-forming atoms of the         aryl or heteroaryl in Cy^(A) to which they are attached         respectively, form C₅₋₁₀ aliphatic cyclyl or 5-10 membered         aliphatic heterocyclyl, unsubstituted or optionally substituted         with 1, 2, 3, 4 or 5 substituents independently selected from         R²².

In some embodiments, each R¹² is independently selected from:

-   -   1) oxo, halogen, cyano, —C(═O)R^(a2), —C(═O)OR^(a2),         —C(═O)NR^(a2)R^(b2), —C(═NR^(d2))NR^(a2)R^(b2), —OR^(a2),         —OC(═O)R^(a2), —OC(═O)OR^(c2), —OC(═O)NR^(a2)R^(b2),         —NR^(a2)R^(b2), —NR^(a2)C(═O)R^(b2), —NR^(a2)C(═O)OR^(c2),         —NR^(e2)C(═O)NR^(a2)R^(b2), —NR^(e2)C(═NR^(d2))NR^(a2)R^(b2),         —NR^(a2)S(═O)₂R^(c2), —NR^(e2)S(═O)₂NR^(a2)R^(b2) and nitro;     -   2) C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, 6-10 membered aryl,         5-10 membered heteroaryl, C₃₋₁₀ cycloalkyl and 3-10 membered         aliphatic heterocyclyl, unsubstituted or optionally substituted         with 1, 2, 3 or 4 substituents independently selected from R²²;     -   3) two R¹², together with two adjacent ring-forming atoms of the         aryl or heteroaryl in Cy^(A) to which they are attached         respectively, form C₄₋₆ aliphatic cyclyl or 4-8 membered         aliphatic heterocyclyl, unsubstituted or optionally substituted         with 1, 2 or 3 substituents independently selected from R²².

In some embodiments, each R¹² is independently selected from:

-   -   1) oxo, halogen, cyano, —C(═O)R^(a2), —C(═O)NR^(a2)R^(b2),         —C(═NR^(d2))NR^(a2)R^(b2), —OR^(a2), —NR^(a2)R^(b2),         —NR^(a2)C(═O)R^(b2), —NR^(e2)C(═O)NR^(a2)R^(b2),         NR^(e2)C(═NR^(d2))NR^(a2)R^(b2), —NR^(a2)S(═O)₂R^(c2), and         —NR^(e2)S(═O)₂NR^(a2)R^(b2);     -   2) C₁₋₆ alkyl, 6-10 membered aryl, 5-10 membered heteroaryl,         C₃₋₁₀ cycloalkyl, and 3-10 membered aliphatic heterocyclyl,         unsubstituted or optionally substituted with 1, 2, 3, 4, 5 or 6         substituents independently selected from R²²;     -   3) two R¹², together with two adjacent ring-forming atoms of the         aryl or heteroaryl in Cy^(A) to which they are attached         respectively, form C₄₋₈ aliphatic cyclyl or 4-8 membered         aliphatic heterocyclyl, unsubstituted or optionally substituted         with 1, 2, 3 or 4 substituents independently selected from R²².

In some embodiments, each R¹² is independently selected from:

-   -   1) oxo, halogen, cyano, —C(═O)R^(a2), —C(═O)NR^(a2)R^(b2),         C(═NR²)NR^(a2)R^(b2), —OR^(a2), —NR^(a2)R^(b2),         —NR^(a2)C(═O)R^(b2), —NR^(a2)C(═O)OR^(c2),         —NR^(e2)C(═O)NR^(a2)R^(b2), —NR^(e2)C(═NR²)NR^(a2)R^(b2),         —NR^(a2)S(═O)₂R², and —NR^(e2)S(═O)₂NR^(a2)R^(b2);     -   2) C₁₋₆ alkyl, phenyl, 5-6 membered heteroaryl, C₃₋₁₀         cycloalkyl, and 3-10 membered aliphatic heterocyclyl,         unsubstituted or optionally substituted with 1, 2, 3 or 4         substituents independently selected from R²²;     -   3) two R¹², together with two adjacent ring-forming atoms of the         aryl or heteroaryl in Cy^(A) to which they are attached         respectively, form C₅, C₆, C₇ aliphatic monocyclyl or 5         membered, 6 membered, 7 membered aliphatic monocyclic         heterocyclyl, unsubstituted or optionally substituted with 1, 2         or 3 substituents independently selected from R²².

In some embodiments, each R¹² independently selected from:

-   -   1) halogen, cyano, —OR^(a), —C(═O)NR^(a2)R^(b2), —NR^(a2)R^(b2),         —NR^(a2)C(═O)R^(b2), —N^(a2)C(═O)OR^(c2),         —NR^(e2)C(═O)NR^(a2)R^(b2), —NR^(e2)(NR^(d2))NR^(a2)R^(b2),         —NR^(a2)S(═O)₂R^(c2), and —NR^(e2)S(═O)₂NR^(a2)R^(b2).     -   2) C₁₋₆ alkyl, phenyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl,         and 3-7 membered aliphatic heterocyclyl, unsubstituted or         optionally substituted with 1, 2, 3 or 4 substituents         independently selected from R²².

In some embodiments, each R¹² is independently selected from:

-   -   1) halogen, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, 3-7 membered aliphatic         heterocyclyl, cyano, —OR^(a2), —C(═O)NR^(a2)R^(b2),         —NR^(a2)R^(b2), —NR^(a2)C(═O)R^(b2), —NR^(e2)C(═O)NR^(a2)R^(b2),         —NR^(e2)C(═NR^(d2))NR^(a2)R^(b2), —NR^(a2)S(═O)₂R^(c2) and         NR^(e2)S(═O)₂NR^(a2)R^(b2);     -   2) two R¹², together with two adjacent ring-forming atoms of the         aryl or heteroaryl in Cy^(A) to which they are attached         respectively, form C₄₋₆ aliphatic cyclyl, 4-8 membered aliphatic         heterocyclyl, unsubstituted or independently optionally         substituted with 1, 2, 3 or 4 substituents independently         selected from R²².

In some embodiments, two R¹², together with two adjacent ring-forming atoms of the aryl or heteroaryl in Cy^(A) to which they are attached respectively, form C₅, C₆, C₇ aliphatic monocyclyl and 5 membered, 6 membered, 7 membered aliphatic monocyclic heterocyclyl, unsubstituted or independently optionally substituted with 1, 2 or 3 substituents independently selected from R²².

In some embodiments, R¹² is selected from 4 membered, 5 membered, 6 membered, 7 membered aliphatic monocyclic heterocyclyl and 7 membered, 8 membered, 9 membered, 10 membered bicylic aliphatic heterocyclyl, which is unsubstituted or optionally substituted with 1, 2, 3 substituents independently selected from R²².

In some embodiments, R¹² is unsubstituted or optionally substituted aliphatic monocyclic heterocyclyl or aliphatic bicyclic heterocyclyl, wherein the aliphatic bicyclic heterocyclyl may be, for example, a bridged ring group, or a spiro-ring group; wherein said aliphatic dicyclic heterocyclyl comprises A1 ring and A2 ring, A1 ring is directly connected to the aryl or heteroaryl of Cy^(A), and A1 ring can be a 3-6 membered ring, and the total number of ring-forming atoms of the aliphatic bicyclic heterocyclyl is no more than 10.

In some embodiments, aliphatic heterocyclyl of R¹² contains 1 or 2 ring-forming heteroatoms selected from N, O, and S.

In some embodiments, each R¹² is independently selected from C₁₋₆ alkyl, halogen, cyano, —OR^(a2) and —NR^(a2)R^(b2) In some embodiments, each R¹² is independently selected from:

-   -   1) C₁₋₆ alkyl, C₁₋₃ alkoxy, C₃₋₈ cycloalkyl, and 3-8 membered         aliphatic heterocyclyl, unsubstituted or optionally substituted         with 1, 2, 3 or 4 substituents independently selected from R²²;         wherein 3-8 membered aliphatic heterocyclyl is monocyclic         aliphatic heterocyclyl or bicyclic aliphatic heterocyclyl, said         aliphatic heterocyclyl may contain ring-forming heteroatoms         selected from N and/or O; R²² is selected from oxo, hydroxyl,         amino, cyano, C₁₋₃ alkylamino, C₁₋₃ alkoxy, 3-6 membered         cycloalkyl and 3-6 membered aliphatic monocyclic heterocyclyl;     -   2) two R¹², together with two adjacent ring-forming atoms of the         aryl or heteroaryl in Cy^(A) to which they are attached         respectively, form C₅, C₆, C₇ aliphatic monocyclyl or 5         membered, 6 membered, 7 membered aliphatic monocyclic         heterocyclyl, unsubstituted or optionally substituted with 1, 2         or 3 substituents each independently selected from R²²; R²² is         selected from oxo, methyl, ethyl, isopropyl, cyclopropyl,         oxetanyl, —N(CH₃)₂, —OH, —CN, —OCH₃, —C(═O)CH₃, —S(═O)₂CH₂CH₃,         —C(═O)NH₂, —S(═O)₂NH₂, —CH₂CH₂OH, —CH₂OH, and —CH₂CH₂N(CH₃)₂.

In some embodiments, Cy^(A) is selected from:

-   -   1) the following structures, wherein the “         ” at the end of the chemical bond in each structure means that         the structure is connected to the rest of the formula (I)         through the bond:

-   -   2) phenyl, pyridyl, pyrimidyl, pyrazolyl, imidazolyl, thiazolyl,         isothiazolyl, oxazolyl or isoxazolyl, unsubstituted or         optionally substituted with 1, 2 or 3 substituents each         independently selected from R¹², wherein:     -   (a) each R¹² is independently selected from fluorine, chlorine,         non-hydrogen R^(G1), and —OR^(G1); or,     -   (b) Cy^(A) contains one R¹² selected from the following         structures, wherein the “         ” at the end of the chemical bond in each structure means that         the structure is connected to the rest of formula (I) through         the bond:

-   -   or,     -   Cy^(A) contains two or three R¹², wherein one of R¹² is selected         from the above structures and the others of R¹² are each         independently selected from fluorine, chlorine, non-hydrogen         R^(G1), and —OR^(G1);     -   wherein,     -   X is selected from CH and N;     -   Y is selected from —CH₂—, NH and O;     -   E₁ and E₂ are each independently selected from —CH₂— and         carbonyl, but E₁ and E₂ cannot be carbonyl simultaneously;     -   R^(G2) is selected from hydrogen, —OR^(G1) and —N(R^(G1))₂;     -   Each R^(G1) is independently selected from:     -   1) hydrogen, methyl, ethyl (optionally substituted with C₁₋₃         alkylamino), propyl (optionally substituted with hydroxyl and         C₁₋₃ alkyl, such as 2-hydroxyl-2-methyl-propyl), isopropyl         (substituted with cyano), cyclopropyl, 3-oxetanyl and         3-methyl-3-azetidinyl; 2) two R^(G1), together with the one atom         to which they are attached to, form a C₃₋₆ monocyclyl or 3-6         membered aliphatic monocyclic heterocyclyl;     -   3) two R^(G1) attached to two different ring-forming atoms of         the same monocycle are connected to form a ring structure         together with part of the ring-forming atoms of said monocycle,         wherein the two connected R^(G1) form a C₂, C₃ or C₄ alkylene.

In some embodiments, Cy^(A) is phenyl, pyridyl, pyrimidyl, pyrazolyl, imidazolyl, thiazolyl or isothiazolyl, unsubstituted or optionally substituted with 1, 2 or 3 substituents each independently selected from R¹²,

-   -   1) each R¹² is independently selected from fluorine, chlorine,         non-hydrogen R^(G1), and —OR^(G1); or,     -   2) Cy^(A) contains one R¹² selected from the following         structures:

-   -   or,     -   Cy^(A) contains two or three R¹², wherein one of R¹² is selected         from the above structures and the others of R¹² are each         independently selected from fluorine, chlorine, non-hydrogen         R^(G1), and —OR^(G1).

Each R^(G1) is independently selected from hydrogen, methyl, ethyl, isopropyl, cyclopropyl, 3-oxetanebutyl and 3-methyl-3-azetidinyl.

In some embodiments, R²² is selected from oxo, cyano, C₃₋₇ cycloalkyl, 3-7 membered aliphatic heterocyclyl, R^(H1), —(CH₂)₀₋₂OH, —(CH₂)₀₋₂OR^(H1), —(CH₂)₀₋₂NH₁₂, —(CH₂)₀₋₂NHR^(H1), —(CH₂)₀₋₂N(R^(H1))₂, aldehyde group, —C(═O)R^(H1), —C(═O)NH₂, —C(═O)NHR^(H1), —C(═O)N(R^(H1))₂, —S(═O)₂R^(H1), —S(═O)₂NH₂, —S(═O)₂N^(H1)R^(H1) and —S(═O)₂N(R^(H1))₂; R^(H1) is independently selected from methyl, ethyl, isopropyl, cyclopropyl, 3-oxetanebutyl and 3-methyl-3-azetidinyl.

In some embodiments, R²² is selected from oxo, cyano, methyl, ethyl, isopropyl, cyclopropyl, oxetanyl, —N(CH₃)₂, —OH, —CN, —OCH₃, —C(═O)CH₃, —S(O)₂CH₂CH₃, —C(═O)NH, —S(O)₂NH₂, —CH₂CH₂OH, —CH₂OH, and —CH₂CH₂N(CH₃)₂.

In some embodiments, Cy^(B) is selected from phenyl, naphthyl and 5-10 membered heteroaryl, unsubstituted or optionally substituted with 1, 2, 3 or 4 substituents independently selected from R¹³; wherein said 5-10 membered heteroaryl contains at least one ring-forming carbon atom and 1, 2, 3 or 4 ring-forming heteroatoms independently selected from N, O and S.

In some embodiments, Cy^(B) is phenyl or 5-6 membered heteroaryl, optionally substituted with 1, 2, 3 or 4 substituents independently selected from R¹³.

In some embodiments, Cy^(B) is phenyl or 5-6 membered heteroaryl containing 1, 2 or 3 ring-forming heteroatoms selected from N and S, said phenyl or 5-6 membered heteroaryl is optionally substituted with 1, 2, or 3 substituents independently selected from R¹³.

In some embodiments, Cy^(B) is phenyl, pyridyl, pyrimidyl, pyridazinyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, thienyl, optionally substituted with 1, 2, or 3 substituents independently selected from R¹³.

In some embodiments, Cy^(B) is phenyl or 5-6 membered heteroaryl, optionally substituted with 1, 2, 3 or 4 substituents independently selected from R¹³; wherein two R¹³, together with two adjacent ring-forming atoms of the phenyl or heteroaryl of Cy^(B) to which they are connected respectively, form a C₅₋₁₂ aliphatic cyclyl or 5-12 membered aliphatic heterocyclyl, unsubstituted or optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from R²³.

In some embodiments, Cy^(B) is phenyl or 5-6 membered heteroaryl, optionally substituted with 1, 2, or 3 substituents independently selected from R¹³; wherein two R¹³, together with two adjacent ring-forming atoms of the phenyl or heteroaryl of Cy^(B) together with the two said ring-forming atoms to which they are connected respectively, form a C₄₋₈ aliphatic cyclyl or 4-8 membered aliphatic heterocyclyl, unsubstituted or optionally substituted with 1, 2 or 3 substituents independently selected from R²³.

In some embodiments, Cy^(B) is phenyl or 5-6 membered heteroaryl, optionally substituted with 1, 2, or 3 substituents independently selected from R¹³; wherein two R¹³, together with two adjacent ring atoms of the phenyl or heteroaryl of Cy^(B) to which they are connected respectively, form a C₅₋₆ aliphatic monocyclyl or 5-6 membered aliphatic monocyclic heterocyclyl, unsubstituted or optionally substituted with 1, 2 or 3 substituents independently selected from R²³;

-   -   R²³ is selected from fluorine, methyl, ethyl, isopropyl,         cyclopropyl, ethylene and 3-oxetanyl.

In some embodiments, each R¹³ is independently selected from:

-   -   1) oxo, halogen, cyano, —C(═O)R^(a3), —C(═O)OR^(a3),         —C(═O)NR^(a3)R^(b3), —C(═NR^(d3))NR^(a3)R^(b3), —OR^(a3),         —OC(═O)R^(a3), —OC(═O)OR^(c3), —OC(═O)NR^(a3)R^(b3), —SR^(a3),         —S(═O)R^(c3), —S(═O)₂R^(c3), sulphonic acid group,         —S(═O)NR^(a3)R^(b3), —S(═O)₂NR^(a3)R^(b3), —S(═O)(═NR^(d3))R³,         —NR^(a3)R^(b3), —NR^(a3)C(═O)R^(b3), —NR^(a3)C(═O)OR^(c3),         —NR^(e3)C(═O)NR^(a3)R^(b3), —NR^(e3)C(═NR^(d3))NR^(a3)R³,         —NR^(a3)S(═O)₂R^(c3), —NR^(e3)S(═O)₂NR^(a3)R^(b3) and nitro;     -   2) C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, 6-10 membered aryl,         5-10 membered heteroaryl, C₃₋₁₂ cycloalkyl and 3-12 membered         aliphatic heterocyclyl, unsubstituted or optionally substituted         with 1, 2, 3, 4, 5 or 6 substituents independently selected from         R²³;     -   3) two R¹³, together with two adjacent ring atoms of the phenyl         or heteroaryl of Cy^(B) to which they are connected         respectively, form a C₅₋₁₂ aliphatic cyclyl or 5-12 membered         aliphatic heterocyclyl, unsubstituted or optionally substituted         with 1, 2, 3, 4 or 5 substituents independently selected from         R²³.

In some embodiments, each R¹³ is independently selected from:

-   -   1) oxo, halogen, cyano, —C(═O)R^(a3), —C(═O)OR^(a3),         —C(═O)NR^(a3)R^(b3), —C(═NR^(d3))NR^(a3)R^(b3), —OR^(a3),         —OC(═O)R^(a3), —OC(═O)OR^(c3), —OC(═O)NR^(a3)R^(b3),         —NR^(a3)R^(b3), —NR^(a3)C(═O)R^(b3), —NR^(a3)C(═O)OR^(c3),         —NR^(e3)C(═O)NR^(a3)R^(b3), —NR^(e3)C(═NR^(d3))NR^(a3)R³,         —NR^(a3)S(═O)₂R^(c3), —NR^(e3)S(═O)₂NR^(a3)R³ and nitro;     -   2) C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, 6-10 membered aryl,         5-10 membered heteroaryl, C₃₋₁₀ cycloalkyl and 3-10 membered         aliphatic heterocyclyl, unsubstituted or optionally substituted         with 1, 2, 3, 4, 5 or 6 substituents independently selected from         R²³; 3) two R¹³, together with two adjacent ring-forming atoms         of the aryl or heteroaryl of Cy^(B) to which they are connected         respectively, form a C₅₋₁₀ aliphatic cyclyl or 5-10 membered         aliphatic heterocyclyl, unsubstituted or optionally substituted         with 1, 2, 3, 4 or 5 substituents independently selected from         R²³.

In some embodiments, each R¹³ is independently selected from:

-   -   1) oxo, halogen, cyano, —C(═O)R^(a3), —C(═O)OR^(a3),         —C(═O)NR^(a3)R^(b3), C(═NR^(d3))NR^(a3)R^(b3), —OR^(a3),         —OC(═O)R^(a3), —OC(═O)OR^(c3), —OC(═O)NR^(a3)R^(b3),         —NR^(a3)R^(b3), —NR^(a3)C(═O)R^(b3), —NR^(a3)C(═O)OR^(c3),         —NR^(e3)C(═O)NR^(a3)R^(b3), —NR^(e3)C(═NR^(d3))NR^(a3)R³,         —NR^(a3)S(═O)₂R^(c3), —NR^(e3)S(═O)₂NR^(a3)R³ and nitro;     -   2) C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, 6-10 membered aryl,         5-10 membered heteroaryl, C₃₋₁₀ cycloalkyl and 3-10 membered         aliphatic heterocyclyl, unsubstituted or optionally substituted         with 1, 2, 3 or 4 substituents independently selected from R²³;     -   3) two R¹³, together with two adjacent ring-forming atoms of the         aryl or heteroaryl of Cy^(B) to which they are connected         respectively, form a C₄₋₈ aliphatic cyclyl or 4-8 membered         aliphatic heterocyclyl, unsubstituted or optionally substituted         with 1, 2 or 3 substituents independently selected from R²³.

In some embodiments, each R¹³ is independently selected from:

-   -   1) oxo, halogen, cyano, —C(═O)R^(a3), —C(═O)NR^(a3)R^(b3),         —C(═NR^(d3))NR^(a3)R^(b3), —OR^(a3)—NR^(a3)R^(b3),         —NR^(a3)C(═O)R^(b3), —NR^(e3)C(═O)NR^(a3)R^(b3),         —NR^(e3)C(═NR^(d3))NR^(a3)R^(b3), —NR^(a3)S(═O)₂R^(c3) and         —NR^(e3)S(═O)₂NR^(a3)R^(b3);     -   2) C₁₋₆ alkyl, 6-10 membered aryl, 5-10 membered heteroaryl,         C₃₋₁₀ cycloalkyl and 3-10 membered aliphatic heterocyclyl,         unsubstituted or optionally substituted with 1, 2, 3, 4, 5 or 6         substituents independently selected from R²³;     -   3) two R¹³, together with two adjacent ring-forming atoms of the         aryl or heteroaryl of Cy^(B) to which they are connected         respectively, form a C₄₋₆ aliphatic cyclyl or 4-8 membered         aliphatic heterocyclyl, unsubstituted or optionally substituted         with 1, 2, 3 or 4 substituents independently selected from R²³.

In some embodiments, each R¹³ is independently selected from:

-   -   1) oxo, halogen, cyano, —C(═O)R^(a3), —C(═O)NR^(a3)R^(b3),         C(═NR^(d3))NR^(a3)R^(b3), —OR^(a3)—NR^(a3)R^(b3),         —NR^(a3)C(═O)R^(b3), —NR^(a3)C(═O)OR^(c3),         —NR^(e3)C(═O)NR^(a3)R^(b3), —NR^(e3)C(═NR^(d3))N^(a3)R^(b3),         —NR^(a3)S(═O)₂R^(c3), and —NR^(e3)S(═O)₂NR^(a3)R^(b3);     -   2) C₁₋₆ alkyl, phenyl, 5-6 membered heteroaryl, C₃₋₁₀ cycloalkyl         and 3-10 membered aliphatic heterocyclyl, unsubstituted or         optionally substituted with 1, 2, 3 or 4 substituents         independently selected from R²³;     -   3) two R¹³, together with two adjacent ring-forming atoms of the         aryl or heteroaryl of Cy^(B) to which they are connected         respectively, form a C₅, C₆, C₇ aliphatic monocyclyl or 5         membered, 6 membered, 7 membered aliphatic monocyclic         heterocyclyl, unsubstituted or optionally substituted with 1, 2         or 3 substituents independently selected from R²³.

In some embodiments, each R¹³ is independently selected from:

-   -   1) oxo, halogen, cyano, C₁₋₄ alkyl, C₃₋₆ cycloalkyl,         —C(═O)R^(a3), —C(═O)NR^(a3)R^(b3), —OR^(a3), NR^(a3)R^(b3),         —NR^(a3)C(═O)R^(b3), —NR^(e3)C(═O)NR^(a3)R^(b3) and         —NR^(e3)C(═NR^(d3))NR^(a3)R^(b3)     -   2) two R¹³, together with two adjacent ring-forming atoms of the         aryl or heteroaryl of Cy^(B) to which they are connected         respectively, form a C₄₋₆ aliphatic cyclyl or 4-8 membered         aliphatic heterocyclyl, unsubstituted or optionally substituted         with 1, 2, 3 or 4 substituents independently selected from R²³.

In some embodiments, each R¹³ is independently selected from:

-   -   1) oxo, fluorine, chlorine, cyano, C₁₋₃ alkyl, C₃₋₄ cycloalkyl,         —C(═O)R^(a3), —C(═O)NR^(a3)R^(b3), —OR^(a3), —NR^(a3)R^(b3),         —NR^(a3)C(═O)R^(b3), —NR^(e3)C(═O)NR^(a3)R³ and         —NR^(e3)C(═NR^(d3))NR^(a3)R^(b3);     -   2) two R¹³, together with two adjacent ring-forming atoms of the         aryl or heteroaryl of Cy^(B) to which they are connected         respectively, form a C₅₋₆ aliphatic monocyclyl or 5-6 membered         aliphatic monocyclic heterocyclyl, unsubstituted or optionally         substituted with 1, 2 or 3 substituents independently selected         from R²³.

In some embodiments, each R¹³ independently selected from:

-   -   1) halogen and cyano;     -   2) C₁₋₄ alkyl, C₃₋₆ cycloalkyl and 3-6 membered aliphatic         heterocyclyl, unsubstituted or optionally substituted with 1, 2         or 3 substituents each independently selected from fluorine,         cyano, —OR^(a5) and —NR^(a5)R^(b5); wherein R^(a5) and R^(b5)         are each independently selected from hydrogen and C₁₋₆ alkyl,         or, R^(a5) and R^(b5) attached to the same N atom, together with         the N atom, form a 3-6 membered aliphatic heterocyclyl.

In some embodiments, each R¹³ is independently selected from halogen, cyano, —OR^(a3) and —NR^(a3)R^(b3); wherein R^(a3) and R^(b3) are each independently selected from:

-   -   1) hydrogen;     -   2) C₁₋₆ alkyl, C₃₋₆ cycloalkyl, and 3-6 membered aliphatic         heterocyclyl, unsubstituted or optionally substituted with 1, 2         or 3 substituents independently selected from fluorine, cyano,         —OR^(a5) and —NR^(a5)R^(b5); wherein R^(a5) and R^(b5) are each         independently selected from hydrogen and C₁₋₄ alkyl, or, R^(a5)         and R^(b5) attached to the same N atom, together with said N         atom, form a 3-6 membered aliphatic heterocyclyl.

In some embodiments, R¹³ is independently selected from:

-   -   1) fluorine, chlorine, cyano, C₁₋₃ alkyl, C₃₋₄ cycloalkyl,         —OR^(a3) and —NR^(a3)R^(b3);     -   2) two R¹³, together with two adjacent ring-forming atoms of the         aryl or heteroaryl of Cy^(B) to which they connected         respectively, form a C₅₋₆ aliphatic monocyclyl or 5-6 membered         aliphatic monocyclic heterocyclyl, unsubstituted or optionally         substituted with 1, 2 or 3 substituents independently selected         from R²³;     -   R^(a3) and R^(b3) are each independently selected from hydrogen,         C₁₋₄ alkyl and C₃₋₆ cycloalkyl, or, R^(a3) and R^(b3) attached         to the same N atom, together said N atom, form a 3-6 membered         aliphatic heterocyclyl; R²³ selected from C₁₋₆ alkyl and C₃₋₆         cycloalkyl.

In some embodiments, two R¹³, together with two adjacent ring-forming atoms of the aryl or heteroaryl of Cy^(B) to which they attached respectively, form a C₃₋₇ aliphatic cyclyl or 3-7 membered aliphatic heterocyclyl, unsubstituted or optionally substituted with 1, 2 or 3 substituents independently selected from oxo, fluorine, cyano, —OR^(a)s and —NR^(a5)R^(b5); wherein said 3-7 membered aliphatic heterocyclyl contains 1 or 2 ring-forming heteroatoms selected from N, O and S; R^(a5) and R^(b5) are each independently selected from hydrogen and C₁₋₄ alkyl, or, R^(a5) and R^(b5) attached to the same N atom, together with said N atom, form a 3-6 membered aliphatic heterocyclyl.

In some embodiments, each R¹³ independently selected from halogen, amino, C₁₋₃ alkyl, substituted C₁₋₃ alkyl, C₁₋₃ alkoxy, substituted C₁₋₃ alkoxy, C₃₋₆ cycloalkoxy, C₁₋₃ alkylamino and —C(═O)NR^(a3)R^(b3); wherein the substituent of substituted C₁₋₃ alkyl is selected from one, two or three of halogen, hydroxyl, C₁₋₃ alkoxy, and C₁₋₃ alkyl; the substituent of substituted C₁₋₃ alkoxy is selected from one, two or three halogens; R^(a3) and R^(b3) are each independently selected from hydrogen and C₁₋₃ alkyl, or, R^(a3), R^(b3) attached to the same N atom, together with said N atom, form a 3-6 membered aliphatic heterocyclyl, unsubstituted or optionally substituted with one or two substituents selected from C₁₋₃ alkyl, C₁₋₃ alkoxy, and hydroxyl.

In some embodiments, each R¹³ is independently selected from —F, —Cl, —NH₂, —CH₃, —CH₂CH₃, —CH(CH₃)CH₃, —CF₃, —CHF₂, —CH₂OCH₃, —OCH₃, —OCH₂CH₃, —OCH(CH₃)CH₃, —OCHF₂, —O(C₃H₅)(cyclopropoxy), —CH₂NHCH₃, —CH₂N(CH₃)₂, —NHCH3, —N(CH₃)₂, —NHCH₂CH₃, —N(CH₃)(CH₂CH₃), —N(CH₂CH₃)₂, —NR^(a3)R^(b3), —C(═O)NHCH₃, —C(═O)N(CH₃)₂, and —C(═O)NR^(a3)R^(b3); in —NR^(a3)R^(b3) and —C(═O)NR^(a3)R^(b3), R^(a3), R^(b3) attached to the same N atom, together with said N atom, form a 4 or 5 membered saturated aliphatic monocyclic heterocyclyl, unsubstituted or optionally substituted with one or two substituents selected from methyl, hydroxyl, and methoxy.

In some embodiments, two R¹³, together with two adjacent ring-forming atoms of the aryl or heteroaryl of Cy^(B) to which they connected respectively, form a 5 membered or 6 membered aliphatic monocyclic heterocyclyl containing one or two ring-forming heteroatoms selected from N and O, said aliphatic monocyclic heterocyclyl is unsubstituted or optionally substituted with 1 or 2 substituents independently selected from R²³; R²³ may be oxo, fluorine, methyl, —CH₂OH, —NHCH₃.

In some embodiments, Cy^(B) is selected from the following structures, wherein the “

” at the end of the chemical bond in each structure means that the structures are connected to the rest of formula (I) through the bond:

-   -   wherein, R^(a3) and R^(b3) are each independently selected from         hydrogent and C₁₋₆ alkyl, or, R^(a3) and R^(b3), together with         two adjacent ring-forming atoms to which they are attached         respectively, form a 5-6 membered aliphatic monocyclyl or 5-6         membered aliphatic monocyclic heterocyclyl.

In some embodiments, R¹ is hydrogen;

-   -   Cy^(A) is selected from phenyl, naphthyl and 5-10 membered         heteroaryl, unsubstituted or optionally substituted with 1, 2, 3         or 4 substituents independently selected from R¹²; wherein 5-10         membered heteroaryl contains at least two ring-forming carbon         atoms and 1, 2, 3 or 4 ring-forming heteroatoms independently         selected from N, O and S;     -   R¹² is selected from:     -   1) oxo, halogen, cyano, —C(═O)R^(a2), carboxyl,         —C(═O)NR^(a2)R^(b2), —OR^(a2)—NR^(a2)R^(b2), —NR^(a2)C(═O)R²,         —NR^(e2)C(═O)NR^(a2)R^(b2), NR^(e2)C(═NR^(d2))NR^(a2)R^(b2),         —NR^(a2)S(═O)₂R² and —NR^(e2)S(═O)₂NR^(a2)R^(b2);     -   2) C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, phenyl, 5-6 membered         heteroaryl, C₃₋₇ monocyclic cycloalkyl, C₆₋₁₀ bicyclic         cycloalkyl, 3-7 membered aliphatic monocyclic heterocyclyl and         6-10 membered biocyclic aliphatic heterocyclyl, unsubstituted or         optionally substituted with 1, 2, 3 or 4 substituents         independently selected from R²²;     -   3) two R¹², together with two adjacent ring-forming atoms of the         aryl or heteroaryl in Cy^(A) to which they connected         respectively, form a C₅₋₁₀ aliphatic cyclyl or 5-10 membered         aliphatic heterocyclyl, unsubstituted or optionally substituted         with 1, 2 or 3 substituents independently selected from R²²;         wherein 5-10 membered aliphatic heterocyclyl contains one or two         ring-forming heteroatoms independently selected from N, O and S;     -   R^(a2), R^(b2) and R^(e2) are each independently selected from:     -   1) hydrogen;     -   2) C₁₋₄ alkyl, phenyl, 5-6 membered heteroaryl, C₃₋₆ cycloalkyl         and 3-6 membered aliphatic heterocyclyl, unsubstituted or         optionally substituted with 1, 2 or 3 substituents independently         selected from R²²;     -   or,     -   R^(a2) and R^(b2), together with the same N atom to which they         are attached, form a 3-8 membered aliphatic heterocyclyl,         unsubstituted or optionally substituted with 1, 2 or 3         substituents independently selected from R²²; wherein 3-8         membered aliphatic heterocyclyl contains 1 or 2 ring-forming         heteroatoms, for example, contains only said N atom, or contains         said N atom and another heteroatom independently selected from         N, O and S atom;     -   R^(c2) is selected from C₁₋₄ alkyl, C₂₋₃ alkenyl, phenyl, 5-6         membered heteroaryl, C₃₋₆ cycloalkyl and 3-6 membered aliphatic         heterocyclyl, unsubstituted or optionally substituted with 1, 2         or 3 substituents independently selected from R²²;     -   R^(d2) is selected from hydrogen, C₁₋₄ alkyl, C₃₋₆ cycloalkyl,         3-6 membered aliphatic heterocyclyl, cyano, nitro and         —S(═O)₂R^(G);     -   R²² is selected from:     -   1) oxo, halogen, cyano, carboxyl, —C(═O)R^(a4),         —C(═O)NR^(a4)R^(b4), —C(═NR^(d4))NR^(a4)R^(b4), —OR^(a4),         —S(═O)R^(c4), —S(═O)₂R^(c4), —S(═O)₂NR^(a4)R⁴,         —S(═O)(═NR^(d4))R⁴, —NR^(a4)R^(b4), —NR^(a4)C(═O)R^(b4),         —NR^(e4)C(═O)NR^(a4)R^(b)4, —NR^(e4)C(═NR^(d4))NR^(a4)R^(b4),         —NR^(a4)S(═O)₂R^(c4), —NR^(e4)S(═O)₂NR^(a4)R^(b4) and imino         group (═N—R^(d4));     -   2) C₁₋₄ alkyl, C₁₋₄ alkylene, phenyl, 5-6 membered heteroaryl,         C₃₋₇ cycloalkyl and 3-7 membered aliphatic heterocyclyl,         unsubstituted or optionally substituted with 1, 2 or 3         substituents independently selected from R³²;     -   R^(a4), R^(b4) and R^(e4) are each independently selected from:     -   1) hydrogen;     -   2) C₁₋₄ alkyl, C₃₋₆ monocyclic cycloalkyl and 3-6 membered         aliphatic monocyclic heterocyclyl, unsubstituted or optionally         substituted with 1, 2 or 3 substituents independently selected         from R³²;     -   or,     -   R^(a4) and R^(b4), together with the same N atom to which they         are attached, form a 3-6 membered aliphatic monocyclic         heterocyclyl or 6-7 membered bicyclic aliphatic heterocyclyl,         unsubstituted or optionally substituted with 1, 2 or 3         substituents independently selected from R³²; wherein 3-6         membered aliphatic monocyclic heterocyclyl and 6-7 membered         bicyclic aliphatic heterocyclyl contain one or two ring-forming         heteroatoms, for example, contains only said N atom, or contains         said N atom and another heteroatom independently selected from         N, O and S atom;     -   R^(c4) is selected from C₁₋₄ alkyl, C₂₋₃ alkenyl, C₃₋₆         monocyclic cycloalkyl and 3-6 membered aliphatic monocyclic         heterocyclyl, unsubstituted or optionally substituted with 1, 2         or 3 substituents independently selected from R³²;     -   R^(d4) is selected from hydrogen, C₁₋₄ alkyl, C₃₋₆ monocyclic         cycloalkyl, 3-6 membered aliphatic monocyclic heterocyclyl,         cyano, nitro and —S(═O)₂R^(G);     -   R³² is selected from oxo, halogen, cyano, hydroxyl, —OR^(G),         amino, —NHR^(G), —N(R^(G))₂, aldehyde group, —C(═O)R^(G),         —S(═O)₂R^(G), carboxyl, —C(═O)OR^(G), —C(═O)NH₂, —C(═O)—NHR^(G),         —C(═O)N(R^(G))₂, —S(═O)₂NH₂, —S(═O)₂—NHR^(G) and         —S(═O)₂N(R^(G))₂;     -   Cy^(B) selected from phenyl, naphthyl and 5-10 membered         heteroaryl, unsubstituted or optionally substituted with 1, 2, 3         or 4 substituents independently selected from R¹³; wherein 5-10         membered heteroaryl contains at least two ring-forming carbon         atoms and 1, 2, 3 or 4 ring-forming heteroatoms independently         selected from N, O and S;     -   R¹³ is selected from:     -   1) oxo, halogen, cyano, —C(═O)R^(a3), carboxyl,         —C(═O)NR^(a3)R^(b3), —OR^(a3), —NR^(a3)R^(b3),         —NR^(a3)C(═O)R^(b3), —NR^(e3)C(═O)NR^(a3)R^(b3),         —NR^(e3)C(═NR^(d3))NR^(a3)R^(b3), —NR^(a3)S(═O)₂R^(c3) and         —NR^(e3)S(═O)₂NR^(a3)R^(b3);     -   2) C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, phenyl, 5-6 membered         heteroaryl, C₃₋₇ monocyclic cycloalkyl, C₆₋₁₀ bicyclic         cycloalkyl, 3-7 membered aliphatic monocyclic heterocyclyl and         6-10 membered bicyclic aliphatic heterocyclyl, unsubstituted or         optionally substituted with 1, 2, 3 or 4 substituents         independently selected from R²³;     -   3) two R¹³, together with two adjacent ring-forming atoms of the         aryl or heteroaryl in Cy^(B) to which they are attached         respectively, form a C₅₋₁₀ aliphatic cyclyl or 5-10 membered         aliphatic heterocyclyl, unsubstituted or optionally substituted         with 1, 2 or 3 substituents independently selected from R²³;         wherein said 5-10 membered aliphatic heterocyclyl contains 1 or         2 ring-forming heteroatoms independently selected from N, O and         S;     -   R^(a3), R^(b3) and R^(e3) are each independently selected from:     -   1) hydrogen;     -   2) C₁₋₄ alkyl, phenyl, 5-6 membered heteroaryl, C₃₋₆ cycloalkyl         and 3-6 membered aliphatic heterocyclyl, unsubstituted or         optionally substituted with 1, 2 or 3 substituents independently         selected from R²³;     -   or,     -   R^(a3) and R^(b3) together with the same N atom to which they         are attached form a 3-8 membered aliphatic heterocyclyl,         unsubstituted or optionally substituted with 1, 2 or 3         substituents independently selected from R²³; wherein 3-8         membered aliphatic heterocyclyl contains one or two ring-forming         heteroatoms, for example, contains only said N atom, or contains         said N atom and another heteroatom independently selected from         N, O and S;     -   R^(c3) is selected from C₁₋₄ alkyl, C₂₋₃ alkenyl, phenyl, 5-6         membered heteroaryl, C₃₋₆ cycloalkyl and 3-6 membered aliphatic         heterocyclyl, unsubstituted or optionally substituted with 1, 2         or 3 substituents independently selected from R²³;     -   R^(d3) is selected from hydrogen, C₁₋₄ alkyl, C₃₋₆ cycloalkyl,         3-6 membered aliphatic heterocyclyl, cyano, nitro and         —S(═O)₂R^(G);     -   R²³ is selected from:     -   1) oxo, halogen, cyano, carboxyl, —C(═O)R^(a5),         —C(═O)NR^(a5)R^(b5), C(═NR^(d5))NR^(a5)R^(b5), —OR^(a5),         —S(═O)R^(c5), —S(═O)₂R^(c5), —S(═O)₂NR^(a5)R^(b5),         —S(═O)(═NR^(d5))R⁵, —NR^(a5)R^(b5)V, —NR^(a5)C(═O)R^(b5),         —NR^(e5)C(═O)NR^(a5)R^(b5), —NR^(e5)C(═NR^(d5))NR^(a5)R^(b5),         —NR^(a5)S(═O)₂R^(c5), NR^(e5)S(═O)₂NR^(a5)R^(b5) and imino group         (═N—R^(d5));     -   2) C₁₋₅ alkyl, C₁₋₅ alkylene, phenyl, 5-6 membered heteroaryl,         C₃₋₇ cycloalkyl and 3-7 membered aliphatic heterocyclyl,         unsubstituted or optionally substituted with 1, 2 or 3         substituents independently selected from R³³;     -   R^(a5), R^(b5) and R^(c5) are each independently selected from:     -   1) hydrogen;     -   2) C₁₋₄ alkyl, C₃₋₆ monocyclic cycloalkyl and 3-6 membered         aliphatic monocyclic heterocyclyl, unsubstituted or optionally         substituted with 1, 2 or 3 substituents independently selected         from R³³;     -   or,     -   R^(a5) and R^(b5) together with the same N atom to which they         are attached form a 3-6 membered aliphatic monocyclic         heterocyclyl or 6-7 membered bicyclic aliphatic heterocyclyl,         unsubstituted or optionally substituted with 1, 2 or 3         substituents independently selected from R³³; wherein 3-6         membered aliphatic monocyclic heterocyclyl and 6-7 membered         bicyclic aliphatic heterocyclyl contains one or two ring-forming         heteroatoms, for example, contains only said N atom, or contains         said N atom and another heteroatom independently selected from         N, O and S;     -   R^(c5) is selected from C₁₋₄ alkyl, C₂₋₃ alkenyl, C₃₋₆         monocyclic cycloalkyl and 3-6 membered aliphatic monocyclic         heterocyclyl, unsubstituted or optionally substituted with 1, 2         or 3 substituents independently selected from R³³;     -   R^(d5) is selected from hydrogen, C₁₋₄ alkyl, C₃₋₆ monocyclic         cycloalkyl, 3-6 membered aliphatic monocyclic heterocyclyl,         cyano, nitro and —S(═O)₂R^(GA);     -   R³³ is selected from oxo, halogen, cyano, hydroxyl, —OR^(GA),         amino, —NHR^(GA) and —N(R^(GA))₂;     -   Each R^(GA) are each independently selected from:     -   C₁₋₄ alkyl, C₁₋₄ alkylene, C₃₋₆ cycloalkyl and 4-6 membered         aliphatic heterocyclyl, unsubstituted or optionally substituted         with 1, 2 or 3 fluorine atoms; or,     -   two R^(GA) together with the same N atom to which they are         attached form a 4-6 membered aliphatic monocyclic heterocyclyl,         unsubstituted or optionally substituted with 1, 2 or 3 fluorine         atoms; wherein 4-6 membered aliphatic monocyclic heterocyclyl         contains one or two ring-forming heteroatoms, for example,         contains only said N atom, or contains said N atom and another         heteroatom independently selected from N, O and S.

In some embodiments, the application provides a pharmaceutical composition including the compound of formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, active metabolite, polymorph, isotope labeled compound, isomer or prodrug thereof and a pharmaceutically acceptable carrier.

The pharmaceutical combination may be prepared in a manner well known in the pharmaceutical field, and may be administered by various routes. The mode of administration may be topical (including transdermal, epidermal, ocular and mucosal, including intranasal, vaginal, and rectal delivery), pulmonary (e.g., by inhalation or insufflation of powders or aerosols, including by nebulizer; intratracheal or intranasal), oral or parenteral.

In some embodiments, the composition is suitable for parenteral administration, including intravenous, intraarterial, subcutaneous, intraperitoneal, intramuscular or infusion; or intracranial, such as intrathecal or intraventricular administration. Parenteral administration may be in the form of a single bolus dose, or (e.g.) continuous perfusion pump.

In some embodiments, the composition is suitable for topical administration, which. may include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous, powdered or oily matrices, thickeners and the like may be necessary or desired.

In some embodiments, the application provides use of the compound of formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, active metabolite, polymorph, isotope labeled compound, isomer or prodrug thereof, or a pharmaceutical composition thereof, for the prevention or treatment of a disease mediated with HIPK1.

In some embodiments, the application provides a method for regulating, for example, inhibiting, the activity of HIPK1, including administering the compound of formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, active metabolite, polymorph, isotope labeled compound, isomer or prodrug thereof, or a pharmaceutical composition thereof to a patient, in order to stimulate and/or boost immunity to cancers or viral diseases.

In some embodiments, the application provides a method for preventing, ameliorating or treating a disease mediated with HPK1 in a patient, including administering therapeutically effective amount of the compound of formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, active metabolite, polymorph, isotope labeled compound, isomer or prodrug thereof, or a pharmaceutical composition thereof to the patient.

In some embodiments, the application provides use of the compound of formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, active metabolite, polymorph, isotope labeled compound, isomer or prodrug thereof, or a pharmaceutical composition thereof, for the treatment or amelioration of benign or malignant tumors, myelodysplastic syndromes and diseases caused by viruses.

In some embodiments, the application provides use of the compound of formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, active metabolite, polymorph, isotope labeled compound, isomer or prodrug thereof, or a pharmaceutical composition thereof, for the treatment or amelioration of benign or malignant tumors.

In some embodiments, the application provides use of the compound of formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, active metabolite, polymorph, isotope labeled compound, isomer or prodrug thereof, or a pharmaceutical composition thereof, for the treatment or amelioration of diseases caused by viruses.

In some embodiments, the application provides use of the compound of formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, active metabolite, polymorph, isotope labeled compound, isomer or prodrug thereof, or a pharmaceutical composition thereof, in the preparation of a medicament for the treatment or amelioration of one or more particular diseases selected from benign or malignant tumors, myelodysplastic syndromes and diseases caused by viruses.

In some embodiments, the application provides use of the compound of formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, active metabolite, polymorph, isotope labeled compound, isomer or prodrug thereof, or a pharmaceutical composition thereof, in the preparation of a medicament for the treatment or amelioration of benign or malignant tumors.

In some embodiments, the application provides use of the compound of formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, active metabolite, polymorph, isotope labeled compound, isomer or prodrug thereof, or a pharmaceutical composition thereof, in the preparation of a medicament for the treatment or amelioration of diseased caused by viruses.

In some embodiments, the malignant tumors include one or more of leukemia, lymphoma, multiple myeloma, lung cancer, hepatocellular carcinoma, cholangiocarcinoma, gallbladder cancer, gastric cancer, colorectal cancer, intestinal leiomyosarcoma, breast cancer, ovarian cancer, cervical cancer, endometrial cancer, vaginal cancer, malignant teratoma, pancreatic cancer, pancreatic ductal adenocarcinoma, nasopharyngeal cancer, oral cancer, laryngeal cancer, esophageal squamous cell carcinoma, thyroid cancer, kidney cancer, bladder cancer, malignant brain tumor, rhabdomyosarcoma, osteosarcoma, chondrosarcoma, osteofibrosarcoma, malignant thymoma, malignant peripheral nerve sheath tumor, prostate cancer, testicular cancer, penile cancer and other malignant tumors, as well as benign and malignant tumors of the skin (including but not limited to melanoma, basal cell carcinoma, squamous cell carcinoma).

In some embodiments, the tumor is a tumor producing PGE2 (e.g., COX-2 overexpressed tumor) and/or an adenosine-producing tumor (e.g., CD39 and CD73 overexpressed tumor), such as colorectal cancer, breast cancer, pancreatic cancer, lung cancer and ovarian cancer.

In some embodiments, the virus includes one or more of hepatitis virus, human immunodeficiency virus, human papillomavirus, herpes simplex virus, measles virus, norovirus, Boca virus, Coxsackie virus, Ebola virus, enterovirus, lymphocytic meningitis virus, influenza virus, SARS virus and novel coronavirus.

Definition of Terms

In this disclosure, unless otherwise specified, a definition of a certain group applies to all groups containing this group. For example, the definition of alkyl is applicable to C1-C6 alkyl, C1-C3 alkyl, etc.; the definition of C1-C6 alkyl is applicable to “C1-C6 alkoxy”, etc., and the following definitions are applicable to the claims and the description.

When a structure contains multiple substituents represented by the same symbol, the substituents may be the same or different; For example, the Cy^(B) contains two R¹³ as substituents, wherein the two R¹³ may be both methoxy, or one may be methoxy, and the other may be methyl.

The term “halogen” includes fluorine, chlorine, bromine, and iodine.

The term “C_(m-n)” (where m and n is an integer, and indicates the range that includes the end point) represents corresponding groups containing m-n carbon atoms, for example, C₁₋₆ alkyl represents an alkyl containing 1-6 carbon atoms, and C₂₋₆ alkenyl represents an alkenyl containing 2-6 carbon atoms.

The term “n membered” (where n is an integer) usually describes the number of ring-forming atoms, where the number of ring-forming atoms is n. “m-n membered” indicates the range that includes the end point, representing that the corresponding ring structure contains m-n ring-forming atoms. For example, piperidinyl is an example of a 6-membered heterocyclyl, and pyrazolyl is an example of a 5-membered heteroaryl.

The term “substituted” refers to a hydrogen of a structure is displaced by a “substituent”. Unless otherwise indicated, the term “substituted” means any degree of substitution as long as said substitution is permitted. The choice of substituents is independent and the substitution may be in any chemically accessible position. It should be understood that substitution on a given atom is limited by chemical valence. It should be understood that substitution on a given atom produces chemically stable molecules. One divalent substituent (e.g., oxo) will displace two hydrogen atoms.

“The rest of the compound” refers to the portion of the whole molecular structure except for the “substituent” described. The rest of the compound is connected to the substituent by one or more unsaturated valences. The rest of the compound may contain one or more “junctions”, and two or more junctions may be on the same atom or different atoms.

The term “alkyl” refers to a straight-chain or branched-chain saturated hydrocarbon group. Alkyl is a group formed by the loss of a hydrogen of an alkane. The examples of alkyl include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, 2-methylbutyl, neopentyl, 1-ethylpropyl, n-hexyl, 1,2,2-trimethylpropyl and the like.

The term “alkenyl” refers to a straight or branched chain hydrocarbon group having one or more carbon-carbon double bonds. Alkenyl are a group formed by the loss of a hydrogen atom in an olefin. The examples of the alkenyl may be vinyl, 1-propenyl, 2-propenyl, allyl, 1-butenyl, 2-butenyl, (E)-but-2-ene-1-yl, (Z)-but-2-ene-1-yl, 2-methyl-propy-1-ene-1-yl, 1,3-butadiene-1-yl, 1,3-butadiene-2-yl and the like.

The term “alkynyl” refers to a straight or branched chain hydrocarbon group having one or more carbon-carbon triple bonds. Alkynyl is a group formed by the loss of one hydrogen atom from an alkyne. Examples of alkynyl may be ethynyl, 1-propynyl, propargyl, 1-butynyl, but-2-yn-1-yl, but-3-yn-1-yl, but-3-ene-1-alkynyl, 3-methylpent-2-ene-4-yn-1-yl and the like.

The term “alkylene” refers to a divalent group formed by losing two hydrogen atoms on the carbon atom of an alkane at the same time, wherein the two valences may be connected to the same atom, or connected to two atoms respectively. For example, methylene (—CH₂— or ═CH₂), 1,1-ethylene (—CH(CH₃)— or ═CH—CH₃), 1,2-ethylene (—CH₂CH₂—), but-1,4-diyl, but-1,3-diyl, 2,2-dimethyl-prop-1,3-diyl, etc.

The term “alkoxy” refers to a group with formula “—O-alkyl”, wherein the alkyl group is as defined above. Alkoxy may be, for example, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, tert-butoxy and n-hexoxy and the like.

The term “alkylthio” refers to a group of formula “—S-alkyl”, wherein the alkyl group is as defined above. “alkylthio” may be, for example, methylthio, ethylthio, n-propylthio, isopropylthio, n-butylthio, tert-butylthio and n-hexylthio and the like.

The term “alkylamino” includes a group of formula “—NH-alkyl” and a group of formula “—N-(alkyl)₂”, wherein the alkyl group is as defined above. The group of formula “—NH-alkyl” may be, for example, methylamino, ethylamino, isopropylamino and n-hexylamino and the like; The group of formula “—N-(alkyl)₂” may be, for example, dimethylamino, diethylamino, methylethylamino, methylisopropylamino and ethyl-n-hexylamino and the like.

The term “alkyl sulfinyl” refers to a group of formula “—S(═O)-alkyl”, wherein the alkyl group is as defined above. For example, it may be methyl sulfinyl, ethyl sulfinyl, isopropyl sulfinyl and the like.

The term “alkyl sulfonyl” refers to a group of formula “—S(═O)₂-alkyl”, wherein the alkyl group is as defined above. For example, it may be methyl sulfonyl, ethyl sulfoyl, isopropyl sulfonyl and the like.

The term “alkylaminosulfinyl” comprises a group of formula “—S(═O)—NH-alkyl” and a group of formula “—S(═O)—N(alkyl)₂”, wherein the alkyl group is as defined above. The group of formula “—S(═O)—NH-alkyl” may be, for example, methylaminosulfinyl, ethylaminosulfinyl, isopropylaminosulfinyl, tert-butylaminosulfinyl and the like. The group of formula “—S(═O)—N(alkyl)₂” may be, for example, dimethylaminosulfinyl, diethylaminosulfinyl, methylethylaminosulfinyl, ethyl isobutylaminosulfinyl and the like.

The term “alkylaminosulfonyl” comprises a group of formula “—S(═O)₂—NH-alkyl” and a group of formula “—S(═O)₂—N(alkyl)₂”, wherein the alkyl group is as defined above. The group of formula “—S(═O)₂—NH-alkyl” may be, for example, methylaminosulfonyl, ethylaminosulfonyl, isopropylaminosulfonyl, tert-butylaminosulfonyl, etc. The group of formula “—S(═O)₂—N(alkyl)₂” may be, for example, dimethylaminosulfonyl, diethylaminosulfonyl, methyl isopropylaminosulfonyl, ethyl tert-butylaminosulfonyl and the like.

The term “carbonyl” refers to a group of formula “—(C═O)—”, which may also be represented by “—C(O)—”.

The term “cyano” refers to a group of formula “—C≡N”, which may also be represented by “—CN”.

The term “hydroxymethyl” refers to a group of formula “—CH₂OH”.

The term “oxo” refers to an oxygen atom as a divalent substituent, when connected to a carbon atom to form a carbonyl group, or to the heteroatom to form a sulfinyl or sulfonyl, or N-oxide group and the like. In some embodiments, cycloalkyl and heterocyclyl may optionally be substituted by one or two oxo groups.

The term “imino group” or “═N—R”, refers to an amino group as a divalent substituent, wherein two valents of the same nitrogen atom are connected to one atom selected from the rest of the compound to form a double bond, and the third valence of the nitrogen atom is connected to the R group defined by the context. The nitrogen atom may form imide, amidine or guanidine when connected to a carbon atom, or forms a sulfinyl imide or the like when connected to a heteroatom.

The term “cyclyl” includes aliphatic and aromatic monocyclyl or polycyclyl. The aliphatic monocyclyl contains a cyclyl, including cyclized alkyl and alkenyl. Aliphatic polycyclyl contains two or more cyclyls wherein at least one cyclyl is an aliphatic monocyclyl (including cyclized alkyl and alkenyl), the other cyclyls may be aliphatic and/or aromatic cyclyls. In aliphatic polycyclyl, any one of the rings is connected to at least one another ring to form a spiro ring (two rings share a ring-forming atom) or a bridged ring (two rings share two or more ring-forming atoms). The polycyclyl is connected to the rest of the compound by a ring carbon atom. It may be, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopentenyl, cyclohexadienyl, dicyclo[3.1.0]hexyl, norbornyl, norpinanyl, dicyclo[1.1.1] pentyl, 1H-inden-1-yl, 2,3-dihydro-1H-inden-2-yl and the like. When a cyclyl only contains saturated rings, the cyclyl is a saturated cyclyl, also named as the “cycloalkyl”.

The term “cycloalkoxy” refers to a group of formula “—O-cycloalkyl”, wherein the cycloalkyl is as defined above. It may be, for example, cyclopropoxy.

The cyclyl includes a “cyclylene”, i.e., the cyclyl is connected by two chemical valences to two connection points of the rest of the compound, and the two chemical valences described may be on the same carbon atom of the cyclylene, or may be on two different carbon atoms of the cyclylene. The two connection points may be located on the same atom of the rest of the compound, or located on two different atoms of the rest of the compound. For example, it may be 1,1-cyclobutylene, 1,3-cyclobutylene, and the like.

The term “aryl” refers to an aromatic monocyclyl or polycyclyl. For example, it may be phenyl, naphthyl, and the like.

The term “heterocyclyl” refers to a monocyclylic or polycyclic group having at least one ring-forming heteroatom selected from oxygen, nitrogen, sulfur and phosphorus. The poly-heterocyclyl contains two or more rings, wherein at least one ring has at least one ring-forming heteroatom selected from oxygen, nitrogen, sulfur and phosphorus, and the other ring may have ring-forming heteroatoms or not. In poly-heterocyclyl, any one of the rings is connected to at least one other ring to form a spiro ring (two rings share a ring-forming atom) or a bridged ring (two rings share two or more ring-forming atoms). The heterocyclyl may be connected to the rest of the compound by an optional ring-forming carbon atom, or by an optional ring-forming heteroatom. In some embodiments, any of the ring carbon atoms in the heterocyclyl may be substituted by an oxo group to form a carbonyl group. In some embodiments, any ring nitrogen atom in the heterocyclyl may be N-oxide. In some embodiments, any ring nitrogen atom in the heterocyclyl may be quaternary ammonium ion.

Heterocyclyl includes aromatic heterocyclyl (i.e., “heteroaryl”) and aliphatic heterocyclyl.

The term “heteroaryl” refers to an aromatic monoheterocyclyl or polyheterocyclyl having at least one ring-forming heteroatom selected from oxygen, nitrogen and sulfur. The heteroaryl group may be connected to the rest of the compound by an optional carbon atom, or by an optional heteroatom, provided that the chemical valence of the carbon atom or heteroatom allows. In some embodiments, any of the ring-forming carbon atoms in the heteroaryl may be substituted by an oxo group to form a carbonyl group. In some embodiments, any ring-forming nitrogen atom in the heteroaryl may be N-oxide. In some embodiments, any ring nitrogen atom in the heteroaryl may be quaternary ammonium ion. For example, the heteroaryl may be pyrrolyl (including pyrrol-1-yl, pyrrol-2-yl and pyrrol-3-yl), pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, tetrazolyl, pyridyl, pyridin-2(1H)-one-1-yl, pyridin-4(1H)-one-1-yl, pyrazinyl, pyrimidinyl, pyridazinyl, pyrazin-3(2H)-one-2-yl, 1,2,4-triazinyl, 1,3,5-triazinyl, indolyl, benzofuranyl, benzothienyl, indazolyl, benzoimidazolyl, benzisothiazolyl, quinolinyl, isoquinolinyl, naphthyridinyl, imidazo[1,2-b]thiazolyl, purinyl, etc..

The term “aliphatic heterocyclyl” includes monocyclic or polycyclic aliphatic heterocyclyl. The monocyclic aliphatic heterocyclyl (aliphatic monoheterocyclyl) may not contain double bond or contain one or more double bonds in the rings. The polycyclic aliphatic heterocyclyl (aliphatic polyheterocyclyl) contains at least one alicycle, and other rings may be aliphatic or aromatic rings. The polycyclic aliphatic heterocyclyl may not contain a double bond or contain one or more double bonds in the rings. For example, it may be azetidinyl, oxetanyl, tetrahydropyrrolyl, tetrahydrofuranyl, 2-oxo-oxazolidinyl, piperidinyl, 3-oxo-piperidinyl, piperazinyl, morpholinyl, azepanyl, 2-oxa-6-azaspiro[3.3]heptyl, 1,2,3,4-tetrahydroquinolinyl, etc.

The term “heterocyclyl” includes a heterocyclylene, i.e., a heterocyclyl is connected to two points of attachment to the rest of the compound through two valences, and the two valences may be in the same ring-forming atom of the heterocyclylene. It may also be located on the two ring-forming atoms of the heterocyclylene group. The two connection points may be located on the same atom in the rest of the compound, or may be located on two atoms in the rest of the compound. For example, 1,1-(3-oxetanylene), 1,3-(2-azacyclopentylene), and the like.

The term “fused rings” refers to a bridged ring system formed by two rings sharing two adjacent ring-forming atoms. The two rings may be saturated alicyclic, unsaturated alicyclic or aromatic rings. The two adjacent ring-forming atoms are optionally carbon atoms or heteroatoms.

The term “n-membered oxaalkylene” refers to a divalent group formed by replacing one or more carbon atoms in the main chain of an n-membered alkylene with oxygen atom(s). The two valences as described may be on the same atom of the rest of the compound, or may be on two atoms of the rest of the compound. For example, 2-oxa-1,3-propylene (—CH2OCH2-) is an example of 3-membered oxaalkylene. 2-oxa-1,4-butylene (—CH2OCH2CH2-) is an example of a 4-membered oxaalkylene and the like. An alkylene group in which only branched-chain carbon atom(s) is replaced by oxygen atom(s) should not be considered “oxaalkylene”; for example, in 2-methyl-1,3-propylene, when the branched-chain methyl is replaced by oxygen, and the resulted group (—CH2CH(OH)CH2-) should be regarded as 2-hydroxy substituted 1,3-propylene.

The term “n-membered azaalkylene” refers to a divalent group formed by replacing one or more carbon atoms in the main chain of an n-membered alkylene with nitrogen atom(s), and the two valences described may be on the same atom of the rest of the compound, or on two separate atoms of the rest of the compound. For example, 2-aza-1,3-propylene (—CH2NHCH2-) is an example of 3-membered azaalkylene, and aza-1,2-ethylene (—CH2NH—) is an example of a 2-membered azaalkylene, and the like. An alkylene group in which only branched-chain carbon atom(s) is substituted with nitrogen atom(s) should not be considered “azaalkylene”; for example, in 2-methyl-1,3-propylene, when the branched-chain methyl is replaced by nitrogen, and the resulted group (—CH2CH(NH2)CH2-) should be regarded as 2-amino substituted 1,3-propylene.

The term “isomer” refers to isomers that result from different spatial arrangements of atoms in a molecule. “Stereoisomers” of the compounds described herein refers to all stereoisomers. For example, when the compound has asymmetric carbon atoms, enantiomers and diastereomers are produced; when the compound has carbon-carbon double bonds, carbon-nitrogen double bonds, or ring structures, cis- or trans-isomers are produced. Unless otherwise indicated, the compounds described herein include all isomers thereof, such as optical isomers, geometric isomers, rotational isomers, tautomers, stably existing conformational isomers, and the like; and the compounds may exist as a mixture of isomers or as isolated isomers.

Methods for preparing optically active products from optically inactive starting materials are known in the art, e.g., by resolution of racemic mixtures or by stereoselective synthesis.

Resolution of racemic mixtures of compounds may be carried out by any of a number of methods known in the art. One method involves fractional recrystallization using a chiral resolving acid that is an optically active salt-forming organic acid. Suitable resolving agents for fractional recrystallization may be optically active acids such as D-tartaric acid, L-tartaric acid, diacetyltartaric acid, dibenzoyltartaric acid, mandelic acid, malic acid, camphorsulfonic acid, etc.

Other suitable resolving agents for fractional recrystallization include, for example, α-methylbenzylamine, 2-phenylglycinol, cyclohexylethylamine and the like in stereoisomerically pure form.

Methods for resolution of racemic mixtures also include, for example, the separation of diastereomers obtained by reaction with appropriate optically active species such as chiral alcohols or Mosher's acid chlorides, and then conversion (such as hydrolysis) to the corresponding single optical isomer. For example, it may be performed by elution on a chromatographic column packed with an optically active resolving agent. Suitable chromatographic column and elution solvents may be determined by those skilled in the art.

The term “isotope labeled compounds” refers to a compound of the present application in which one or more atoms are replaced by a particular isotopic atom thereof. For example, the isotopic atom in the compound of the present application may include various isotopes of elements H, C, N, O, F, P, S, Cl and I, such as ²H, ³H, ¹³C, ¹⁴C, ¹⁵N, ¹⁷O, ¹⁸O; ¹⁸F, ³⁰P, ³²P, ³⁵S, ³⁶, ¹²³I, ¹²⁴I and ¹²⁵I, etc. This application includes various isotope labeled compounds as defined. For example, they may be those compounds in which radioactive isotopes such as ³H and ¹⁴C are present, or those in which non-radioactive isotopes such as ²H and ¹³C are present. Such isotope labeled compounds are suitable for metabolic studies (using ¹⁴C), reaction kinetic studies (using e.g, ²H or ³H), detection or imaging techniques such as positron emission tomography (PET) or single photon emission computed tomography (SPECT), including drug or substrate tissue distribution analysis; or radiotherapy for patients, etc.

In particular, ¹⁸F compounds may be particularly desirable for PET or SPECT studies. Isotope labeled compounds of formula (I) may generally be prepared by conventional techniques known to those skilled in the art or by methods analogous to those described in the accompanying examples and preparations using an appropriate isotope labeled reagent in place of the unlabeled reagents.

Furthermore, substitution with heavier isotopes, especially deuterium (i.e, ²H or D), may yield certain therapeutic advantages resulting from greater metabolic stability, such as increased in vivo half-life or reduced dose requirements or improved therapeutic index, and thus in some cases it may be preferred.

The term “pharmaceutically acceptable” refers to those compounds, materials, compositions and/or dosage forms, which are within the scope of sound medical judgment, suitable for use in contact with human and animal tissue without excessive of toxicity, irritation, allergic reactions or other problems or complications commensurate with a reasonable benefit/risk ratio.

The term “a pharmaceutically acceptable salt” refers to a salt that retains the biological activity and properties of the compounds of the present application and generally have no biologically or otherwise undesirable effects. In many cases, the compounds of the present application are capable of forming acid and/or base addition salts via the presence of amino and/or carboxyl groups or the like.

The term “pharmaceutically acceptable acid addition salts” may be formed with inorganic and organic acids.

The term “pharmaceutically acceptable base addition salts” may be formed with inorganic and organic bases.

All compounds and pharmaceutically acceptable salts thereof may be found (e.g., hydrates and solvates) with other substances (e.g., solvents, including water and other solvents, etc.) or may be isolated. When in the solid state, the compounds described herein and salts thereof may exist in various forms, including hydrates and solvates. Hydrates and solvates of compounds and salts thereof described herein include those in which water and solvents may be isotopically labeled, such as D₂O, methanol-d₃, methanol-d₄, acetone-d₆, DMSO-d₆. The presence of hydrates and solvates may be identified by those skilled in the art using means such as nuclear magnetic resonance (NMR).

The term “polymorph” refers to compounds of the present application that exist in different crystal lattice forms, as well as in amorphous form. Polymorphs of the compounds of the present application and salts thereof also include mixtures of various lattice forms, as well as mixtures of one or several lattice forms and amorphous form. The presence of polymorphs may be identified by those skilled in the art using means such as X-ray diffraction.

Therefore, unless expressly stated otherwise, references to compounds and salts thereof in this specification are to be understood to encompass any solid state form of the compounds.

The term “active metabolite” refers to an active derivative of a compound that is formed when the compound is metabolized.

The term “a pharmaceutically acceptable prodrug” refers to any pharmaceutically acceptable ester, salt of the ester, amide or other derivative of the compound of the present application, which, upon administration to a subject, is capable of directly or indirectly providing the compound of the present application or its pharmacologically active metabolites or residues. Particularly preferred derivatives or prodrugs are those that increase the bioavailability of the compound of the present application when administered to a patient (e.g., make orally administered compounds more readily absorbed into the blood), or promote the delivery of the compound to biological organs or the site of action.

The term “a pharmaceutical composition” refers to a biologically active compound optionally in admixture with at least one pharmaceutically acceptable chemical component or agent, which is a “carrier” that facilitates for introducing the active compound into cells or tissues, include but are not limited to stabilizers, diluents, suspending agents, thickening agents and/or excipients. The pharmaceutical composition includes, but are not limited to, the following forms: tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (solid or dissolved in liquid vehicles), ointments, soft and hard gelatin capsules, suppositories, transdermal patches, sterile injectable solutions and sterile packaged powders, etc.

The term “pharmaceutically acceptable carriers” includes solvents, dispersion media, coatings, surfactants, antioxidants, preservatives (e.g., antibacterial, antifungal), isotonic agents, absorption delaying agents, salts, preservatives, pharmaceutical stabilizers, binders, excipients, disintegrants, lubricants, sweeteners, flavoring agents, dyes, and the like, well known to those skilled in the art, and combinations thereof. Unless being incompatible with the active compound, any conventional carrier is included in the therapeutic or pharmaceutical compositions.

The term “therapeutically effective amount” refers to the amount of the compound of the present application that induces a biological or medical response in a subject, such as reducing or inhibiting activity of enzyme or protein or ameliorating symptoms, alleviating a condition, slowing or delaying disease progression, or preventing disease, etc.

The term “subject” or “patient” refers to an individual, including mammals and non-mammals, suffering from a disease, disorder, condition, or the like. Examples of mammal include, but are not limited to, any member of the class mammalia: humans; non-human primates (e.g., chimpanzees and other apes and monkeys); livestock, such as cattle, horses, sheep, goats, pigs; other domesticated animals, such as rabbits, dogs, and cats; laboratory animals, including rodents, such as rats, mice, and guinea pigs, and the like. Examples of non-mammals include, but are not limited to, birds, fish, and the like.

Synthesis

The compounds of the present application and their salts may be prepared using known organic synthesis techniques and may be prepared according to any of some synthetic routes such as those in the schemes below.

The reactions used to prepare the compounds of the present application may be carried out in suitable solvents. Suitable solvents may be substantially unreactive with the starting materials (reactants), intermediates or products at temperatures at which the reaction is carried out (e.g., temperatures that may range from the melting point to the boiling point of the solvent). A given reaction may be carried out in one solvent or a mixture of solvents. Depending on a particular reaction step, one skilled in the art may select an appropriate solvent for a particular reaction step.

The preparation of the compounds of the present application may involve the protection and deprotection of various chemical groups. The need for protection and deprotection and the selection of appropriate protecting groups may be readily determined by those skilled in the art.

The following schemes provide general guidance related to the preparation of the compounds of the present application. Those skilled in the art will appreciate that general knowledge of organic chemistry may be used to modify or optimize the methods shown in the schemes to prepare the various compounds of the present application.

Compounds of formula (I) may be prepared according to the methods as illustrated in the schemes below.

Various compounds of formula (I) may be prepared using the methods illustrated in Scheme 1. In the method shown in Scheme 1, the compound of formula 1-1 is transformed by diazotization and coupling reaction to the compound of formula 1-2. The compound of formula 1-2 is converted to the compound of formula 1-3 by ring closure reactions such as thermal ring closure, as well as acid or base catalyzed ring closure reactions. The compound of formula 1-3 is amidated to form the compound of formula 1-4. The compound of formula 1-4 is chlorinated and dehydrated (e.g., chlorination and dehydration in the presence of phosphorus oxychloride) to form the compound of formula 1-5. The compound of formula 1-5 is converted to the compound of formula 1-6 by condensation and ring-closing with hydrazine (or hydrazine hydrate). The compound of formula 1-6 undergoes Sandmeyer or similar reactions to form the halogenated (e.g., chloro, bromo, or iodo) compound of formula 1-7. The NH group of the pyrazolyl of formula 1-7 is protected by a suitable protecting group to form the compound of formula 1-8. The compound of formula 1-8 is then transformed by various cross-coupling reactions (e.g., Suzuki reaction, Stille reaction, etc.) to the compound of formula 1-9. Finally, the compound of formula (I) is generated by deprotection. By selection of suitable catalyst (e.g. SPhos-Pd-G2), the compound of formula 1-7 may directly undergo various cross-coupling reactions (e.g. Suzuki reaction, Stille reaction, etc.) and subsequent reactions (such as reductive amination, carboxylic acid-amine condensation, etc.) to form the desired compound of formula (I).

Alternatively, the compounds of formula (I) may be prepared using the methods illustrated in Scheme 2. In the method shown in Scheme 2, firstly, the compound of formula 1-1 is transformed to the compound of formula 1-3 by the same method as shown in Scheme 1. The compound of formula 1-3 is then chlorinated to form the compound of formula 2-4. The compound of formula 2-4 is condensed with excessive hydrazine (or hydrazine hydrate) to form the compound of formula 2-5A; or the compound of formula 2-4 is condensed with one equivalent of hydrazine (or hydrazine hydrate) to form the compound of formula 2-5B. The compound of formula 2-5A or 2-5B may undergo ring closure reactions (e.g., thermal ring closure, and acid- or base-catalyzed ring closure reactions) to form the compound of formula 2-6. The compound of formula 2-6 is halogenated (e.g., chloro, bromo, etc.) to form the compound of formula 1-7. The compound of formula 1-7 may be transformed in a manner as shown in Scheme 1 to form the desired compound of formula (I). Scheme 2 is subdivided into Scheme 2A and Scheme 2B according to different intermediates of formula 2-5A or formula 2-5B.

Alternatively, the compounds of formula (I) may be prepared using the method illustrated in Scheme 3A. In the method shown in Scheme 3A, the carboxylic acid derivative compound of formula 3-1a (wherein X is a halogen or a halogen-like group, such as bromine, iodine, etc.; L1 is an aromatic or heteroaromatic ring; LG is a leaving group such as halogen, alkoxy, —N(Me)OMe, etc.) is converted to the compound of formula 3-2a by condensation. The compound of formula 1-1 is diazotizated and coupled with the compound of formula 3-2a to form the compound of formula 3-3. The compound of formula 3-3 is transformed to the compound of formula 3-4 by ring closure reaction. The compound of formula 3-4 is condensed with hydrazine (or hydrazine hydrate) to form the compound of formula 3-5A. The NH group of pyrazolyl in the compound of formula 3-5A is protected with an appropriate protecting group to form the compound of formula 3-6. The compound of formula 3-6 undergoes various cross-coupling reactions (e.g., Suzuki reaction, Stille reaction, Buchwald-Hartwig amination, etc.) to form the compound of formula 1-9. Finally, the compound of formula (I) is formed by deprotection of compound 1-9. By selection of suitable catalyst, the compound of formula 3-5A can then be converted to the desired compound of formula (I) through various cross-coupling reactions (e.g. Suzuki reaction, Stille reaction, Buchwald-Hartwig amination, ect.).

Alternatively, the compound of formula (I) may be prepared by the method illustrated in Scheme 3B. The compound of formula 3-4 is condensed with a substituted hydrazine to form the compound of formula 3-5B. The compound of formula 3-5B undergoes various cross-coupling reactions (e.g. Suzuki reaction, Stille reaction, Buchwald-Hartwig amination, etc.) to form the compound of formula 1-9B. Finally, the compound of formula (I) is formed by deprotection of the compound 1-9B.

Alternatively, the compound of formula (I) may be prepared using the method illustrated in Scheme 4. In the method shown in Scheme 4, the carboxylic acid derivative compound of formula 3-1a (wherein X is a halogen or a halogen-like group, such as bromine, iodine, etc.; L1 is an aromatic or heteroaromatic ring; LG is a leaving group such as halogen, alkoxy, —N(Me)OMe, etc.) is converted to the compound of formula 4-3 by condensation; or the aldehyde compound of formula 4-1 is converted to the compound of formula 4-3 by addition reaction and then oxidation (such as using Dess-Martin periodinane). The compound of formula 1-1 is diazotized and then coupled with the compound of formula 4-3 to form the compound of formula 4-4. The compound of formula 4-4 is subjected to ring closure reaction to generate the compound of formula 3-4. The compound of formula 3-4 can then be converted to the desired compound of formula (I) in a manner as shown in Schemes 3A or 3B.

All methods described in this specification may be performed in any suitable order unless otherwise indicated or clearly contradicted by context. All examples or exemplary language (e.g., “such as”) provided in this specification are used only to better clarify the invention, and are not intended to limit the scope of the application as otherwise claimed.

Hereinafter, the preparation and properties of the compounds of formula (I) in some embodiments will be further described with reference to specific examples. Among them, the starting materials used are known and commercially available, or may be synthesized using or according to methods known in the art.

Unless otherwise specified, all reactions in the examples were carried out under continuous magnetic stirring, and the reaction temperature was in degrees Celsius.

The reactions may be monitored according to any suitable method known in the art, such as nuclear magnetic resonance spectroscopy (NMR), infrared spectroscopy (IR), spectrophotometry (e.g., UV-Vis spectroscopy), liquid mass spectrometry (LC-MS), mass spectrometry, high performance liquid chromatography, thin layer chromatography and so on. The products may be purified by any suitable method known in the art, such as column chromatography (normal or reverse phase), preparative thin layer chromatography, trituration, recrystallization, and the like.

Generally, 100-200 mesh silica gel from Qingdao Haiyang Chemical Co., Ltd. is used as carrier (stationary phase) in normal phase column chromatography. Silica gel 60 F254 silica gel plate from Merck Ltd. is used in thin layer chromatography (TLC), and GF254 preparative silica gel plate from Anhui Liangchen Silicon Material Co., Ltd. is used in preparative thin layer chromatography (pre-TLC).

The structures of the compounds in the examples were determined by nuclear magnetic resonance spectroscopy (NMR) and/or liquid chromatography-mass spectrometry (LC-MS). The nuclear magnetic resonance spectrum was measured by Bruker AVANCE-400 nuclear magnetic resonance apparatus, and the solvent was usually deuterated dimethyl sulfoxide (DMSO-d₆) or deuterated chloroform (CDCl₃). NMR chemical shifts (6) were given in parts per million (ppm) using tetramethylsilane (TMS) as the internal standard. LC-MS was performed on an Agilent 1100 series liquid chromatograph and a Bruker HCT-Ultra ion trap mass spectrometer.

Abbreviation Table

-   DIPEA N,N-diisopropylethylamine -   BINAP 1,1′-binaphthalene-2,2′-bisdiphenylphosphine -   Pd₂(dba)₃ tris(dibenzylideneacetone)dipalladium -   Pd(dppf)Cl₂ (1,1′-bis(diphenylphosphino)ferrocene)palladium     dichloride -   Pd(dppf)Cl₂-DCM (1,1′-bis(diphenylphosphino)ferrocene)palladium     dichloride-dichloromethane adduct -   SPhos-Pd-G2     chloro(2-dicyclohexylphosphino-2′,6′-dimethoxy-1,1′-biphenyl)(2′-amino)-1,1′-biphenyl-2-yl)palladium(II)

EXAMPLE 1 Compound 1: Preparation of 5-(2-fluoro-6-methylphenyl)-3-(4-(4-methylpiperazin-1-yl)phenyl)-1H-pyrazolo[4,3-c]pyridazin-6(5H)-one (Scheme 1)

Step 1: Preparation of dimethyl 2-(2-(2-fluoro-6-methylphenyl)hydrazino)-3-oxo-glutarate

To a there-necked flask containing 2-fluoro-6-methylaniline (5.0 g, 40 mmol) was added hydrochloric acid (4M, 54 mL). The mixture was cooled to 0° C. An aqueous solution (30 mL) of sodium nitrite (2.8 g, 40 mmol) was added dropwise, while keeping the temperature of the reaction mixture at 5-10° C. After stirring for additional 2 hours at 5-10° C., the mixture formed was then added rapidly to a vigorously stirred solution of dimethyl 3-oxo-glutarate (7.0 g, 40 mmol) and sodium acetate (21.0 g, 264 mmol) in a solvent mixture of ethanol (30 mL) and water (60 mL) at room temperature, the product precipitated. The reaction mixture was further stirred at room temperature for 2 hours and then filtered with suction. The filter cake was dried to give crude dimethyl 2-(2-(2-fluoro-6-methylphenyl)hydrazino)-3-oxo-glutarate (6.0 g) as a yellow solid. The crude product was directly used in the next step.

ESI-MS: m/z=310.9 ([M+H]⁺).

Step 2: Preparation of methyl 1-(2-fluoro-6-methylphenyl)-4-hydroxy-6-oxo-1,6-dihydropyridazine-3-carboxylate

Dimethyl 2-(2-(2-fluoro-6-methylphenyl)hydrazino)-3-oxo-glutarate (6.0 g, 19 mmol) was dissolved in 1,2-dichlorobenzene (100 mL) in a sealed tube, and was heated to reflux. After heating for 4 hours, the reaction mixture was cooled to room temperature, and cyclohexane (300 mL) was added dropwise. The product was crystallized and filtered with suction. The filter cake was dried to give methyl 1-(2-fluoro-6-methylphenyl)-4-hydroxy-6-oxo-1,6-dihydropyridazine-3-carboxylate as a brown solid (2.0 g, 7.2 mmol). Yield: 37%.

ESI-MS: m/z=279.1 ([M+H]⁺).

Step 3: Preparation of 1-(2-fluoro-6-methylphenyl)-4-hydroxy-6-oxo-1,6-dihydropyridazine-3-carboxamide

Methyl 1-(2-fluoro-6-methylphenyl)-4-hydroxy-6-oxo-1,6-dihydropyridazine-3-carboxylate (2.0 g, 7.2 mmol) was dissolved in ammonia in methanol (7N, 20 mL) in a sealed tube, and was heated to reflux overnight. The reaction mixture was cooled to room temperature and concentrated to dryness to give the crude product of 1-(2-fluoro-6-methylphenyl)-4-hydroxy-6-oxo-1,6-dihydropyridazine-3-carboxamide (1.6 g) as oil. The crude product was directly used in the next step.

ESI-MS: m/z=264.1 ([M+H]⁺).

Step 4: Preparation of 4-chloro-1-(2-fluoro-6-methylphenyl)-6-oxo-1,6-dihydropyridazine-3-carbonitrile

To a solution of 4-chloro-1-(2-fluoro-6-methylphenyl)-6-oxo-1,6-dihydropyridazine-3-carbonitrile (1.6 g) in acetonitrile (16 mL) was added phosphorus oxychloride (8 mL) and heated to reflux overnight. The reaction mixture was poured into ice and stirred for 1 hour, and then extracted with ethyl acetate for three times (30 mL×3). The organic phases were combined, dried, filtered and concentrated to dryness. The residue was purified by column chromatography (petroleum ether/ethyl acetate: 20/1 to 10/1) to give 4-chloro-1-(2-fluoro-6-methylphenyl)-6-oxo-1,6-dihydropyridazine-3-carbonitrile as a white solid (800 mg, 3.04 mmol). Overall yield for two steps: 50%.

ESI-MS: m/z=264.0 ([M+H]⁺).

Step 5: Preparation of 3-amino-5-(2-fluoro-6-methylphenyl)-1H-pyrazolo[4,3-c]pyridazin-6(5H)-one

4-Chloro-1-(2-fluoro-6-methylphenyl)-6-oxo-1,6-dihydropyridazine-3-carbonitrile (800 mg, 3.04 mmol) was dissolved in ethanol (8 mL), and 98% hydrazine hydrate (760 mg, 15 mmol) was added. The reaction tube was sealed and heated to 100° C. overnight. The reaction mixture was cooled to room temperature, and the product was precipitated and filtered. The filter cake was dried to give 3-amino-5-(2-fluoro-6-methylphenyl)-1H-pyrazolo[4,3-c]pyridazin-6(5H)-one (600 mg, 2.3 mmol) as a red solid. Yield: 75%.

ESI-MS: m/z=260.1 ([M+H]⁺).

Step 6. Preparation of 3-bromo-5-(2-fluoro-6-methylphenyl)-1H-pyrazolo[4,3-c]pyridazin-6(5H)-one

3-Amino-5-(2-fluoro-6-methylphenyl)-1H-pyrazolo[4,3-c]pyridazin-6(5H)-one (600 mg, 2.3 mmol) was dissolved in acetonitrile (12 mL), and tert-butyl nitrite (240 mg) was added dropwise at 0° C. The reaction mixture was stirred at 0° C. for 10 minutes, then copper bromide (510 mg) was added and further stirred for 20 minutes. The reaction mixture was poured into water (20 mL) and filtered. The filtrate was extracted with ethyl acetate (20 mL×3) for three times. The combined organic phase was washed with brine, dried, filtered, and concentrated to give crude 3-bromo-5-(2-fluoro-6-methylphenyl)-1H-pyrazolo[4,3-c]pyridazine-6(5H)-one (400 mg). The crude product was directly used in the next step.

ESI-MS: m/z=323.0 ([M+H]⁺).

Step 7: Preparation of Compound 1

To a single-necked flask was added crude 3-bromo-5-(2-fluoro-6-methylphenyl)-1H-pyrazolo[4,3-c]pyridazin-6(5H)-one (400 mg, 1.24 mmol), (4-(4-methylpiperazin-1-yl)phenyl)boronic acid pinacol ester (376 mg, 1.24 mmol), potassium carbonate (340 mg, 2.48 mmol), Pd(dppf)Cl₂-DCM (108 mg, 0.147 mmol), 1,4-dioxane (2 mL) and water (2 mL). The mixture was heated to 80° C. under nitrogen and stirred for 3 hours. The reaction mixture was cooled to room temperature and concentrated. The residue was purified by preparative high pressure liquid chromatography (pre-HPLC) to give compound 1 (as the trifluoroacetate salt, 5.3 mg, 0.010 mmol) as a brown solid.

EXAMPLE 2

Compound 2: Preparation of 5-(2-methoxy-6-methylphenyl)-3-(4-(4-methylpiperazin-1-yl)phenyl)-1H-pyrazolo[4,3-c]pyridazin-6(5H)-one (Scheme 2A)

Step 1: Preparation of dimethyl 2-(2-(2-methoxy-6-methylphenyl)hydrazino)-3-oxo-glutarate

This compound was prepared according to the procedure described in Example 1 (step 1) using 2-methoxy-6-methylaniline instead of 2-fluoro-6-methylaniline as the starting material. Yield: 79%.

ESI-MS: m/z=323.2 ([M+H]⁺).

Step 2: Preparation of methyl 4-hydroxy-1-(2-methoxy-6-methylphenyl)-6-oxo-1,6-dihydropyridazine-3-carboxylate

This compound was prepared according to the procedure described in Example 1 (step 2) using dimethyl 2-(2-(2-(2-methoxy-6-methylphenyl)hydrazino)-3-oxo-glutarate instead of dimethyl 2-(2-(2-fluoro-6-methylphenyl)hydrazino)-3-oxo-glutarate as starting material. Yield: 83%.

ESI-MS: m/z=291.2 ([M+H]⁺).

Step 3: Preparation of methyl 4-chloro-1-(2-methoxy-6-methylphenyl)-6-oxo-1,6-dihydropyridazine-3-carboxylate

To phosphorus oxychloride (15 mL) was added methyl 4-hydroxy-1-(2-methoxy-6-methylphenyl)-6-oxo-1,6-dihydropyridazine-3-carboxylate (3.12 g, 10.8 mmol), and heated to 100° C. under nitrogen for 14 hours. The reaction was complete. The reaction mixture was cooled to room temperature, concentrated to dryness, and the residue was purified by column chromatography (petroleum ether/ethyl acetate: 3/1) to obtain methyl 4-chloro-1-(2-methoxy-6-methylphenyl)-6-oxo-1,6-dihydropyridazine-3-carboxylate (2.39 g, 7.74 mmol) as an orange solid. Yield: 72%.

ESI-MS: m/z=309.1 ([M+H]⁺).

Step 4: Preparation of 4-hydrazino-1-(2-methoxy-6-methylphenyl)-6-oxo-1,6-dihydropyridazine-3-carbohydrazide

Methyl 4-chloro-1-(2-methoxy-6-methylphenyl)-6-oxo-1,6-dihydropyridazine-3-carboxylate (2.39 g, 7.74 mmol), hydrazine hydrate (1.45 g, 23.2 mmol) and DIPEA (3.84 mL, 23.2 mmol) were added into absolute ethanol (24 mL), and was heated to 80° C. under nitrogen for 2 hours. The reaction was complete. The reaction mixture was cooled to 0° C. A precipitate was formed, and collected by filtration. The filter cake was rinsed with cold absolute ethanol (about 0° C.) and dried in vacuo to give 4-hydrazino-1-(2-methoxy-6-methylphenyl)-6-oxo-1,6-dihydropyridazine-3-carbohydrazide (2.06 g, 6.77 mmol) as a yellow solid. Yield: 88%.

ESI-MS: m/z=305.2 ([M+H]⁺).

Step 5: Preparation of 5-(2-methoxy-6-methylphenyl)-1H-pyrazolo[4,3-c]pyridazin-3,6(2H,5H)-dione

4-hydrazino-1-(2-methoxy-6-methylphenyl)-6-oxo-1,6-dihydropyridazine-3-carbohydrazide (2.06 g, 6.78 mmol), glacial acetic acid (2.33 mL, 40.7 mmol) and DIPEA (5.60 mL, 33.9 mmol) were added into n-butanol (20 mL), and heated to 120° C. under nitrogen for 15 hours. The reaction was complete. The reaction mixture was cooled to room temperature and concentrated to dryness. The residue was purified by column chromatography (dichloromethane/methanol: 40/1 to 8/1) to give 5-(2-methoxy-6-methylphenyl)-1H-pyrazolo[4,3-c]pyridazin-3,6(2H,5H)-dione (1.67 g, 6.14 mmol) as a reddish-brown solid. Yield: 90%.

ESI-MS: m/z=273.1 ([M+H]⁺).

Step 6: Preparation of 3-chloro-5-(2-methoxy-6-methylphenyl)-1H-pyrazolo[4,3-c]pyridazin-6(5H)-one

To a solution of 5-(2-methoxy-6-methylphenyl)-1H-pyrazolo[4,3-c]pyridazin-3,6(2H,5H)-dione (200 mg, 0.74 mmol) in acetonitrile (100 mL) was added phosphorus oxychloride (334 uL, 3.67 mmol) and benzyltrimethylammonium chloride (136 mg, 0.74 mmol). The mixture was heated to 70° C. under nitrogen, and stirred for 18 hours. The reaction mixture was cooled to room temperature, and concentrated to dryness. The residue was purified by thin layer chromatography (dichloromethane/methanol: 20/1) to give 3-chloro-5-(2-methoxy-6-methylphenyl)-1H-pyrazolo[4,3-c]pyridazin-6(5H)-one (95 mg, 0.33 mmol) as a yellow solid. Yield: 44%.

ESI-MS: m/z=291.2 ([M+H]⁺).

Step 7: Preparation of Compound 2

3-Chloro-5-(2-methoxy-6-methylphenyl)-1H-pyrazolo[4,3-c]pyridazin-6(5H)-one (50 mg, 0.17 mmol), 4-(4-methyl-1-piperazinyl)phenylboronic acid (76 mg, 0.34 mmol), SPhos-Pd-G2 (10 mg, 0.014 mmol) and potassium phosphate (110 mg, 0.52 mmol) were added to a mixture of 1,4-dioxane (4 mL) and water (1 mL). The mixture was heated to 100° C. under nitrogen for 14 hours to complete the reaction. The reaction mixture was cooled to room temperature and concentrated to dryness. The residue was purified by thin layer chromatography (dichloromethane/methanol: 20/1) to give a crude product, which was slurried with methanol (1 mL) in ice-water bath to give compound 2 (61 mg, 0.14 mmol) as a yellow solid. Yield: 82%.

EXAMPLE 4

Compound 4: 5-(2,4-dimethoxyphenyl)-3-(4-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)phenyl)-1H-pyrazolo[4,3-c]pyridazin-6(5H)-one (Scheme 3A)

Step 1: Preparation of 4-bromo-N-methoxy-N-methylbenzamide

To a solution of 4-bromobenzoyl chloride (5.0 g, 22.8 mmol) in dichloromethane (50 mL) cooled in ice-water bath under nitrogen Was added N,O-dimethylhydroxylamine hydrochloride (2.667 g, 27.34 mmol) and triethylamine (6.32 mL, 45.6 mmol) successively. The mixture was warmed to room temperature gradually and further stirred for 2 hours. Dilute hydrochloric acid (0.1M, 100 mL) was added to quench the reaction. The reaction mixture was extracted with dichloromethane for three times (100 mL×3). The combined organic phase was washed with brine, dried and filtered. The filtrate was concentrated to dryness under reduced pressure to give 4-bromo-N-methoxy-N-methylbenzamide (5.46 g, 22.4 mmol) as a yellow oil. Yield: 98%.

ESI-MS: m/z=244.0 ([M+H]⁺).

Step 2: Preparation of methyl 5-(4-bromophenyl)-3,5-dioxopentanoate

To an ice water bath-cooled suspension of sodium hydride (360 mg, 9.01 mmol) in dry tetrahydrofuran (20 mL) under nitrogen was added methyl acetoacetate (951 mg, 8.19 mmol) dropwise with stirring. The mixture was stirred for 0.5 hour at the same temperature. The reaction was then cooled to −70° C. in a dry ice-acetone bath, and n-butyllithium (2.5M in n-hexane, 3.3 mL, 8.2 mmol) was added dropwise. The mixture was stirred for 10 minutes with the temperature maintained. Then, a solution of 4-bromo-N-methoxy-N-methylbenzamide (2.00 g, 8.19 mmol) in tetrahydrofuran (10 mL) was added dropwise, and then stirred for 1 hour. The reaction was warmed to 0° C., and quenched with saturated ammonium chloride solution (100 mL). The reaction mixture was extracted with ethyl acetate (100 mL×2). The combined organic phase was washed with saturated brine (100 mL), dried over anhydrous sodium sulfate, and then filtered.

The filtrate was concentrated under reduced pressure, and the residue was purified by column chromatography (petroleum ether/ethyl acetate: 10/1) to give methyl 5-(4-bromophenyl)-3,5-dioxopentanoate (1.346 g, 4.5 mmol)) as a yellow oil. Yield: 54%.

ESI-MS: m/z=299.0 ([M+H]⁺).

Step 3: Preparation of methyl 5-(4-bromophenyl)-4-(2-(2,4-dimethoxyphenyl)hydrazino)-3,5-dioxopentanoate

To an ice bath-cooled mixture of 2,4-dimethoxyaniline (200 mg, 1.31 mmol) in water (1.6 mL) was added concentrated hydrochloric acid (0.8 mL) and aqueous solution (1.2 mL) of sodium nitrite (90 mg, 1.31 mmol) dropwise, successively. The resultant solution was stirred for 0.5 hours with the temperature maintained to obtain a diazonium salt solution. To a solution of methyl 5-(4-bromophenyl)-3,5-dioxopentanoate (391 mg, 1.31 mmol) and sodium acetate (643 mg, 7.83 mmol) in absolute ethanol (1.2 mL) and water (2.4 mL) was added the above obtained diazonium salt solution dropwise. After the addition, the mixture was stirred at room temperature for 2 hours. The reaction mixture was extracted with dichloromethane for three times (20 mL×3), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure, and the residue was purified by column chromatography (petroleum ether/ethyl acetate: 10/1 to 1/8) to give methyl 5-(4-bromophenyl)-4-(2-(2,4)-dimethoxyphenyl)hydrazino)-3,5-dioxopentanoate (325 mg, 0.70 mmol) as an orange solid. Yield: 54%.

ESI-MS: m/z=463.1 ([M+H]⁺).

Step 4: Preparation of 6-(4-bromobenzoyl)-2-(2,4-dimethoxyphenyl)-5-hydroxypyridazin-3(2H)-one

Methyl 5-(4-bromophenyl)-4-(2-(2,4-dimethoxyphenyl)hydrazinomethylene)-3,5-dioxopentanoate (100 mg, 0.22 mmol) was dissolved in o-dichlorobenzene (2 mL), heated to 175° C. and stirred for 5 hours under nitrogen. The reaction mixture was cooled to room temperature, diluted with ethyl acetate (10 mL), and extracted with saturated sodium bicarbonate solution for three times (10 mL×3). The combined aqueous phases was adjusted to pH=4-5 with saturated citric acid solution, and extracted with ethyl acetate twice (20 mL×2). The organic phases were combined, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated to dryness under reduced pressure to give 6-(4-bromobenzoyl)-2-(2,4-dimethoxyphenyl)-5-hydroxypyridazin-3(2H)-one (67 mg, 0.16 mmol) as a yellow solid. Yield: 72%.

ESI-MS: m/z=431.1 ([M+H]⁺).

Step 5: Preparation of 3-(4-bromophenyl)-5-(2,4-dimethoxyphenyl)-1H-pyrazolo[4,3-c]pyridazin-6(5H)-one

To a solution of 6-(4-bromobenzoyl)-2-(2,4-dimethoxyphenyl)-5-hydroxypyridazin-3(2H)-one (47 mg, 0.11 mmol) in n-butanol (2 mL) was added glacial acetic acid (31 uL, 0.55 mmol) and hydrazine hydrate (33 uL, 0.55 mmol). The mixture was heated to 120° C. under nitrogen and stirred for 15 hours. The reaction mixture was cooled to room temperature. Precipitate formed. The solid was collected by filtration and dried in vacuo to give 3-(4-bromophenyl)-5-(2,4-dimethoxyphenyl)-1H-pyrazolo[4,3-c]pyridazine-6(5H)-one (27 mg, 0.063 mmol) as a yellow solid. Yield: 58%.

ESI-MS: m/z=427.1 ([M+H]⁺).

Step 6: Preparation of Compound 4

3-(4-Bromophenyl)-5-(2,4-dimethoxyphenyl)-1H-pyrazolo[4,3-c]pyridazin-6(5H)-one (10.0 mg, 0.023 mmol), 1-methyl-1,2,3,6-tetrahydropyridine-4-boronic acid pinacol ester (10.4 mg, 0.047 mmol), SPhos-Pd-G2 (1.7 mg, 0.002 mmol) and potassium phosphate (14.9 mg, 0.070 mmol) were added to a solvent mixture of 1,4-dioxane (1.6 mL) and water (0.4 mL). The resultant mixture was heated to 100° C. under nitrogen and stirred for 15 hours. The reaction mixture was cooled to room temperature, concentrated to dryness, and the residue was purified by thin layer chromatography (dichloromethane/methanol: 10/1) to obtain the crude product, which was slurried with methanol (0.5 mL) at room temperature to obtain compound 4 (3.4 mg, 0.0077 mmol) as a yellow solid. Yield: 33%.

EXAMPLE 23 Compound 23: 5-(2-fluoro-6-methoxyphenyl)-3-(4-(1-methyl-1,2,3,6-tetrahydro-pyridin-4-yl)phenyl)-1H-pyrazolo[4,3-c]pyridazin-6(5H)-one (Scheme 4)

Step 1: Preparation of 2-methoxy-6-fluorophenyldiazonium tetrafluoroborate

To dry methyl tert-butyl ether (8 mL) cooled to −5° C. under nitrogen was added boron trifluoride diethyl ether complex (1.1 mL, 8.9 mmol) and a solution of 2-fluoro-6-methoxyaniline (614 mg, 4.35 mmol) in dry methyl tert-butyl ether (3 mL) successively. After stirring for 15 minutes, the reaction mixture was cooled to −15° C. A solution of tert-butyl nitrite (0.62 mL, 5.2 mmol) in dry methyl tert-butyl ether (3 mL) was added dropwise. After the addition, the reaction mixture was gradually warmed to 0° C. Dry tetrahydrofuran (5 mL) was added, and stirring was continued at 0° C. for 2 hours. The reaction mixture was filtered, and the filter cake was washed with methyl tert-butyl, collected, and dried at room temperature to give 2-methoxy-6-fluorophenyldiazonium tetrafluoroborate (955 mg, 3.98 mmol) as a gray solid, Yield: 91%.

Step 2: Preparation of 6-(2-(4-bromophenyl)-1-(2-(2-fluoro-6-methoxyphenyl)-hydrazino)-2-oxo-ethyl)-2,2-dimethyl-4H-1,3-dioxin-4-one

To a solution of 6-(2-(4-bromophenyl)-2-oxo-ethyl)-2,2-dimethyl-4H-1,3-dioxin-4-one (694 mg, 2.13 mmol) in ethanol (20 mL) was added sodium acetate (506 mg, 6.16 mmol), and cooled to −5° C. To the above mixture was added a solution of 2-methoxy-6-fluorophenyldiazonium tetrafluoroborate (539 mg, 2.25 mmol) in acetonitrile (3 mL) dropwise, and stirred for 20 minutes. The reaction mixture was poured into a mixture of ethyl acetate and aqueous ammonium chloride solution with stirring. After phase separation, the aqueous phase was extracted with ethyl acetate. The combined organic phase was dried and concentrated to give the crude product of 6-(2-(4-bromophenyl)-1-(2-(2-fluoro-6-methoxyphenyl)hydrazino)-2-oxo-ethyl)-2,2-dimethyl-4H-1,3-dioxin-4-one. The crude product was used directly in the next step without purification.

ESI-MS: m/z=477.1 ([M+H]⁺).

Step 3: Preparation of 6-(4-bromobenzoyl)-2-(2-fluoro-6-methoxyphenyl)-5-hydroxypyridazin-3(2H)-one

To a solution of 6-(2-(4-bromophenyl)-1-(2-(2-fluoro-6-methoxyphenyl)hydrazino)-2-oxo-ethyl)-2,2-dimethyl-4H-1,3-dioxin-4-one (970 mg, 2.03 mmol) in 1,2-dichlorobenzene (4 mL) was added glacial acetic acid (485 L), and heated to 130° C. for 1 hour. The reaction mixture was cooled to room temperature, and poured into n-heptane (120 mL) cooled in an ice-water bath with stirring. The resultant precipitate was collected by filtration, dried in vacuo to give 6-(4-bromobenzoyl)-2-(2-fluoro-6-methoxyphenyl)-5-hydroxypyridazin-3(2H)-one (518 mg, 1.23 mmol) as an orange-red solid. Yield: 61%.

ESI-MS: m/z=419.1 ([M+H]⁺).

Step 4: Preparation of 3-(4-bromophenyl)-5-(2-fluoro-6-methoxyphenyl)-1H-pyrazolo[4,3-c]pyridazin-6(5H)-one

This compound was prepared according to the procedure described in Example 4 (step 5) using 6-(4-bromobenzoyl)-2-(2-fluoro-6-methoxyphenyl)-5-hydroxypyridazine-3(2H)-one instead of 6-(4-bromobenzoyl)-2-(2,4-dimethoxyphenyl)-5-hydroxypyridazin-3(2H)-one as starting material. Yield: 70%.

ESI-MS: m/z=415.1 ([M+H]⁺).

Step 5: Preparation of Compound 23

This compound was prepared according to the procedure described in Example 4 (step 6) using 3-(4-bromophenyl)-5-(2-fluoro-6-methoxyphenyl)-1H-pyrazolo[4,3-c]pyridazin-6(5H)-one instead of 3-(4-bromophenyl)-5-(2,4-dimethoxyphenyl)-1H-pyrazolo[4,3-c]pyridazin-6(5H)-one as starting material with yield of 58%.

EXAMPLE 24 Compound 24: 5-(2-fluoro-6-methoxyphenyl)-3-(4-(1-methylpiperidin-4-yl)phenyl)-1H-pyrazolo[4,3-c]pyridazin-6(5H)-one

To a solution of compound 23 (60 mg, 014 mmol) in a solvent mixture of anhydrous methanol (6 mL) and tetrahydrofuran (6 mL) was added 10% Pd/C (12 mg), and stirred at room temperature overnight under a hydrogen atmosphere. The Pd/C was removed by filtration, and the filtrate was concentrated to dryness. The residue was purified by thin layer chromatography (dichloromethane/anhydrous methanol: 10/1) to give 5-(2-fluoro-6-methoxyphenyl)-3-(4-(1-methylpiperidin-4-yl)phenyl)-1H-pyrazolo[4,3-c]pyridazin-6(5H)-one (32 mg, 0.074 mmol).

Yield: 53%.

EXAMPLE 25 Compound 25: 5-(2,4-dimethoxyphenyl)-3-(4-(4-methylpiperazin-1-yl)phenyl)-1H-pyrazolo[4,3-c]pyridazin-6(5H)-one (Scheme 3B)

Step 1: Preparation of 3-(4-Bromophenyl)-1-(2,4-dimethoxybenzyl)-5-(2,4-dimethoxyphenyl)-1H-pyrazolo[4,3-c]pyridazin-6(5H)-one

6-(4-bromobenzoyl)-2-(2,4-dimethoxyphenyl)-5-hydroxypyridazin-3(2H)-one was prepared according to the procedure described in Example 4 (step 4). 6-(4-bromobenzoyl)-2-(2,4-dimethoxyphenyl)-5-hydroxypyridazin-3(2H)-one (840 mg, 1.95 mmol), 2,4-dimethoxyphenylhydrazine dihydrochloride (646 mg, 2.53 mmol) and anhydrous sodium acetate (479 mg, 5.84 mmol) were added to n-butanol (10 mL), heated to 100° C. for 1 hour. The reaction mixture was cooled to room temperature, and the precipitate was collected by filtration. The solid was purified by column chromatography (petroleum ether/ethyl acetate: 1/9 to 0/10) to give 3-(4-bromophenyl)-1-(2,4-dimethoxybenzyl)-5-(2,4-dimethoxyphenyl)-1H-pyrazolo[4,3-c]pyridazin-6(5H)-one (532 mg, 0.92 mmol). Yield: 36%.

ESI-MS: m/z=577.2 ([M+H]⁺).

Step 2: Preparation of 1-(2,4-dimethoxybenzyl)-5-(2,4-dimethoxyphenyl)-3-(4-(4-methylpiperazin-1-yl)phenyl)-1H-pyrazolo[4,3-c] pyridazin-6(5H)-one

To a mixture of 3-(4-bromophenyl)-1-(2,4-dimethoxybenzyl)-5-(2,4-dimethoxyphenyl)-1H-pyrazolo[4,3-c]pyridazin-6(5H)-one (450 mg, 0.78 mmol), methylpiperazine (390 mg, 3.9 mmol), Pd₂(dba)₃ (71 mg, 0.078 mmol) and BINAP (121 mg, 0.195 mmol) in toluene (9 mL) was added a solution of sodium tert-pentoxide in toluene (3.5M, 1.1 mL) under nitrogen. The resultant mixture was heated to 100° C. and stirred overnight. The reaction mixture was diluted with dichloromethane and washed with water. The organic phase was dried and concentrated. The residue was purified by column chromatography (dichloromethane/methanol: 100/1 to 30/1) to give 1-(2,4-dimethoxybenzyl)-5-(2,4-dimethoxyphenyl)-3-(4-(4-methylpiperazin-1-yl)phenyl)-1H-pyrazolo[4,3-c]pyridazin-6(5H)-one (203 mg, 0.34 mmol) as an orange-red solid. Yield: 44%.

ESI-MS: m/z=597.4 ([M+H]⁺).

Step 3: Preparation of Compound 25

To a solution of 1-(2,4-dimethoxybenzyl)-5-(2,4-dimethoxyphenyl)-3-(4-(4-methylpiperazin-1-yl)phenyl)-1H-pyrazolo[4,3-c]pyridazin-6(5H)-one (200 mg, 0.34 mmol) in trifluoroacetic acid (6 mL) was added anisole (0.3 mL), and heated to 80° C. for 2 hours. The reaction mixture was cooled to room temperature, diluted with water (20 mL), and extracted with ethyl acetate for three times. The aqueous phase was adjusted to pH=8 with sodium carbonate solution, and solid precipitated. The solid was collected by filtration, dried, and slurried with methanol to give compound 25 (90 mg, 0.20 mmol) as an orange solid. Yield: 60%.

EXAMPLE 29 Compound 33: 5-(2-fluoro-6-methoxyphenyl)-3-(4-(4-methyl-3-oxo-piperazin-1-yl)phenyl)-1H-pyrazolo [4,3-c]pyridazin-6(5H)-one (Scheme 2B)

Step 1: Preparation of dimethyl 2-(2-(2-(2-fluoro-6-methoxyphenyl)hydrazino)-3-oxo-glutarate

This compound was prepared according to the procedure described in Example 2 (step 1) using 2-fluoro-6-methoxyaniline instead of 2-methoxy-6-methylaniline as the starting material. Yield: 94%.

ESI-MS: m/z=327.2 ([M+H]⁺).

Step 2: Preparation of methyl 4-hydroxy-1-(2-fluoro-6-methoxyphenyl)-6-oxo-1,6-dihydropyridazine-3-carboxylate

This compound was prepared according to the procedure described in Example 2 (step 2) using dimethyl 2-(2-(2-(2-fluoro-6-methoxyphenyl)hydrazino)-3-oxo-glutarate instead of dimethyl 2-(2-(2-(2-methoxy-6-methylphenyl)hydrazino)-3-oxo-glutarate as starting material. Yield: 90%.

ESI-MS: m/z=295.2 ([M+H]⁺).

Step 3: Preparation of methyl 4-chloro-1-(2-fluoro-6-methoxyphenyl)-6-oxo-1,6-dihydropyridazine-3-carboxylate

This compound was prepared according to the procedure described in Example 2 (step 3) using methyl 4-hydroxy-1-(2-fluoro-6-methoxyphenyl)-6-oxo-1,6-dihydropyridazine-3-carboxylate instead of methyl 4-hydroxy-1-(2-methoxy-6-methylphenyl)-6-oxo-1,6-dihydropyridazine-3-carboxylate as starting material. Yield: 84%.

ESI-MS: m/z=313.2 ([M+H]⁺).

Step 4: Preparation of methyl 4-hydrazino-1-(2-fluoro-6-methoxyphenyl)-6-oxo-1,6-dihydropyridazine-3-carboxylate

To a suspension of methyl 4-chloro-1-(2-fluoro-6-methoxyphenyl)-6-oxo-1,6-dihydropyridazine-3-carboxylate (4.0 g, 12.8 mmol, 1.0 eq) and DIPEA (8.4 mL, 51.3 mmol, 4.0 eq) in ethanol (40 mL) was added a solution of 98% hydrazine hydrate (785 mg, 15.4 mmol, 1.2 eq) in ethanol (40 mL) at room temperature. After the addition, the mixture was stirred at room temperature for 4 hours. The reaction mixture was diluted with water (150 mL) and extracted with ethyl acetate for three times. The organic phases were combined, washed with brine, dried, filtered and concentrated to dryness. The residue was purified by column chromatography (dichloromethane/methanol: 100/1) to give methyl 4-hydrazino-1-(2-fluoro-6-methoxyphenyl)-6-oxo-1,6-dihydropyridazine-3-carboxylate (2.3 g) as a yellow solid. Yield: 59%.

ESI-MS: m/z=309.1 ([M+H]⁺).

Step 5: Preparation of 5-(2-fluoro-6-methoxyphenyl)-1H-pyrazolo[4,3-c]pyridazine-3,6(2H,5H)-dione

To a solution of methyl 4-hydrazino-1-(2-fluoro-6-methoxyphenyl)-6-oxo-1,6-dihydropyridazine-3-carboxylate (1.6 g, 5.19 mmol, 1.0 eq) in a solvent mixture of methanol (15 mL) and tetrahydrofuran (15 mL) was added aqueous solution (15 mL) of lithium hydroxide monohydrate (436 mg, 10.38 mmol, 2.0 eq), and the mixture was stirred at room temperature for 2 hours. The reaction mixture was concentrated to dryness. The residue was purified by column chromatography (dichloromethane/methanol: 15/1) to give 5-(2-fluoro-6-methoxyphenyl)-1H-pyrazolo[4,3-c]pyridazine-3,6(2H,5H)-dione (1.4 g) as a brown-red solid. Yield: 99%.

ESI-MS: m/z=277.2 ([M+H]⁺).

Step 6: Preparation of 3-chloro-5-(2-fluoro-6-methoxyphenyl)-1H-pyrazolo[4,3-c]pyridazin-6(5H)-one

This compound was prepared according to the procedure described in Example 2 (step 6) using 5-(2-fluoro-6-methoxyphenyl)-1H-pyrazolo[4,3-c]pyridazine-3,6(2H,5H)-dione instead of 5-(2-methoxy-6-methylphenyl)-1H-pyrazolo[4,3-c]pyridazine-3,6(2H,5H)-dione as starting material. Yield: 28%.

ESI-MS: m/z=295.1 ([M+H]⁺).

Step 7: Preparation of Compound 33

This compound was prepared according to the procedure described in Example 2 (step 7) using 3-chloro-5-(2-fluoro-6-methoxyphenyl)-1H-pyrazolo[4,3-c]pyridazine-6(5H)-one instead of 3-chloro-5-(2-methoxy-6-methylphenyl)-1H-pyrazolo[4,3-c]pyridazine-6(5H)-one, and using (4-(4-methyl-3-oxo-piperazin-1-yl)phenyl)boronic acid pinacol ester instead of 4-(4-methyl-1-piperazinyl)phenylboronic acid as starting materials. Yield: 25%.

EXAMPLE 30 Compound 34: 5-(2-fluoro-6-cyclopropylphenyl)-3-(4-(4-methylpiperazin-1-yl)phenyl)-1H-pyrazolo[4,3-c]pyridazin-6(5H)-one (Scheme 3A)

Step 1: Preparation of tert-butyl (2-fluoro-6-cyclopropylphenyl)carbamate

This compound was prepared according to the procedure described in Example 29 (step 2) using cyclopropylboronic acid instead of 4,4,5,5-tetramethyl-2-(prop-1-en-2-yl)-1,3,2-dioxaborane as the starting material. Yield: 65%.

ESI-MS: m/z=196.1 ([M+H−C₄H₈]⁺).

Step 2: Preparation of 2-fluoro-6-cyclopropylaniline

This compound was prepared according to the procedure described in Example 29 (step 4) using tert-butyl (2-fluoro-6-cyclopropylphenyl)carbamate as starting material. Yield: 87%.

ESI-MS: m/z=152.1 ([M+H]⁺).

Step 3: Preparation of 2-cyclopropyl-6-fluorophenyldiazonium tetrafluoroborate

To a solvent mixture of dry methyl tert-butyl ether (3 mL) and dry tetrahydrofuran (3 mL) cooled to −5° C. was added boron trifluoride ether complex (489 L, 3.97 mmol) and a solution of 2-fluoro-6-cyclopropylaniline (300 mg, 1.98 mmol) in dry tetrahydrofuran (3 mL) successively, under nitrogen. After stirring for 15 minutes, the reaction mixture was cooled to −15° C. A solution of tert-butyl nitrite (246 mg, 2.38 mmol) in dry methyl tert-butyl ether (3 mL) was added dropwise. After the addition, the reaction mixture was gradually warmed to 0° C., and further stirred for 1.5 hours. The reaction mixture was filtered, and the filter cake was washed with methyl tert-butyl (50 mL) and dried at room temperature to give 2-cyclopropyl-6-fluorophenyldiazonium tetrafluoroborate (426 mg, 1.70 mmol) was a white solid. Yield: 86%.

ESI-MS: m/z=163.1 ([M+H−BF₄]⁺).

Step 4: Preparation of methyl 5-(4-bromophenyl)-4-(2-(2-fluoro-6-cyclopropylphenyl)hydrazino)-3,5-dioxopentanoate

To a mixture of methyl 5-(4-bromophenyl)-3,5-dioxopentanoate (920 mg, 3.07 mmol) and anhydrous sodium acetate (757 mg, 9.22 mmol) in absolute ethanol (20 mL) cooled to −15° C. was added a solution of 2-cyclopropyl-6-fluorophenyldiazonium tetrafluoroborate (384 mg, 1.54 mmol) in acetonitrile (4 mL) dropwise. After the addition, the reaction mixture was gradually warmed to 0° C. and further stirred for 1.5 hours. The reaction mixture was concentrated under reduced pressure, diluted with water (60 mL), and extracted with ethyl acetate (20 mL*3). The combined organic phase was washed with saturated brine (60 mL), dried over anhydrous sodium sulfate, and filtered with suction. The filtrate was concentrated to dryness. The residue was purified by column chromatography (petroleum ether/ethyl acetate:15/1) to give methyl 5-(4-bromophenyl)-4-(2-(2-fluoro-6-cyclopropylphenyl)hydrazino)-3,5-dioxopentanoate (435 mg, 0.94 mmol) as a yellow solid. Yield: 61%.

ESI-MS: m/z=461.0 ([M+H]⁺).

Step 5: Preparation of 6-(4-bromobenzoyl)-2-(2-fluoro-6-cyclopropylphenyl)-5-hydroxypyridazin-3(2H)-one

This compound was prepared according to the procedure described in Example 4 (step 4) using methyl 5-(4-bromophenyl)-4-(2-(2-fluoro-6-cyclopropylphenyl)hydrazinomethylene)-3,5-dioxopentanoate instead of methyl 5-(4-bromophenyl)-4-(2-(2,4-dimethoxyphenyl)hydrazinomethylene)-3,5-dioxopentanoate as the starting material. Yield: 38%.

ESI-MS: m/z=429.0 ([M+H]⁺).

Step 6: Preparation of 3-(4-bromophenyl)-5-(2-fluoro-6-cyclopropylphenyl)-1H-pyrazolo[4,3-c]pyridazin-6(5H)-one

This compound was prepared according to the procedure described in Example 4 (step 5) using 6-(4-bromobenzoyl)-2-(2-fluoro-6-cyclopropylphenyl)-5-hydroxypyridazine-3(2H)-one instead of 6-(4-bromobenzoyl)-2-(2,4-dimethoxyphenyl)-5-hydroxypyridazin-3(2H)-one as starting material. Yield: 71%.

ESI-MS: m/z=425.1 ([M+H]⁺).

Step 7: Preparation of 3-(4-bromophenyl)-5-(2-cyclopropyl-6-fluorophenyl)-1-(2-(trimethylsilyl)ethoxymethyl)-1H-pyrazolo[4,3-c]pyridazin-6(5H)-one

To a solution of 3-(4-bromophenyl)-5-(2-fluoro-6-cyclopropylphenyl)-1H-pyrazolo[4,3-c]pyridazin-6(5H)-one (92 mg, 0.22 mmol) in dry N,N-dimethylformamide (5 mL) at 0° C. was added sodium hydride (26 mg, 0.65 mmol) under nitrogen, and the mixture was stirred at 0° C. for 20 min. 2-(Trimethylsilyl)ethoxymethyl chloride (111 mg, 0.67 mmol) was then added dropwise, and the mixture was warmed to room temperature and stirred for 2 hours. The reaction mixture was poured into water (50 mL), extracted with ethyl acetate for three times (15 mL*3). The combined organic phase was washed with saturated brine (50 mL*3), dried over anhydrous sodium sulfate, and filtered with suction. The filtrate was concentrated to dryness, and the residue was purified by column chromatography (petroleum ether/ethyl acetate: 5/1) to give 3-(4-bromophenyl)-5-(2-cyclopropyl-6-fluorophenyl)-1-(2-(trimethylsilyl)ethoxymethyl)-1H-pyrazolo[4,3-c]pyridazin-6(5H)-one (82 mg, 0.15 mmol) as a yellow solid. Yield: 67%.

ESI-MS: m/z=555.0 ([M+H]⁺).

Step 8: Preparation of 5-(2-cyclopropyl-6-fluorophenyl)-3-(4-(4-methylpiperazin-1-yl)phenyl)-1-(2-(trimethylsilyl)ethoxymethyl)-1H-pyrazolo[4,3-c]pyridazin-6(5H)-one

To a mixture of 3-(4-bromophenyl)-5-(2-cyclopropyl-6-fluorophenyl)-1-(2-(trimethylsilyl)ethoxymethyl)-1H-pyrazolo[4,3-c]pyridazin-6(5H)-one (82 mg, 0.15 mmol), methylpiperazine (74 mg, 0.74 mmol), Pd₂(dba)₃ (13 mg, 0.015 mmol) and BINAP (23 mg, 0.037 mmol) in toluene (7 mL) was added a solution of sodium tert-pentoxide in toluene (3.5 M, 0.21 mL) under nitrogen. The mixture was heated to 100° C. and stirred overnight. The reaction mixture was poured into saturated aqueous ammonium chloride solution (60 mL), and extracted with ethyl acetate for three times (20 mL*3). The combined organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, and filtered with suction. The filtrate was concentrated to dryness, and the residue was purified by column chromatography (ethyl acetate/triethylamine: 100/3) to give 5-(2-cyclopropyl-6-fluorophenyl)-3-(4-(4-methylpiperazin-1-yl)phenyl)-1-(2-(trimethylsilyl)ethoxymethyl)-1H-pyrazolo[4,3-c]pyridazin-6(5H)-one (36 mg, 0.063 mmol) as a red solid. Yield: 42%.

ESI-MS: m/z=575.2 ([M+H]⁺).

Step 9: Preparation of Compound 34

To a solution of 5-(2-cyclopropyl-6-fluorophenyl)-3-(4-(4-methylpiperazin-1-yl)phenyl)-1-(2-(trimethylsilyl)ethoxymethyl)-1H-pyrazolo[4,3-c]pyridazin-6(5H)-one (36 mg, 0.063 mmol) in dichloromethane (10 mL) was added trifluoroacetic acid (2.5 mL) at 0° C. The reaction mixture was warmed to room temperature and stirred for 2 hours. The reaction mixture was neutralized with saturated aqueous sodium carbonate solution, extracted with dichloromethane for three times (30 mL*3). The combined organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, and filtered with suction. The filtrate was concentrated to dryness. The residue was re-dissolved in methanol (5 mL), and a small amount of aqueous ammonia was added. After stirring at room temperature for 1 hour, the mixture was concentrated to dryness, and the residue was purified by thin layer chromatography (DCM/MeOH: 10/1) to give compound 34 (10 mg, 0.022 mmol) as a red solid. Yield: 36%.

Other compounds in the Examples were synthesized by methods similar to those described in the above synthetic schemes, and their characterization data are listed in the table below.

Synthetic Example Compound Structural Formula Spectrum Data Scheme Example 1 Compound 1

ESI-MS: m/z = 419.2 ([M + H]⁺). ¹H NMR (400 MHZ, DMSO-d₆) δ 12.91 (s, 1H), 9.65 (s, 1H), 8.01 (d, J = 8.8 Hz, 2H), 7.52-7.46 (m, 1H), 7.30 (t, J = 7.8 Hz, 2H), 7.13 (d, J = 9.2 Hz, 1H), 6.71 (s, 1H), 3.96-3.92 (m, 2H), 3.55-3.52 (m, 2H), 3.18-3.10 (m, 2H), 3.04-2.98 (m, 2H), 2.85 (s, 3H), 2.10 (s, 3H). 1 Example 2 Compound 2

ESI-MS: m/z = 431.2 ([M + H]⁺). ¹H NMR (400 MHZ, DMSO-d₆) δ 12.71 (s, 1H), 7.95 (d, J = 9.0 Hz, 2H), 7.39 (t, J = 8.0 Hz, 1H), 7.10- 6.96 (m, 4H), 6.59 (s, 1H), 3.69 (s, 3H), 3.24-3.16 (m, 4H), 2.47-2.37 (m, 4H), 2.21 (s, 3H), 1.99 (s, 3H). 2A Example 3 Compound 3

ESI-MS: m/z = 417.3 ([M + H]⁺). ¹H NMR (400 MHZ, DMSO-d₆) δ 12.68 (s, 1H), 7.97 (d, J = 9.0 Hz, 2H), 7.52-7.48 (m, 1H), 7.41 (dd, J = 7.7, 1.6 Hz, 1H), 7.24 (dd, J = 8.4, 0.8 Hz, 1H), 7.11 (td, J = 7.6, 1.0 Hz, 1H), 7.02 (d, J = 9.0 Hz, 2H), 6.55 (s, 1H), 3.74 (s, 3H), 3.24-3.17 (m, 4H), 2.46- 2.40 (m, 4H), 2.21 (s, 3H). 2A Example 4 Compound 4

ESI-MS: m/z = 444.3 ([M + H]⁺). ¹H NMR (400 MHZ, DMSO-d₆) δ 12.90 (s, 1H), 8.09 (d, J = 8.5 Hz, 2H), 7.56 (d, J = 8.5 Hz, 2H), 7.32 (d, J = 8.6 Hz, 1H), 6.76 (d, J = 2.5 Hz, 1H), 6.66 (dd, J 8.6, 2.5 Hz, 1H), 6.59 (s, 1H), 6.27-6.22 (m 1H), 3.86 (s, 3H), 3.73 (s, 3H), 3.05-3.00 (m, 2H), 2.60- 2.54 (m, 2H), 2.50-2.45 (m, 2H), 2.28 (s, 3H). 3A Example 5 Compound 5

ESI-MS: m/z = 401.3 ([M + H]⁺). ¹H NMR (400 MHZ, DMSO-d₆) δ 12.73 (s, 1H), 7.98 (d, J = 9.0 Hz, 2H), 7.45-7.35 (m, 4H), 7.02 (d, J = 9.0 Hz, 2H), 6.62 (s, 1H), 3.30 (s, 3H), 3.23-3.18 (m, 4H), 2.46-2.40 (m, 4H), 2.07 (s, 3H). 2A Example 6 Compound 6

ESI-MS: m/z = 405.3 ([M + H]⁺). ¹H NMR (400 MHZ, DMSO-d₆) δ 12.77 (s, 1H), 7.99 (d, J = 9.0 Hz, 2H), 7.69-7.55 (m, 2H), 750-7.38 (m, 2H), 7.03 (d, J = 9.0 Hz, 2H), 6.63 (s, 1H), 3.24-3.19 (m, 4H), 2.46-2.40 (m, 4H), 2.21 (s, 3H). 2A Example 7 Compound 7

ESI-MS: m/z = 421.3 ([M + H]⁺). ¹HNMR (400 MHZ, DMSO-d₆) δ 12.78 (s, 1H), 7.97 (d, J = 9.0 Hz, 2H), 7.73-7.69 (m, 1H), 7.68-7.64 (m, 1H), 7.61-7.53 (m, 2H), 7.03 (d, J = 9.0Hz,2H), 6.64 (s, 1H), 3.23-3.18 (m, 4H), 2.46-2.40 (m, 4H), 2.21 (s, 3H). 2A Example 8 Compound 8

ESI-MS: m/z = 433.3 ([M + H]⁺). ¹H NMR (400 MHZ, DMSO-d6) δ 12.82 (s, 1H), 7.96 (d, J = 9.0 Hz, 2H), 7.57-7.50 (m, 1H), 7.34-7.26 (m, 2H), 7.03 (d, J = 9.0 Hz, 1H), 6.67 (s, 1H), 3.24-3.16 (m, 2 H), 2.45-2.35 (m, 6H), 2.21 (s, 3H), 1.06 (t, J = 7.6 Hz, 3H). 2A Example 9 Compound 9

ESI-MS: m/z = 435.3 ([M + H]⁺). ¹H NMR (400 MHZ, DMSO-d₆) δ 12.77 (s, 1H), 9.75 (d, J = 9.0 Hz, 2H), 7.59-7.52 (m, 1H), 7.12 (d, J = 8.6 Hz, 1H), 7.09-7.02 (m, 3H), 6.61 (s, 1H), 3.78 (s, 3H), 3.24-3.17 (m, 4H), 2.46-2.40 (m, 4H), 2.21 (s, 3H). 2A Example 10 Compound 10

ESI-MS: m/z = 436.3 (M + H]⁺). ¹H NMR (400 MHZ, DMSO-d₆) δ 12.84 (s, 1H), 8.82 (d, J = 2.2 Hz, 1H), 8.13 (dd, J = 9.0,2.4 Hz, 1H), 7.60-7.521 (m, 1H), 7.12 (d, J = 8.6 Hz, 1H), 7.09- 7.03 (m, 1H), 6.96 (d, J = 9.0 Hz, 1H), 6.64 (s,1H), 3.79 (s, 3H), 3.60-3.52 (m, 4H), 2.42-2.35 (m, 4H), 2.21 (s, 3H). 2A Example 11 Compound 11

ESI-MS: m/z = 420.3 ([M + H]⁺). ¹HNMR (400 MHZ, DMSO-d₆) δ 12.89 (s, 1H), 8.83 (d, J = 2.2 Hz, 1H), 8.13 (dd, J = 9.0, 2.4 Hz, 1H), 7.53-7.45 (m, 1H), 7.33-7.25 (m, 2H), 6.96 (d, J = 9.0 Hz, 1H), 6.70 (s, 1H), 3.60-3.52 (m, 4H), 2.41- 2.34 (m, 4H), 2.21 (s, 3H), 2.10 (s, 3H). 2A Example 12 Compound 12

ESI-MS: m/z = 433.3 ([M + H]⁺). ¹H NMR (400 MHZ, DMSO-d₆) δ 12.89 (s, 1H), 8.83 (d, J = 2.2 Hz, 1H), 8.13 (dd, J = 9.0,2.4 Hz,1H), 7.53-7.45 (m, 1H), 7.33-7.25 (m, 2H), 6.96 (d, J = 9.0 Hz, 1H), 6.70 (s, 1H), 3.60-3.52 (m, 4H), 2.41- 2.34 (m, 4H), 2.21 (s, 3H), 2.10 (s, 3H). 2A Example 13 Compound 13

ESI-MS: m/z = 447.3 ([M + H]⁺). ¹H NMR (400 MHZ, DMSO-d₆) δ 12.97 (s, 1H), 7.70 (s, 2H), 7.52-7.46 (m, 1H), 7.32-7.26 (m, 2H), 6.71 (s, 1H), 3.60-3.52 (m, 4H), 2.41-2.34 (m, 4H), 2.28 (s, 6H), 2.23 (s, 3H), 2.11 (s, 3H). 2A Example 14 Compound 14

ESI-MS: m/z = 449.3 ([M + H]⁺). ¹H NMR (400 MHZ, DMSO-d₆) δ 12.92 (s, 1H), 7.70 (dd, J = 8.2, 1.8 Hz, 1H), 7.61 (d, J = 1.8 Hz, 1H), 7.53-7.45 (m, 1H), 7.33-7.25 (m, 2H), 6.98 (d, J = 8.3 Hz, 1H), 6.71 (s, 1H), 3.80 (s, 3H), 3.02 (br, 4H), 2.47 (br, 4H), 2.22 (s, 3H), 2.11 (s, 3H). 2A Example 15 Compound 15

ESI-MS: m/z = 447.3 ([M + H]⁺). ¹H NMR (400 MHZ, DMSO-d₆) δ 13.08 (s, 1H), 8.08 (d, J = 8.3 Hz, 2H), 7.53-7.45 (m, 1H), 7.37-7.26 (m, 4H), 6.76 (s, 1H), 4.54 (s, 2H), 3.21 (t, J = 5.5 Hz, 2H), 3.01 (s, 2H), 2.56 (t, J = 5.4 Hz, 2H), 2.20 (s, 3H), 2.10 (s, 3H). 2A Example 16 Compound 16

ESI-MS: m/z = 449.3 ([M + H]⁺). ¹H NMR (400 MHZ, DMSO-d₆) δ 12.78 (s, 1H), 7.48-7.39 (m, 2H), 7.28-7.22 (m, 2H), 6.63 (s, 1H), 6.61-6.56 (m, 2H), 3.71 (s, 3H), 3.25-3.20 (m, 4H), 2.46-2.41 (m, 4H), 2.21 (s, 3H), 2.07 (s, 3H). 2A Example 17 Compound 17

ESI-MS: m/z = 325.3 ([M + H]⁺). ¹H NMR (400 MHZ, DMSO-d₆) δ 12.77 (s, 1H), 8.21 (s, 1H), 7.93 (s, 1H), 7.52-7.45 (m, 2H), 7.32-7.25 (m, 2H), 6.66 (s, 1H), 3.89 (s, 3H), 2.09 (s, 3H). 2A Example 18 Compound 18

ESI-MS: m/z = 325.3 ([M + H]⁺). ¹H NMR (400 MHZ, DMSO-d₆) δ 12.95 (s, 1H), 7.79 (d, J = 2.2 Hz, 1H), 7.52-7.45 (m, 1H), 7.32-7.24 (m, 2H), 6.74 (d, J = 2.2 Hz, 1H), 6.70 (s, 1H), 3.90 (s, 3H), 2.07 (s, 3H). 2A Example 19 Compound 19

ESI-MS: m/z = 408.2 ([M + H]⁺). ¹H NMR (400 MHZ, DMSO-d₆) δ 12.77 (s, 1H), 8.26 (s, 1H), 7.97 (s, 1H), 7.52-7.44 (m, 1H), 7.32-7.26 (m, 2H), 6.66 (s, 1H), 4.31-4.22 (m, 1H), 2.90-2.84 (m, 2H), 2.22 (s, 3H), 2.12-1.90 (m, 9H). 2A Example 20 Compound 20

ESI-MS: m/z = 424.2 ([M + H]⁺). ¹H NMR (400 MHZ, DMSO-d₆) δ 12.73 (s, 1H), 8.24 (s, 1H), 7.96 (s, 1H), 7.60-7.50 (m, 1H), 7.12 (d, J = 8.6 Hz, 1H), 7.06 (t, J = 8.7 Hz, 1H), 6.60 (s, 1H), 4.31-4.21 (m, 1H), 3.78 (s, 3H), 2.90-2.81 (m, 2H), 2.20 (s, 3H), 2.08-1.90 (m, 6H). 2A Example 21 Compound 21

ESI-MS: m/z = 341.2 ([M + H]⁺). ¹H NMR (400 MHZ, DMSO-d₆) 8 12.73 (s, 1H), 8.20 (s, 1H), 7.93 (s, 1H), 7.59-7.51 (m, 1H), 7.12 (d, J = 8.6 Hz, 1H), 7.05 (t, J = 8.7 Hz, 1H), 6.61 (s, 1H), 3.89 (s, 3H), 3.78 (s, 3H). 2A Example 22 Compound 22

ESI-MS: m/z = 341.2 ([M + H]⁺). ¹H NMR (400 MHZ, DMSO-d₆) δ 12.91 (s, 1H), 7.79 (d, J= 1.9 Hz, 1H), 7.60-7.51 (m, 1H),7.14-7.02 (m, 2H), 6.73 (d, J = 1.9 Hz, 1H), 6.64 (s, 1H), 3.90 (s, 3H), 3.78 (s, 3H). 2A Example 23 Compound 23

ESI-MS: m/z = 432.4 ([M + H]⁺). ¹H NMR (400 MHZ, DMSO-d₆) δ 13.04 (br, 1H), 8.07 (d, J = 8.4 Hz, 2H), 7.61-7.53 (m 3H), 7.15-7.03 (m, 2H), 6.70 (s, 1H), 6.25 (s, 1H), 3.79 (s, 3H), 3.12 (s, 2H), 2.70-2.62 (m, 2H), 2.56-2.50 (m, 2H), 2.34 (s, 3H). 4 Example 24 Compound 24

ESI-MS: m/z = 434.4 ([M + H]⁺). ¹H NMR (400 MHZ, DMSO-d₆) δ 12.96 (br, 1H), 8.02 (d, J = 8.2 Hz, 1H), 7.60-7.52 (m, 1H), 7.37 (d, J = 8.2 Hz, 1H), 7.12 (d, J = 8.6 Hz, 1H), 7.06 (t, J = 8.92 Hz, 1H), 6.68 (s, 1H), 2.86 (d, J = 11.2 Hz, 2H), 2.50-2.42 (m, 1H), 2.19 (s, 3H), 1.97 (t, J = 10.6 Hz, 2H), 1.77-1.60 (m, 4H). 4 Example 25 Compound 25

ESI-MS: m/z = 447.3 ([M + H]⁺). ¹H NMR (400 MHZ, DMSO-d₆) δ 12.65 (s, 1H), 9.78 (d, J = 9.0 Hz, 2H), 7.30 (d, J = 8.6 Hz, 1H), 7.02 (d, J = 9.0 Hz, 2H), 6.76 (d, J = 2.5 Hz, 1H), 6.65 (dd, J = 8.6, 2.6 Hz, 1H), 6.51 (s, 1H), 3.85 (s, 3H), 3.73 (s, 3H), 3.23-3.18 (m, 4H), 2.45-2.41 (m, 4H), 2.21 (s, 3H). 3B Example 26 Compound 26

ESI-MS: m/z = 446.3 ([M + H]⁺). ¹H NMR (400 MHZ, DMSO-d₆) δ 12.88 (s, 1H), 8.05 (d, J = 8.3 Hz, 2H), 7.37 (d, J = 8.4 Hz,2H), 7.31 (d, J = 8.6 Hz, 1H), 6.76 (d, J = 2.5 Hz, 1H), 6.66 (dd, J = 8.6, 2.5 Hz, 1H), 6.59 (s, 1H), 3.86 (s, 3H), 373 (s, 3H), 3.08-2.98 (m, 2H), 2.62-2.52 (m, 1H), 2.40-2.20 3A (m, 5H), 1.84-1.68 (m, 4H). Example 27 Compound 27

ESI-MS: m/z = 423.3 ([M + H]⁺). ¹H NMR (400 MHZ, DMSO-d₆) δ 12.88 (s, 1H), 8.84 (d, J = 2.2 Hz, 1H), 8.16 (dd, J = 9.0,2.4 Hz, 1H), 7.60-7.52 (m, 1H), 7.12 (d, J = 8.6 Hz, 1H), 7.06 (t, J = 8.8 Hz, 1H), 6.97 (d, J = 9.0 Hz, 1H), 6.65(s, 1H), 3.79 (s, 3H), 3.72-3.66 (m, 4H), 3.54-3.50 (m, 4H). 2A Example 28 Compound 28

ESI-MS: m/z = 437.3 ([M + H]⁺). ¹H NMR (400 MHZ, DMSO-d₆) δ 12.97 (br, 1H), 8.94 (s, 2H), 7.60-7.52 (m, 1H), 7.12 (d, J = 8.6 Hz, 1H), 7.06 (t, J = 8.8 Hz, 1H), 6.68 (s, 1H), 3.82-3.76 (m, 7H), 3.38-3.32 (m, 4H), 2.20 (s, 3H). 2A Example 29 Compound 29

ESI-MS: m/z = 447.3 ([M + H]⁺). ¹H NMR (400 MHZ, DMSO-d₆) δ 12.83 (s, 1H), 7.96 (d, J = 9.0 Hz, 2H), 7.57-7.50 (m, 1H), 7.39 (d, J = 7.9 Hz, 1H), 7.31-7.25 (m, 1H), 7.03 (d, J = 9.0 Hz, 2H), 6.66 (s, 1H), 3.24-3.16 (m, 4H), 2.61 (sept, 1H), 2.45-2.35 (m, 4H), 2.21 (s, 3H), 1.15-1.11 (m, 6H). 2A Example 30 Compound 32

ESI-MS: 408.1 [M + H]⁺ ¹H NMR (400 MHZ, DMSO-d₆) δ 13.04 (s, 1H), 8.98 (s, 2H), 7.52-7.46 (m, 1H), 7.32-7.27 (m, 2H), 6.75 (s, 1H), 3.77 (t, J = 4.4 Hz, 4H), 3.66 (t, J = 4.4 Hz, 4H), 2.10 (s, 3H). 2A Example 31 Compound 33

ESI-MS: m/z = 449.1 ([M + H]⁺). ¹H NMR (400 MHZ, DMSO-d₆) δ 12.81 (brs, 1H), 7.98 (d, J = 8.9 Hz, 2H), 7.56 (q, J = 7.9 Hz, 1H), 7.15-7.02 (m, 4H), 6.63 (s, 1H), 3.83 (s, 2H), 3.79 (s, 3H), 3.59-3.53 (m, 2H), 3.47-3.41 (m, 2H), 3.32 (s, 3H). 2B Example 32 Compound 34

ESI-MS: m/z = 445.2 ([M + H]⁺). ¹H NMR (400 MHZ, DMSO-d₆) δ 12.83 (s, 1H), 7.96 (d, J = 9.0 Hz, 2H), 7.51-7.44 (m, 1H), 7.26 (t, J = 8.8 Hz, 1H), 7.06-6.96 (m, 3H), 6.67 (s, 1H), 3.24- 3.18 (m, 4H), 2.45-2.39 (m, 4H), 2.21 (s, 3H),1.61- 1.52 (m, 1H), 0.82-0.62 (m, 4H). 3A Example 33 Compound 42

ESI-MS: 444.3 [M + H]⁺ ¹H NMR (400 MHz, DMSO-d₆) δ 12.89 (s, 1H), 8.01 (d, J = 9.2 Hz, 1H), 7.95 (d, J = 8.8Hz,2H),7.89 (s, 1H), 7.03 (d, J = 8.8 Hz, 2H), 6.71 (s, 1H), 3.23-3.20 (m, 4H), 2.45-2.41 (m, 4H), 2.21 (s, 3H), 2.17 (s, 3H). 2A Example 34 Compound 47

ESI-MS: m/z = 402.2 ([M + H]⁺). ¹H NMR (400 MHZ, DMSO-d₆) δ 12.81 (brs, 1H), 8.59-8.55 (m, 2H), 7.98 (d, J = 8.8 Hz, 2H), 7.49 (d, J = 4.2, 1H), 7.03 (d, J = 8.0 Hz, 2H), 6.66 (s, 1H), 3.32-3.21 (m, 4H), 2.58-2.42 (m, 4H), 2.25 (s, 3H), 2.15 (s, 3H). 4 Example 35 Compound 48

ESI-MS: m/z = 418.1 ([M + H]⁺). ¹H NMR (400 MHZ, DMSO-d₆) δ 12.76 (brs, 1H), 8.68-8.48 (m, 2H), 7.97 (d, J = 8.4 Hz, 2H), 7.33 (d, J = 5.6 Hz, 1H), 7.02 (d, J = 8.4 Hz, 2H), 6.59 (s, 1H), 3.85 (s, 3H), 3.29-3.08 (m, 4H), 2.48-2.31 (m, 4H), 2.21 (s, 3H). 4 Example 36 Compound 55

ESI-MS: 433.2 [M + H]⁺ ¹HNMR (400 MHZ, DMSO-d₆) δ 12.90 (s, 1H), 7.98 (d, J = 8.8 Hz, 2H), 7.51-7.45 (m, 1H), 7.32-7.27 (m, 2H), 7.03 (d, J = 9.2 Hz, 2H), 3.20 (t, J = 4.8 Hz, 4H), 2.43 (t, J = 4.8 Hz, 4H), 2.28 (s, 3H), 2.21 (s, 3H), 2.07 (s, 3H). 3A Example 37 Compound 58

ESI-MS: 445.3 [M + H]⁺ ¹H NMR (400 MHZ, DMSO-d₆) δ 12.84 (s, 1H), 7.96 (d, J = 8.9 Hz, 2H), 7.55-7.44 (m, 1H),, 7.35-7.25 (m, 2H), 7.04 (d, J = 8.6 Hz, 2H), 6.68 (s, 1H), 3.17 (br, 4H), 2.67 (br, 4H), 2.10 (s, 3H), 1.65 (br, 1H), 0.56-0.30 (m, 4H). 4 Example 38 Compound 61

ESI-MS: 445.3[M + H]⁺ ¹H NMR (700 MHZ, DMSO-d₆) δ 12.82 (s, 1H), 7.94 (d, J = 8.9 Hz, 2H), 7.51-7.46 (m, 1H), 7.32-7.28 (m, 2H), 6.95-6.89 (m, 2H), 6.67 (s, 1H), 3.51-3.44 (m, 2H), 3.42-3.35 (m, 2H), 3.06 - 2.84 (m, 2H), 2.33 (brs, 3H), 2.09 (s, 3H), 2.06 - 1.94 (m, 2H), 1.79- 1.52 (m, 2H). 2A Example 39 Compound 72

ESI-MS: 406.3 [M + H]⁺ ¹H NMR (400 MHZ, DMSO-d₆) δ 13.01 (s, 1H), 8.05-7.75 (m, 2H), 7.63-7.45 (m, 1H), 7.22-6.99 (m, 3H), 6.69 (s, 1H), 3.79 (s, 3H), 3.53 (s, 2H), 2.86 (s, 2H), 2.62 (s, 2H), 2.35 (s, 3H). 2A Example 40 Compound 73

ESI-MS: m/z = 406.2 ([M + H]⁺). ¹H NMR (400 MHZ, DMSO-d₆) δ 12.80 (brs, 1H), 7.77 (s, 1H), 7.61-7.51 (m, 1H), 7.12 (d, J = 8.6 Hz, 1H), 7.06 (t, J = 8.9 Hz, 1H), 6.63 (s, 1H), 3.79 (s, 3H), 3.75-3.68 (m, 4H), 3.51-3.44 (m, 4H). 2A Example 41 Compound 74

ESI-MS: m/z = 460.2 ([M + H]⁺). ¹H NMR (400 MHz, DMSO-d₆) δ 12.91 (brs, 1H), 7.96 (d, J = 8.7 Hz, 2H), 7.85-7.70 (m, 2H), 7.08 (d, J = 8.7 Hz, 2H), 6.85 (s, 1H), 3.87 (s, 3H), 3.39-3.30 (m, 4H), 3.02-2.78 (m, 4H), 2.55 (s, 3H). 4 Example 42 Compound 75

ESI-MS: m/z = 429.2 ([M + H]⁺). ¹H NMR (400 MHZ, DMSO-d₆) δ 12.76 (brs, 1H), 8.01 (d, J = 8.8 Hz, 2H), 7.53-7.42 (m, 3H), 7.04(d, J = 8.9 Hz, 2H), 6.62 (s, 1H), 5.11 (s, 2H), 4.95 (s, 2H), 3.27-3.17 (m, 4H), 2.48-2.41 (m, 4H), 2.22 (s, 3H). 4 Example 43 Compound 76

ESI-MS: m/z = 431.2 ([M + H]⁺). ¹H NMR (400 MHZ, DMSO-d₆) δ 12.75 (brs, 1H), 8.01 (d, J = 8.8 Hz, 2H), 7.15-6.96 (m, 5H), 6.60 (s, 1H), 6.10 (s, 2H), 3.28-3.17 (m, 4H), 2.47-2.36 (m, 4H), 2.22 (s, 3H). 4 Example 44 Compound 77

ESI-MS: 453.2 [M + H]⁺ 1H NMR (400 MHZ, DMSO-d₆) δ 12.81 (s, 1H), 7.95 (d, J = 9.0 Hz, 2H), 7.17-7.08 (m, 2H), 7.04 (d, J = 9.0 Hz, 2H), 6.62 (s, 1H), 3.80 (s, 3H), 3.25-3.19 (m, 4H), 2.47-2.42 (m, 4H), 2.22 (s, 3H). 2A Example 45 Compound 78

ESI-MS: 453.1 [M + H]⁺ 2A Example 46 Compound 79

ESI-MS: 492.2 [M + H]⁺ ¹H NMR (400 MHZ, DMSO-d₆) δ 12.83 (s, 1H), 8.70 (d, J = 4.3 Hz, 1H), 7.95 (d, J = 8.3 Hz, 2H), 7.54 (s, 1H), 7.47 (d, J = 10.0 Hz, 1H), 7.03 (d, J = 8.4 Hz, 2H), 6.64 (s, 1H), 3.85 (s, 3H), 3.23-3.18 (m, 4H), 2.85 (d, J = 3.5 Hz, 3H), 2.46-2.40 (m, 4H), 2.21 (s, 3H). 4 Example 47 Compound 80

ESI-MS: 506.1 [M + H]⁺ ¹H NMR (400 MHZ, DMSO-d₆) δ 12.83 (s, 1H), 7.95 (d, J = 8.6 Hz, 2H), 7.17-7.11 (m, 2H), 7.04 (d, J = 8.6 Hz, 2H), 6.64 (s, 1H), 3.81 (s, 3H), 3.24-3.17 (m, 4H), 3.03 (s, 3H), 3.00 (s, 3H), 2.46-2.40 (m, 4H), 2.21 (s, 3H). 4 Example 48 Compound 81

ESI-MS: 422.3 [M + H]⁺ ¹H NMR (400 MHZ, DMSO-d₆) δ 12.81 (s, 1H), 7.96 (d, J = 8.8 Hz, 2H), 7.52-7.46 (m, 1H), 7.32-7.26 (m, 2H), 7.03 (d, J = 9.0 Hz, 1H), 6.67 (s, 1H), 3.23-3.19 (m, 2H), 2.46-2.42 (m, 4H), 2.10 (s, 3H). 2A Example 49 Compound 82

ESI-MS: 501.3 [M + H]⁺ ¹H NMR (700 MHZ, DMSO-d₆) δ 8.02-8.00 (m, 1H), 8.00-7.95 (m, 2H), 7.90 (s, 1H), 7.08-7.04 (m, 2H), 6.73-6.71 (m, 1H), 3.83-3.78 (m, 1H), 3.70- 3.54 (m, 4H), 3.28-3.15 (m, 6H), 2.17 (s, 3H), 1.10-1.09 (m, 3H). 2B Example 50 Compound 83

ESI-MS: 502.2 [M + H]⁺ ¹H NMR (700 MHZ, DMSO-d₆) δ 12.93 (s, 1H), 8.02 (dd, J = 9.2, 1.7 Hz, 1H), 7.98 (d, J = 9.0 Hz, 2H), 7.90 (s, 1H), 7.07 (d, J = 9.0 Hz, 2H), 6.73 (s, 1H), 4.98 (d, J = 6.9 Hz, 1H), 4.48-4.44 (m, 1H), 3.73- 3.62 (m, 3H), 3.58-3.52 (m, 1H), 3.30-3.16 (m, 4H), 2.17 (s, 3H), 1.20 (d, J = 6.6 Hz, 3H). 2B Example 51 Compound 84

ESI-MS: 469.1 [M + H]⁺ ¹HNMR (400 MHZ, DMSO-d₆) δ 12.86 (s, 1H), 7.97 (d, J = 9.0 Hz, 2H), 7.54-7.45 (m, 1H), 7.35-7.26 (m, 2H), 7.04 (d, J = 9.0 Hz, 2H), 6.68 (s, 1H), 6.18 (tt, J = 55.6, 4.3 Hz, 1H), 3.26 - 3.20 (m, 4H), 2.78 (td, J = 4 15.6, 4.1 Hz, 2H), 2.69- 2.62 (m, 4H), 2.10 (s, 3H). Example 52 Compound 85

ESI-MS: 500.3 [M + H]⁺ ¹H NMR (400 MHZ, DMSO-d₆) δ 12.91 (s, 1H), 8.04-7.98 (m, 1H), 7.95 (d, J = 8.9 Hz, 2H), 7.88 (s, 1H), 7.02 (d, J = 8.9 Hz, 2H), 6.71 (s, 1H), 3.83-3.75 (m, 2H), 3.68-3.62 (m, 1H), 3.54-3.49 (m, 1H), 3.21 (t, J = 5.0 Hz, 4H), 2.95-2.87 (m, 1H), 2.60-2.42 (m, 2B 4H), 2.17 (m, 3H), 2.03-1.94 (m, 1H), 1.81-1.71 (m, 1H). Example 53 Compound 86

ESI-MS: 502.2 [M + H]⁺ ¹H NMR (400 MHZ, DMSO-d₆) δ 12.87 (s, 1H), 7.94 (d, J = 8.9 Hz, 2H), 7.79 (d, J = 8.9 Hz, 1H), 7.73 (s, 1H), 7.04 (d, J = 8.9 Hz, 2H), 6.67 (s, 1H), 4.56 (t, J = 6.5 Hz, 2H), 4.47 (t, J = 6.5 Hz, 2H), 3.87 (s, 3H), 3.47-3.40 (m, 1H), 3.26- 3.23 (m, 4H), 2.41-2.37 (m, 4H). 2A Example 54 Compound 87

ESI-MS: 431.2 [M + H]⁺ ¹H NMR (400 MHZ, DMSO-d₆) δ 12.72 (s, 1H), 7.93 (d, J = 8.8 Hz, 2H), 7.53-7.44 (m, 1H), 7.33-7.27 (m, 2H), 6.68 (d, J = 8.9 Hz, 2H), 6.64 (s, 1H), 4.35 (s, 2H), 3.46 (br, 1H), 3.30-3.28 (m, 1H), 3.21 (d, J = 9.3 Hz, 2H), 2.79 (d, J = 9.4 Hz, 1H), 2.52-2.50 (m, 4 1H), 2.27 (brs, 3H), 2.10 (s, 3H), 1.93-1.86 (m, 1H), 1.81-1.75 (s, 1H). Example 55 Compound 88

ESI-MS: 431.2 [M + H]⁺ ¹H NMR (400 MHZ, DMSO-d6) δ 12.72 (s, 1H), 7.93 (d, J = 8.8 Hz, 2H), 7.53-7.44 (m, 1H), 7.33-7.27 (m, 2H), 6.68 (d, J = 8.9 Hz, 2H), 6.64 (s, 1H), 4.35 (s, 2H), 3.46 (br, 1H), 3.30-3.28 (m, 1H), 3.21 (d, J = 9.3 Hz, 2H), 2.79 (d, J = 4 9.4 Hz, 1H), 2.52-2.50 (m, 1H), 2.27 (brs, 3H), 2.10 (s, 3H), 1.93-1.86 (m, 1H), 1.81-1.75 (s, 1H). Example 56 Compound 89

ESI-MS: 447.1 [M + H]⁺ ¹HNMR (400 MHZ, DMSO-d₆) δ 12.85 (s, 1H), 7.95 (d, J = 8.9 Hz, 2H), 7.53-7.44 (m, 1H), 7.34-7.25 (m, 2H), 7.02 (d, J = 8.9 Hz, 2H), 6.67 (s, 1H), 3.20 (br, 2H), 2.99 (br, 2H), 2.63- 2.52 (m, 2H), 2.16 (br, 3H), 2.10 (s, 3H), 1.01 (s, 6H). 4 Example 57 Compound 90

ESI-MS: 447.1 [M + H]⁺ ¹H NMR (400 MHZ, DMSO-d₆) δ 12.81 (s, 1H), 7.96 (d, J = 9.0 Hz, 2H), 7.58- 7.42 (m, 1H), 7.36-7.25 (m, 2H), 7.03 (d, J = 9.0 Hz, 2H), 6.67 (s, 1H), 3.66 (d, J = 11.7 Hz, 2H), 2.48- 2.42 (m, 2H), 2.29- 2.14 (m, 5H), 2.10 (s, 3H), 1.06 (d, J = 4 6.1 Hz, 6H). Example 58 Compound 91

ESI-MS: 431.2 [M + H]⁺ ¹H NMR (400 MHz, DMSO-d₆) δ 12.74 (br, 1H), 7.99 (d, J = 9.0 Hz, 2H), 7.52- 7.46 (m, 1H), 7.32- 7.26 (m, 2H), 6.84 (d, J = 9.0 Hz, 2H), 6.64 (s,1H), 3.56 (d, J = 5.8 Hz, 2H), 3.47 (d, J = 11.2 Hz, 2H), 3.30-3.27 (m, 2H), 2.42 (q, J = 6.7 Hz, 1H), 2.10 (s, 4 3H), 1.99 (s, 3H), 1.50 (d, J = 8.2 Hz, 1H). Example 59 Compound 92

ESI-MS: 422.2 [M + H]⁺ ¹H NMR (400MHZ, DMSO-d₆) δ 12.81 (s, 1H), 7.97 (d, J = 8.8 Hz, H), 7.59- 7.53 (m, 1H), 7.12 (d, J = 8.4 Hz, 1H), 7.09-7.04 (m, 3H), 6.63 (s, 1H), 3.78 (s, 3H), 3.73 (t, J = 4.8 Hz, 4H), 3.18 (t, J = 4.8 Hz, 4H). 2A Example 60 Compound 93

ESI-MS: 435.2 [M + H]⁺ ¹H NMR (400 MHZ, DMSO-d₆) δ 13.05 (s, 1H), 9.79 (br, 3H), 8.10 (d, J = 8.5 Hz, 2H), 7.54-7.45 (m, 1H), 7.34-7.26 (m, 2H), 7.17 (d, J = 8.6 Hz, 2H), 6.74 (s, 1H), 4.38-4.28 (m, 2H), 4.01-3.92 (m, 1H), 3.66-3.17 (m, 4H), 2.10 (s, 3H). 4 Example 61 Compound 94

ESI-MS: 437.2 [M + H]⁺ ¹H NMR (400 MHZ, DMSO-d₆) δ 12.89 (br, 1H), 7.87 (dd, J = 8.4, 2.0 Hz, 1H), 7.75 (dd, J = 14.2, 2.0 Hz, 1H), 7.55 - 7.46 (m, 1H), 7.33 - 7.27 (m, 2H), 7.15 (t, J = 8.9 Hz, 1H), 6.72 (s, 1H), 3.10-3.04 (m, 4H), 2.48-2.43 (m, 4H), 2.21 (s, 3H), 2.10 (s, 3H). 2A Example 62 Compound 95

ESI-MS: 476.4 [M + H]⁺ ¹H NMR (400 MHZ, DMSO-d₆) δ 13.04 (s, 1H), 8.18 (s, 1H), 8.00 (d, J = 8.1 Hz, 1H), 7.49 (q, J = 7.0 Hz, 1H), 7.35-7.19 (m, 3H), 6.74 (s, 1H), 3.59 (br, 2H), 3.00 (s, 4H), 2.70 (br, 4H), 2.39 (s, 3H), 2.27 (s, 6H), 2.12 (s, 3H). 2A Example 63 Compound 96

ESI-MS: 462.4 [M + H]⁺ 2A Example 64 Compound 97

ESI-MS: 432.2 [M + H]⁺ ¹HNMR (400 MHZ, DMSO-d₆), δ 12.79 (s, 1H), 8.82 (d, J = 2.2 Hz, 1H), 8.12 (dd, J = 9.0, 2.4 Hz, 1H), 7.39 (t, J = 8.0 Hz, 1H), 7.06 (d, J = 8.2 Hz,1H), 6.99 (d, J = 7.6 Hz, 1H), 6.95 (d, J = 9.0 Hz, 1H), 6.62 (s, 1H), 3.70 (s, 3H), 3.60-3.50 (m, 4H), 2A 2.42-2.32 (m, 4H), 2.20 (s, 3H), 2.00 (s, 3H). Example 65 Compound 98

ESI-MS: 434.2 [M + H]⁺ ¹HNMR (400 MHZ, DMSO-d₆) δ 12.92 (s, 1H), 8.83 (d, J = 2.4 Hz, 1H), 8.14 (dd, J = 9.2, 2.4 Hz, 1H), 7.57- 7.51 (m, 1H), 7.33- 7.28 (m, 2H), 6.97 (d, J = 9.2 Hz, 1H), 6.71 (s, 1H), 3.59-3.52 (m, 4H), 2.47- 2.34 (m, 6H), 2.22 (s, 3H), 1.06 (t, J = 7.6 Hz, 3H). 2A Example 66 Compound 99

ESI-MS: 445.2 [M + H]⁺ ¹H NMR (400 MHZ, DMSO-d₆) δ 12.99 (br, 1H), 8.82 (s, 1H), 8.13 (d, J = 8.0 Hz, 1H), 8.01 (d, J = 9.2 Hz, 1H), 7.89 (s, 1H), 6.96 (d, J = 9.2 Hz, 1H), 6.74 (s, 1H), 3.56 (s, 4H), 2.38 (s, 4H), 2.21 (s, 3H), 2.17 (s, 3H). 2A Example 67 Compound 100

ESI-MS: 422.1 [M + H]⁺ ¹H NMR (400 MHZ, DMSO-d₆) δ 12.82 (s,1H), 10.37 (s, 1H), 8.85 (d, J = 2.4 Hz, 1H), 8.14 (dd, J = 8.8, 2.4 Hz, 1H), 7.40-7.33 (m, 1H), 6.97 (d, J = 9.2 Hz, 1H), 6.83-6.89 (m, 2H), 6.64 (s, 1H), 3.60-3.54 (m, 4H), 2.44-2.37 (m, 4H), 2.22 (s, 3H). 2A Example 68 Compound 101

ESI-MS: m/z = 434.2 ([M + H]⁺). ¹H NMR (400 MHZ, DMSO-d₆) δ 12.96 (brs, 1H), 8.83 (s, 1H), 8.14 (d, J = 8.9 Hz, 1H), 7.55-7.42 (m, 1H), 7.35-7.22 (m, 2H), 6.95 (d, J = 9.0 Hz, 1H), 6.67 (s, 1H), 3.65-3.46 (m, 4H), 2.46-2.38 (m, 4H), 2.38- 2.26 (m, 2H), 2.10 (s, 3H), 1.02 (t, J = 7.0 Hz, 3H). 2B Example 69 Compound 102

ESI-MS: m/z = 448.2 ([M + H]⁺). ¹H NMR (400 MHZ, DMSO-d₆) δ 12.93 (brs, 1H), 8.85 (d, J = 2.2 Hz, 2H), 8.17 (d, J = 9.2 Hz, 1H), 7.54-7.46 (m, 1H), 7.34-7.26 (m, 2H), 6.99 (d, J = 9.1 Hz, 1H), 6.71 (s, 1H), 3.67-3.60 (m, 2H), 3.59- 3.49 (m, 6H), 2.10 (s, 3H), 2.04(s, 3H). 2B Example 70 Compound 103

ESI-MS: m/z = 462.2 ([M + H]⁺). ¹H NMR (400 MHZ, DMSO-d₆) δ 12.92 (brs, 1H), 8.85 (s, 1H), 8.15 (d, J = 9.2 Hz, 1H), 7.55-7.45 (m, 1H), 7.35-7.26 (m, 2H), 6.99 (d,J=8.6 Hz, 1H), 6.71 (s, 1H), 4.64-4.39 (m, 4H), 3.69-3.49 (m, 4H), 3.48- 3.36 (m, 1H), 2.41-2.24 (m, 4H), 2.11 (s, 3H). 2B Example 71 Compound 104

ESI-MS: m/z =455.1 ([M + H]⁺). ¹H NMR (400 MHZ, DMSO-d₆) δ 12.97 (brs, 1H), 8.88 (d,J = 2.2 Hz, 1H), 8.21 (d, J = 9.0, 2.3 Hz, 1H), 7.55-7.44 (m, 1H), 7.35-7.25 (m, 2H), 7.17 (d, J = 9.0 Hz, 1H), 6.73 (s, 1H), 4.20-3.99 (m, 4H), 3.19- 3.05 (m, 4H), 2.10 (s, 3H). 2B Example 72 Compound 105

ESI-MS: 498.1 [M + H]⁺ ¹H NMR (400 MHZ, DMSO-d₆) δ 12.94 (s, 1H), 8.86 (d, J = 2.0 Hz, 1H), 8.18 (dd, J = 9.2, 2.4 Hz, 1H), 7.52-7.47 (m, 1H), 7.34-7.26 (m, 2H), 7.03 (d, J = 8.8 Hz, 1H), 6.72 (s, 1H), 3.71-3.65 (m, 4H), 3.29- 3.22 (m, 4H), 3.08 (q, J = 7.6 Hz, 2H), 2.10 (s, 3H), 1.21 (t.,J = 2B 7.2 Hz, 3H). Example 73 Compound 106

ESI-MS: 476.2 [M + H]⁺ ¹H NMR (400 MHZ, DMSO-d₆) δ 12.91 (s, 1H), 8.83 (d, J = 2.0 Hz, 1H), 8.14 (dd, J = 9.2, 2.4Hz, 1H), 7.52-7.47 (m, 1H), 7.34-7.26 (m, 2H), 6.96 (d, J = 8.8 Hz, 1H), 6.70 (s, 1H), 3.83-3.74 (m, 2H), 3.64 (q, J = 7.6 Hz, 1H), 3.58-3.48 2A (m, 5H), 2.94-2.87 (m, 1H), 2.55-2.47 (m, 1H), 2.43-2.38 (m, 2H), 2.10 (s, 3H), 2.02-1.94 (m, 1H), 1.80-1.71 (m, 1H). Example 74 Compound 107

ESI-MS: 440.1 [M + H]⁺ ¹H NMR (400 MHZ, DMSO-d₆) δ 12.97 (s, 1H), 8.83 (d, J = 2.2 Hz, 1H), 8.13 (dd, J = 9.0, 2.4 Hz, 1H), 7.70-7.60 (m, 2H), 7.57-7.52 (m, 1H), 6.98 (d, J = 9.0 Hz, 2H), 6.74 (s, 1H), 3.62-3.52 (m, 4H), 2.48- 2.38 (m, 4H), 2.24 (s, 3H). 2A Example 75 Compound 108

ESI-MS: 454.3 [M + H]⁺ ¹H NMR (400 MHZ, DMSO-d₆) δ 12.82 (br, 1H), 8.83 (d, J = 2.3 Hz, 1H), 8.13 (dd, J = 9.0, 2.4 Hz, 1H), 7.58 (dd, J = 9.3, 2.3 Hz, 1H), 7.46 (s,1H),6.96 (d, J = 9.0 Hz, 1H), 6.72 (s, 1H), 3.58-3.54 (m, 4H), 2.39-2.36 (m, 4H), 2.21 (s, 3H), 2.11 (s, 3H). 2A Example 76 Compound 109

ESI-MS: 446.3 [M + H]⁺ ¹H NMR (400 MHZ, DMSO-d₆) δ 12.88 (s, 1H), 8.81 (s, 1H) 8.12-8.10 (m, 1H), 7.52-7.48 (m, 1H), 7.31-7.28 (m, 2H), 6.82 (d, J = 9.2 Hz, 1H), 6.69 (s,1H), 3.86 (d, J = 11.2 Hz, 2H), 3.23 (s, 2H), 2.99 (d, J = 11.2 Hz, 2H), 2.24 (s, 3H), 2.10 (s, 3H), 1.94-1.92 (m, 2H), 1.57-1.46 (m, 2H). 2A Example 77 Compound 110

ESI-MS: 435.2 [M + H]⁺ ¹H NMR (400 MHZ, DMSO-d₆,) δ 13.03 (s, 1H), 8.95 (s, 2H), 7.57-7.51 (m, 1H), 7.33-7.25 (m, 2H), 6.74 (s, 1H), 3.79 (t, J = 4.4 Hz, 4H), 2.45-2.38 (m, 2H), 2.35 (t, J = 4.4 Hz, 4H), 2.20 (s, 3H), 1.05 (t, J = 7.6 Hz, 3H). 2A Example 78 Compound 111

ESI-MS: m/z = 424.1 ([M + H]⁺). ¹H NMR (400 MHZ, DMSO-d₆) δ 13.00 (brs, 1H), 8.97 (s, 2H), 7.56 (q, J = 8.0 Hz, 1H), 7.12 (d, J = 8.6 Hz, 1H), 7.06 (t, J = 8.9 Hz, 1H), 6.70 (s, 1H), 3.80- 3.74 (m, 7H), 3.70-3.61 (m, 4H). 2B Example 79 Compound 112

ESI-MS: 463.4 [M + H]⁺ ¹H NMR (700 MHZ, DMSO-d₆) δ 12.86 (s, 1H), 7.97 (d, J = 9.0 Hz, 2H), 7.56-7.52 (m, 1H), 7.33-7.30 (m, 2H), 7.03 (d, J = 9.0 Hz, 2H), 6.68 (s, 1H), 4.44 (s, 1H), 3.53 (q, J = 5.8 Hz, 2H), 3.22-3.19 (m, 4H), 2.56-2.52 (m, 4H), 2.45-2.37 (m, 4H), 1.06 (t, J =7.6 Hz, 3H). 2A Example 80 Compound 113

ESI-MS: 465.3 [M + H]⁺ ¹H NMR (400 MHZ, DMSO-d₆) δ 12.77 (s, 1H), 7.95 (d, J = 8.9 Hz, 2H), 7.60-7.51 (m, 1H), 7.17-6.98 (m, 4H), 6.61 (s, 1H), 4.41 (t, J = 5.3 Hz, 1H), 3.78 (s, 3H), 3.53 (q, J = 6.0 Hz, 2H), 3.24- 3.17 (m, 4H), 2.60 - 2.52 (m, 4H), 2.42 (t, J = 6.2 Hz, 2H). 2A Example 81 Compound 114

ESI-MS: 490.2 [M + H]⁺ ¹H NMR (400 MHZ, DMSO-d₆) δ 12.88 (s, 1H), 7.93 (d, J = 8.9 Hz, 2H), 7.78 (dd, J = 8.9, 1.5 Hz, 1H), 7.73 (s, 1H), 7.03 (d, J = 8.9 Hz, 2H), 6.66 (s, 1H), 4.43 (s, 1H), 3.87 (s, 3H), 3.26-3.12 (m, 6H), 2.60-2.52 (m, 4H), 2.47-2.40 (m, 2H). 2B Example 82 Compound 115

ESI-MS: 493.3 [M + H]⁺ ¹H NMR (400 MHZ, DMSO-d₆) δ 1 2.78 (s, 1H), 7.95 (d, J = 9.0 Hz, 2H), 7.61-7.50 (m, 1H), 7.12 (d, J = 8.6 Hz, 1H), 7.09- 6.96 (m, 3H), 6.62 (s, 1H), 4.12 (s, 1H), 3.78 (s, 3H), 3.27 - 3.12 (m, 4H), 2.72- 2.59 (m, 4H), 2.23 (s, 2H), 1.10 (s, 6H). 2A Example 83 Compound 116

ESI-MS: 494.3 [M + H]⁺ ¹H NMR (700 MHz, DMSO-d₆) δ 12.83 (s, 1H), 7.96 (d, J = 8.9 Hz, 2H), 7.56- 7.51 (m, 1H), 7.33-7.28 (m, 2H), 7.02 (d, J = 9.0 Hz, 2H),6.67 (s, 1H), 4.12 (s, 1H), 3.24-3.18 (m, 4H), 2.68-2.60 (m, 4H), 2.45-2.37 (m, 2H), 2.24 (s, 2H), 1.10 (s, 6H), 1.06 (t, J = 7.6 Hz, 3H). 2A Example 84 Compound 117

ESI-MS: 475.1 [M + H]⁺ ¹H NMR (400 MHZ, DMSO-d₆) δ 12.77 (s, 1H), 7.94 (d, J = 8.9 Hz, 2H), 7.53-7.46 (m, 1H), 7.33-7.25 (m, 2H), 6.89 (d, J = 9.0 Hz, 2H), 6.66 (s, 1H), 4.36 (t, J = 5.3 Hz, 1H), 3.50 (q, J = 5.9 Hz, 2H), 3.45-3.33 (m, 4H), 2.88 (d, J = 9.8 Hz, 2H), 2.43 (t, J = 6.2 Hz, 2H), 2.09 (s, 3H), 1.95- 1.83 (m, 2H), 1.65-1.54 (m, 2H). 2A Example 85 Compound 118

ESI-MS: 450.2 [M + H]⁺ ¹H NMR (400 MHZ, CD₃OD) δ 8.98 (d, J = 2.0 Hz, 1H), 8.31 (dd, J = 8.8, 2.4 Hz, 1H), 7.52-7.46 (m, 1H), 7.28 (d, J = 8.0 Hz, 1H), 7.21 (t, J = 8.8 Hz, 1H), 6.92 (d, J = 8.8 Hz, 1H), 6.74 (s, 1H), 3.74 (t, J = 5.6 Hz, 2H), 3.66 (t, J = 5.2 Hz, 4H), 2.66 (t, J = 5.2 Hz, 4H), 2.61 (t, J = 5.6 Hz, 2H), 2.18 (s, 3H). 2A Example 86 Compound 119

ESI-MS: 464.2 [M + H]⁺ ¹H NMR (400 MHZ, DMSO-d₆) δ 12.90 (s, 1H), 8.83 (d, J = 2.4 Hz, 1H), 8.14 (dd, J = 9.2, 2.4 Hz, 1H), 7.52-7.47 (m, 1H), 7.33- 7.26 (m, 2H), 6.96 (d, J = 8.8 Hz, 1H), 6.70 (s, 1H), 3.58-3.51 (m, 4H), 3.46 (t, J = 6.0 Hz, 2H), 3.24 (s, 3H), 2.52-2.45 (m, 6H), 2.10 (s, 3H). 2A Example 87 Compound 120

ESI-MS: 449.2 [M + H]⁺ ¹H NMR (400 MHZ, DMSO-d₆) δ 12.83 (s, 1H), 7.97 (d, J = 8.9 Hz, 2H), 7.53-7.45 (m, 1H), 7.34-7.25 (m, 2H), 7.02 (d, J = 9.0 Hz, 2H), 6.67 (s, 1H), 4.60-4.54 (m, 2H), 3.75 (d, J = 11.6 Hz, 1H), 3.69-3.57 (m, 2H), 3.40-3.34 (m, 1H), 2.89-2.73 (m, 2H), 4 2.62-2.53 (m, 1H), 2.30-2.19 (m, 4H), 2.14-2.06 (m, 4H). Example 88 Compound 121

ESI-MS: 465.2 [M + H]⁺ ¹H NMR (400 MHZ, DMSO-d₆) δ 12.75 (br, 1H), 7.95 (d, J = 8.9 Hz, 2H), 7.59-7.51 (m, 1H), 7.14- 6.99 (m, 4H), 6.60 (s, 1H), 4.56 (s, 1H), 3.78 (s, 3H), 3.77-3.71 (m, 1H), 3.69- 3.56 (m, 2H), 3.40-3.34 (m, 1H), 2.88-2.74 (m, 2H), 2.58 (dd, J = 12.0, 10.2 Hz, 1H), 2A 2.28-2.20 (m, 4H), 2.15-2.06 (m, 1H). Example 89 Compound 122

ESI-MS: 461.2 [M +H]⁺ ¹H NMR (400 MHZ, DMSO-d₆) 8 12.87 (s, 1H), 7.99 (d, J = 8.9 Hz, 2H), 7.53-7.45 (m, 1H), 7.35-7.25 (m, 2H), 7.13-7.04 (m, 2H), 6.69 (s, 1H), 4.41 (t, J = 8.1 Hz, 1H), 4.01-3.90 (m, 3H), 3.85-3.75 (m, 1H), 3.62 (dd, J = 13.3, 3.2 Hz, 1H), 3.16-3.07 (m, 1H), 2.85 - 2.62 (m, 2H), 4 2.10 (s, 3H). Example 90 Compound 123

ESI-MS: 477.2 [M + H]⁺ ¹H NMR (400 MHZ, DMSO-d₆) δ 12.81 (s, 1H), 7.97 (d, J = 8.9 Hz, 2H), 7.66-7.47 (m, 1H), 7.15-7.01 (m, 4H), 6.63 (s, 1H), 4.46-4.36 (m, 1H), 4.03-3.89 (m, 3H), 3.84-3.75 (m, 4H), 3.62 (dd, J = 13.1, 2.6 Hz, 1H), 3.17-3.07 (m, 1H), 2.82-2.65 (m, 2H). 2A Example 91 Compound 124

ESI-MS: 502.2 [M + H]⁺ ¹H NMR (400 MHZ, DMSO-d₆) δ 12.89 (s, 1H), 7.96 (d, J = 9.0 Hz, 2H), 7.78 (dd, J = 8.9, 1.4 Hz, 1H), 7.74-7.70 (m, 1H), 7.08 (d, J = 9.0 Hz, 2H), 6.67 (s, 1H), 4.41 (t, J = 8.1 Hz, 1H), 4.02-3.91 (m, 3H), 3.86 (s, 3H), 3.83-3.76 (m, 1H), 3.62 (dd, J = 13.1, 2.7 Hz, 1H), 3.12 (td, J = 12.7, 3.6 Hz, 1H), 2.82- 2.65 (m, 2H). 2B Example 92 Compound 125

ESI-MS: 477.1 [M + H]⁺ ¹H NMR (400 MHZ, DMSO-d₆) δ 12.79 (s, 1H), 7.96 (d, J = 8.8 Hz, 2H), 7.59-7.52 (m, 1H), 7.33-7.26 (m, 2H), 6.93 (d, J = 8.8 Hz, 2H), 6.66 (s, 1H), 4.29 (s, 1H), 3.65-3.58 (m, 1H), 3.56-3.49 (m, 1H), 2.98-2.81 (m, 3H), 2.62- 2.55 (m, 1H), 2.41 (s, 3H), 2A 2.28-2.20 (m, 1H), 2.10 (s, 3H), 1.13 (s, 3H), 1.11 (s, 3H). Example 93 Compound 126

ESI-MS: 493.3[M + H]⁺ ¹H NMR (400 MHZ, DMSO-d₆) δ 12.74 (s, 1H), 7.95 (d, J = 8.9 Hz, 2H), 7.65-7.50 (m, 1H), 7.12 (d, J = 8.6 Hz, 1H), 7.06 (t, J = 8.8 Hz, 1H), 6.93 (d, J = 9.0 Hz, 2H), 6.61 (s, 1H), 4.29 (s, 1H), 3.78 (s, 3H), 3.61 (dd, J = 12.8, 3.9 Hz, 1H), 3.58-3.48 2A (m, 1H), 3.01-2.77 (m, 3H), 2.63-5.52 (m, 1H), 2.40 (s, 3H), 2.24 (dd, J = 9.1, 3.9 Hz, 1H), 1.13 (s, 3H) , 1.11 (s, 3H). Example 94 Compound 127

ESI-MS: 507.3 [M + H]⁺ ¹H NMR (400 MHZ, DMSO-d₆) δ 12.73 (s, 1H), 7.95 (d, J = 8.8 Hz, 2H), 7.59-7.52 (m, 1H), 7.12 (d, J = 8.6 Hz, 1H), 7.06 (t, J = 8.8 Hz, 1H), 6.93 (d, J = 8.8 Hz, 2H), 6.60 (s, 1H), 3.78 (s, 3H), 3.60-3.52 (m, 2H), 3.11 (s, 3H), 2.95-2.80 (m, 3H), 2A 2.62-2.55 (m, 1H), 2.44 (dd, J = 9.0, 3.6 Hz, 1H), 2.39 (s, 3H), 1.15 (s, 3H), 1.11 (s, 3H). Example 95 Compound 128

ESI-MS: 450.3 [M + H]⁺ ¹H NMR (400 MHZ, DMSO-d₆) δ 12.83 (br, 1H), 8.83 (d, J = 2.2 Hz, 1H), 8.13 (dd, J = 9.0, 2.4 Hz, 1H), 7.54-7.44 (m, 1H), 7.34-7.25 (m, 2H), 6.93 (d, J = 9.1 Hz, 1H), 6.69 (s, 1H), 4.60 (br, 1H), 4.29 (d, J = 12.0 Hz, 1H), 4.10 (d, J = 12.2 Hz, 1H), 3.65 (dd, 2A J = 11.0, 3.6 Hz, 1H), 3.02 - 2.94 (m, 1H), 2.81- 2.69 (m, 2H), 2.23 (s, 3H), 2.19-2.13 (m, 1H), 2.10 (s, 3H), 2.07-1.92 (m, 1H). Example 96 Compound 129

ESI-MS: 436.1 [M + H]⁺ ¹H NMR (400 MHz, DMSO-d₆) δ 12.95 (s, 1H), 8.85 (d, J = 2.2 Hz, 1H), 8.17 (dd, J = 9.0, 2.4 Hz, 1H), 7.54-7.45 (m, 1H), 7.35-7.26 (m, 2H), 7.04 (d, J = 9.1 Hz, 1H), 6.72 (s, 1H), 4.58 (dd, J = 13.0, 2.8 Hz, 1H), 4.44-4.35 (m, 2H), 3.99 (dd, J = 8.8, 5.6 Hz, 1H), 3.92 - 3.79 (m, 1H), 3.65-3.58 (m, 1H), 3.07- 2A 2.99 (m, 1H), 2.96-2.79 (m, 2H), 2.10 (s, 3H). Example 97 Compound 130

ESI-MS: 449.2 [M + H]⁺ ¹H NMR (400 MHZ, DMSO-d₆) δ 12.92 (s, 1H; NH), 8.02-7.90 (m, 2H), 7.55- 7.43 (m, 1H), 7.35-7.24 (m, 2H), 7.03-6.94 m, 2H), 6.66 (s, 1H), 3.84-3.78 (m, 1H), 3.74-3.65 (m, 1H), 3.52-3.44 (m, 1H), 3.07- 3.01 (m, 1H), 3.00-2.90 (m, 1H), 2.84-2.77(m, 1H), 2.20 (s, 3H), 2.10 (d, J = 4 3.5 Hz, 3H), 2.06-1.93 (m, 3H). Example 98 Compound 131

ESI-MS: 463.3 [M + H]⁺ ¹H NMR (400 MHZ, DMSO-d₆) δ 12.97 (s, 1H), 10.58 (br, 1H), 8.02 (d, J = 8.8 Hz, 2H), 7.52-7.46 (m, 1H), 7.34-7.28 (m, 2H), 7.15 (d, J = 8.4 Hz, 2H), 6.71 (s, 1H), 4.34-4.24 (m, 1H), 4.18-4.04 (m, 1H), 3.94-3.80 (m, 1H), 3.36-3.20 (m, 4H), 2.92 (s, 3H), 2.10 (s, 3H). 2A Example 99 Compound 132

ESI-MS: 504.3 [M + H]⁺ ¹H NMR (400 MHZ, DMSO-d₆) δ 12.80 (s, 1H), 7.97 (d, J = 9.0 Hz, 2H), 7.59-7.53 (m,1H), 7.14-7.04 (m, 4H), 6.62 (s, 1H), 4.44- 4.36 (m, 1H), 3.84-3.77 (m, 5H), 3.65-3.56 (m, 1H), 3.07 (d, J = 15.6 Hz, 1H), 2.92-2.87 (m, 1H), 2.84-2.75 (m, 2H), 2A 2.71-2.56 (m, 2H), 2.26 (dd, J = 11.8, 8.0 Hz, 1H), 2.21 (s, 3H). Example 100 Compound 133

ESI-MS: 461.3 [M + H]⁺ ¹H NMR (400 MHZ, DMSO-d₆) δ 12.81 (s, 1H), 7.96 (d, J = 8.9 Hz, 2H), 7.52-7.46 (m, 1H), 7.32-7.27 (m, 2H), 7.03 (d, J = 8.9 Hz, 2H), 6.67 (s, 1H), 3.79-3.69 (m, 3H), 3.60 (d, J = 11.5 Hz, 1H), 3.56-3.49 (m,1H), 3.15 (t, J = 2A 10.4 Hz, 1H), 2.85-2.76 (m, 2H), 2.67 (d, J = 11.5 Hz, 1H), 2.36-2.16 (m, 4H), 2.10 (s, 3H). Example 101 Compound 134

ESI-MS: 461.3 [M + H]⁺ ¹HNMR (400 MHZ, DMSO-d₆) δ 12.81 (s, 1H), 7.96 (d, J = 8.9 Hz, 2H), 7.52-7.46 (m, 1H), 7.32-7.27 (m, 2H), 7.03 (d, J = 8.9 Hz, 2H), 6.67 (s, 1H), 3.79-3.69 (m, 3H), 3.60 (d, J = 11.5 Hz, 1H), 3.56-3.49 (m, 1H), 3.15 (t, J = 10.4 Hz, 1H), 2.85-2.76 2A (m, 2H), 2.67 (d, J = 11.5 Hz, 1H), 2.36-2.16 (m, 4H), 2.10 (s, 3H). Example 102 Compound 135

ESI-MS: 477.2 [M + H]⁺ ¹H NMR (400 MHZ, DMSO-d₆) δ 12.78 (s, 1H), 7.95 (d, J = 8.9 Hz, 2H), 7.59-7.52 (m, 1H), 7.12 (d, J = 8.6 Hz, 1H), 7.09-7.02 (m, 3H), 6.61 (s, 1H), 3.78- 3.69 (m, 6H), 3.60 (d, J = 11.5 Hz, 1H), 3.56-3.49 (m, 1H), 3.15 (t, J = 10.4 Hz, 1H), 2.85-2.76 (m, 2H), 2.67 (d, J = 11.5 Hz, 2A 1H), 2.36-2.16 (m, 4H). Example 103 Compound 136

ESI-MS: 477.2 [M + H]⁺ ¹HNMR (400 MHZ, DMSO-d₆) δ 12.80 (s, 1H), 7.95 (d, J = 8.9 Hz, 2H), 7.59-7.52 (m, 1H), 7.12 (d, J = 8.6 Hz, 1H), 7.09-7.02 (m, 3H), 6.62 (s, 1H), 3.78- 3.69 (m, 6H), 3.60 (d, J = 11.5 Hz, 1H), 3.56-3.49 (m, 1H), 3.15 (t, J = 10.4 Hz, 1H), 2.85-2.76 (m, 2H), 2.67 (d, J = 11.5 Hz, 1H), 2.36-2.16 (m, 4H). 2A Example 104 Compound 137

ESI-MS: 442.2 [M + H]⁺ ¹H NMR (400 MHZ, DMSO-d₆) δ 12.85 (s, 1H), 8.03-8.00 (m, 2H), 7.53-7.46 (m, 1H), 7.33-7.27 (m, 2H), 7.19-7.16 (m, 2H), 7.10 (d, J=1.0 Hz, 1H), 6.88 (d, J = 1.2 Hz, 1H), 6.69 (s, 1H), 4.47 (s, 2H), 4.09 (t, J = 5.3 Hz, 2H), 3.79 (t, J = 5.3 Hz, 2H), 2.10 (s, 3H). 4 Example 105 Compound 138

ESI-MS: 420.2 [M + H]⁺ ¹H NMR (400 MHZ, DMSO-d₆) δ 12.80 (s, 1H), 7.95 (d, J = 8.9 Hz, 2H), 7.52-7.46 (m, 1H), 7.33-7.27 (m, 2H), 7.02 (d, J = 8.9 Hz, 2H), 6.67 (s, 1H), 4.67 (d, J = 4.2 Hz, 1H), 3.69-3.59 (m, 3H), 2.98-2.88 (m, 2H), 2.10 (s, 3H), 1.84- 1.72 (m, 2H), 1.47-1.36 4 (m, 2H). Example 106 Compound 139

ESI-MS: 436.2 [M + H]⁺ ¹H NMR (400 MHZ, DMSO-d₆) δ 12.77 (s, 1H), 7.93 (d, J= 8.8 Hz, 2H), 7.59-7.53 (m, 1H), 7.13-7.01 (m, 4H), 6.61 (s, 1H), 4.68 (d, J = 4.4 Hz, 1H), 3.78 (s, 3H), 3.68-3.60 (m, 3H), 2.97-2.90 (m, 2H), 1.84-1.74 (m, 2H), 1.48-1.36 (m, 2H). 2A Example 107 Compound 140

ESI-MS: 450.2 [M + H]⁺ ¹H NMR (400 MHZ, DMSO-d₆) δ 12.77 (br, 1H), 7.93 (d, J = 8.8 Hz, 2H), 7.59-7.52 (m,1H), 7.12 (d, J = 8.8 Hz, 1H), 7.09-7.00 (m, 3H) , 6.61(s, 1H), 4.32 (s, 1H), 3.78 (s, 3H), 3.44-3.30 (m, 2H), 3.22- 3.16 (m, 2H), 1.54-1.50 (m, 4H), 1.13 (s, 3H). 2A Example 108 Compound 141

ESI-MS: 464.3 [M + H]⁺ ¹H NMR (400 MHZ, DMSO-d₆) δ 12.77 (s, 1H), 7.93 (d, J = 8.8 Hz, 2H), 7.59-7.52 (m, 1H), 7.12 (d, J = 8.6 Hz, 1H), 7.09-7.00 (m, 3H), 6.61 (s, 1H), 3.79 (s, 3H), 3.46-3.39 (m, 2H), 3.12 (s, 3H), 3.12-3.04 (m, 2H), 1.77-1.70 (m, 2H), 1.57-1.48 (m, 2H), 1.12 (s, 3H). Example 109 Compound 142

ESI-MS: 489.2 [M + H]⁺ ¹H NMR (400 MHZ, DMSO-d₆) δ 12.81 (s, 1H), 7.95 (d, J = 9.0 Hz, 2H), 7.52 - 7.46 (m, 1H), 7.33-7.26 (m, 2H), 7.03 (d, J = 9.1 Hz, 2H), 6.67 (s, 1H), 3.88-3.77 (m, 2H), 3.60-3.51 (m, 4H), 2.79-2.69 (m, 2H), 2.48-2.42 (m, 4H), 2.35-2.27 (m, 1H), 2.10 (s, 3H), 1.87-1.78 (m, 2H), 1.50-1.38 (m, 2H). 4 Example 110 Compound 143

ESI-MS: 502.2 [M + H]⁺ ¹H NMR (400 MHZ, DMSO-d₆) δ 12.80 (s, 1H), 7.95 (d, J = 9.0 Hz, 2H), 7.53-7.45 (m, 1H), 7.34-7.25 (m, 2H), 7.02 (d, J = 9.0 Hz, 2H), 6.67 (s, 1H), 3.82 (d, J = 12.5 Hz, 2H), 3.32 (s, 2H), 2.79- 2.69 (m, 2H), 2.52-2.43 (m, 2H), 2.40-2.21 (m, 5H), 2.15 (s, 3H), 2.10 (s, 3H), 1.84-1.75 (m, 2H), 1.51-1.38 (m, 2H). 4 Example 111 Compound 144

ESI-MS: 505.3 [M + H]⁺ ¹HNMR (400 MHZ, DMSO-d₆) δ 12.75 (s, 1H), 7.93 (d, J = 9.0 Hz, 2H), 7.59-7.52 (m, 1H), 7.12 (d, J = 8.6 Hz, 1H), 7.09-7.01 (m, 3H), 6.61 (s, 1H), 3.85- 3.77 (m, 5H), 3.57-3.53 (m, 4H), 2.78-2.70 (m, 2H), 2.48-2.43 (m, 4H), 2.36-2.26 (m, 1H), 1.87-1.80 (m, 2H), 1.50-1.39 (m, 2H). 2A Example 112 Compound 145

ESI-MS: 518.3 [M + H]⁺ ¹H NMR (400 MHZ, DMSO-d6) δ 12.77 (s, 1H), 7.93 (d, J = 9.0 Hz, 2H), 7.59-7.52 (m, 1H), 7.12 (d, J = 8.6 Hz, 1H), 7.09-7.01 (m, 3H), 6.61 (s, 1H), 3.85-3.77 (m, 5H), 2.78-2.70 (m, 2H), 2.50-2.43 (m, 2H), 2.40-2.26 (m, 5H), 2.15 (s, 3H), 1.84-1.76 (m, 2H), 1.50-1.39 (m, 2H). 2A Example 113 Compound 146

ESI-MS: 449.3 [M + H]⁺ ¹H NMR (400 MHZ, DMSO-d₆) δ 7.95 (d, J = 8.9 Hz, 2H), 7.59-7.52 (m, 1H), 7.12 (d, J = 8.6 Hz, 1H), 7.09-7.02 (m, 3H), 6.61 (s, 1H), 3.78 (s, 3H), 3.55-3.46 (m, 2H), 3.23-3.15 (m, 2H), 1.70-1.58 (m,4H), 1.24 (s, 3H). 4 Example 114 Compound 147

ESI-MS: 477.3 [M + H]⁺ ¹HNMR (400 MHZ, DMSO-d₆) δ 12.81 (s, 1H), 7.96 (d, J = 8.9 Hz, 2H), 7.59-7.52 (m, 1H), 7.14-7.02 (m, 4H), 6.62 (s, 1H), 3.90-3.60 (m, 5H), 2.97 (br, 2H), 2.61 (br, 6H), 1.83 (br, 4H), 1.26 (br, 3H). 4 Example 115 Compound 148

ESI-MS: m/z = 429.1 ([M + H]⁺). ¹H NMR (400 MHZ, DMSO-d₆) δ 12.80 (brs, 1H), 7.77 (s, 1H), 7.61-7.51 (m, 1H), 7.12 (d, J = 8.6 Hz, 1H), 7.06 (t, J = 8.9 Hz, 1H), 6.63 (s, 1H), 3.79 (s, 3H), 3.75-3.68 (m, 4H), 3.51-3.44 (m, 4H). 2A Example 116 Compound 149

ESI-MS: m/z = 432.2 ([M + H]⁺). ¹H NMR (400 MHZ, DMSO-d₆) δ 12.78 (brs, 1H), 8.20 (s, 1H), 7.99 (d, J = 8.8 Hz, 2H), 7.03 (d, J = 8.8, 2H), 6.90 (s, 1H), 6.63 (s, 1H), 3.91 (s, 3H), 3.26-3.12 (m, 4H), 2.54-2.48 (m, 4H), 2.24 (s, 3H), 2.08 (s, 3H). 4 Example 117 Compound 150

ESI-MS: 399.2 [M + H]⁺ ¹H NMR (400 MHZ, DMSO-d₆) δ 13.07 (s, 1H), 8.66-8.54 (m, 2H), 8.11 (d, J = 8.0 Hz, 2H), 7.58 (d, J = 8.1 Hz, 2H), 7.50 (d, J = 4.8 Hz, 1H), 6.74 (s, 1H), 6.26 (s, 1H), 3.32 (s, 2H), 3.06 (s, 2H), 2.64- 2.56 (m, 2H), 2.30 (s, 3H), 2.16 (s, 3H). 4 Example 118 Compound 151

ESI-MS: 415[M + H]⁺ ¹H NMR (400 MHZ, DMSO-d₆) δ 13.01 (s, 1H), 8.61 (d, J = 5.8 Hz, 1H), 8.53 (s, 1H), 8.09 (d, J = 8.5 Hz, 2H), 7.57 (d, J = 8.5 Hz, 2H), 7.34 (d, J = 5.8 Hz, 1H), 6.67 (s, 1H), 6.25 (s, 1H), 3.85 (s, 3H), 3.36-3.32 (m, 2H), 3.07-2.99 (m, 2H), 2.58 (t, J = 4 5.5 Hz, 2H), 2.28 (s, 3H). Example 119 Compound 152

ESI-MS: 400.1[M + H]⁺ ¹H NMR (400 MHZ, DMSO-d₆) δ 12.99 (s, 1H), 8.61 (d, J = 5.8 Hz, 1H), 8.54 (s, 1H), 8.16 (s, 1H), 8.11 (d, J = 8.5 Hz, 2H), 7.89 (s, 1H), 7.69 (d, J = 8.5 Hz, 2H), 7.34 (d, J = 5.8 Hz, 1H), 6.67 (s, 1H), 3.87 (s, 4 3H), 3.86 (s, 3H). Example 120 Compound 153

ESI-MS: m/z = 418.2 ([M + H]⁺). ¹H NMR (300 MHZ, DMSO-d₆) δ 12.78 (brs, 1H), 8.65 (s, 1H), 8.42 (d, J = 2.7 Hz, 1H), 7.97 (d ,J = 9.0 Hz, 2H), 7.56 (d, J= 4.8 Hz, 1H), 7.03 (d, J = 9.0Hz, 2H), 6.60 (s, 1H), 3.89 (s, 3H), 3.28-3.18 (m, 4H), 2.48-2.38 (m, 4H), 2.23 (s, 3H). 4 Example 121 Compound 154

ESI-MS: 449.2 [M + H]⁺ ¹H NMR (400 MHZ, DMSO-d₆) δ 12.86 (s, 1H), 7.96 (d, J = 9.2 Hz, 2H), 7.58-7.52 (m, 1H), 7.11 (d, J = 8.8 Hz, 1H), 7.08-7.01 (m, 1H), 3.77 (s, 3H), 3.22-3.18 (m, 4H), 2.46-2.42 (m, 4H), 2.25 (s, 3H), 2.21 (s, 3H). 3A Example 122 Compound 155

ESI-MS: 436.2 [M + H]⁺ ¹H NMR (400 MHZ, DMSO-d₆) δ 12.88 (s, 1H), 7.99 (d, J = 8.8 Hz, 2H), 7.58-7.51 (m, 1H), 7.13-7.02 (m, 4H), 3.77 (s, 3H), 3.76-3.70 (m, 4H), 3.20-3.14 (m, 4H), 2.26 (s, 3H). 3A Example 123 Compound 156

ESI-MS: 390.3 [M + H]⁺ ¹H NMR (400 MHz, DMSO-d₆) δ 13.11 (s, 1H), 7.93 (d, J = 8.1 Hz, 1H), 7.81 (s, 1H), 7.54-7.44 (m, 1H), 7.35-7.23 (m, 3H), 6.76 (s, 1H), 3.91 (br, 2H), 2.97 (br, 4H), 2.58 (s, 3H), 2.10 (s, 3H). 2A Example 124 Compound 157

ESI-MS: 393.2 [M + H]⁺ ¹HNMR (400 MHZ, DMSO-d₆) δ 13.02 (s, 1H), 7.87 (dd, J = 8.0, 1.4 Hz, 1H), 7.76 (s, 1H), 7.52-7.46 (m, 1H), 7.32-7.26 (m, 2H), 7.22 (d, J = 8.0 Hz, 1H), 6.74 (s, 1H), 3.52 (br, 2H), 2.83 (t, J = 5.7 Hz, 2H), 2.61 (d, J = 5.7 Hz, 2H), 2.10 (s, 3H). 2A Example 125 Compound 158

ESI-MS: 424.2 [M + H]⁺ ¹H NMR (400 MHZ, DMSO-d₆) δ 13.05 (s, 1H), 7.85 (dd, J = 8.0, 1.5 Hz, 1H), 7.75 (s, 1H), 7.23 (d, J = 8.0 Hz, 1H), 7.17 - 7.09 (m, 2H), 6.69 (s, 1H), 3.80 (s, 3H), 3.52 (s, 2H), 2.84 (t, J = 5.8 Hz, 2H), 2.60 (t, J = 5.9 Hz, 2H), 2.34 (s, 3H). 2A Example 126 Compound 159

ESI-MS: 431.1 [M + H]⁺ ¹H NMR (400 MHZ, DMSO-d₆) δ 13.07 (s, 1H), 7.84 (dd, J = 8.0, 1.8 Hz, 1H), 7.79 (dd, J = 9.0, 1.3 Hz, 1H), 7.76 - 7.72 (m, 2H), 7.22 (d, J = 8.0 Hz, 1H), 6.73 (s, 1H), 3.87 (s, 3H), 3.52 (s, 2H), 2.84 (t, J = 5.9 Hz, 2H), 2.61 (t, J = 5.9 Hz, 2H), 2.34 (s, 3H). 2B Example 127 Compound 160

ESI-MS: 404.3 [M + H]⁺ ¹H NMR (400 MHZ, DMSO-d₆) δ 13.05 (s, 1H), 7.87 (dd, J = 8.0, 1.6 Hz, 1H), 7.77 (s, 1H), 7.57-7.51 (m, 1H), 7.34-7.28 (m, 2H), 7.22 (d, J = 8.0 Hz, 1H), 6.73 (s, 1H), 3.50 (s, 2H), 2.83 (t, J = 5.6 Hz, 2H), 2.59 (t, J =6.0 Hz, 2H), 2.47- 2.36 (m, 2H), 2.33 (s, 3H), 1.07 (t, J = 7.6 Hz, 3H). 2A Example 128 Compound 161

ESI-MS: 376.3 [M + H]⁺ ¹H NMR (400 MHZ, DMSO-d₆) δ 13.19 (s, 1H), 9.25 (s, 2H), 8.00 (dd, J = 8.0, 1.5 Hz, 1H), 7.94- 7.91 (m, 1H), 7.54- 7.46 (m, 1H), 7.36 (d, J = 8.1 Hz, 1H), 7.33-7.27 (m, 2H), 6.78 (s, 1H), 4.33 (t, J = 4.0 Hz, 2H), 3.41-3.33 (m, 2H), 2A 3.03 (t, J = 6.2 Hz, 2H), 2.10 (s, 3H). Example 129 Compound 162

ESI-MS: 420.2 [M + H]⁺ ¹H NMR (400 MHZ, DMSO-d6) δ 13.04 (s, 1H), 7.91-7.83 (m, 1H), 7.75 (s, 1H), 7.54-7.45 (m, 1H), 7.36-7.26 (m, 2H), 7.21 (d, J = 8.0 Hz, 1H), 6.74(s, 1H), 4.44 (t, J = 5.2 Hz, 1H), 3.63 (s, 2H), 3.58 (q, J = 5.7 Hz, 2H), 2.82 (t, J = 5.5 Hz, 2H), 2.71 (t, J = 5.5 Hz, 2H), 2.56 (t, J = 6.2 Hz, 2H), 2.10 (s, 3H). 2A Example 131 Compound 163

ESI-MS: 445.3 [M + H]⁺ ¹H NMR (400 MHZ, DMSO-d₆) δ 13.22 (s, 1H), 11.70 (br, 1H), 8.41 (br, 3H), 8.02 (d, J = 8.2 Hz, 1H), 7.92 (s, 1H), 7.54-7.45 (m, 1H), 7.39 (d, J = 8.1 Hz, 1H), 7.35 - 7.25 (m, 2H), 6.78 (s, 1H), 4.66-4.54 (m, 1H), 4.30-4.18 (m, 1H), 3.77-3.58 (m, 2H), 3.33-3.16 (m, 2H), 3.13-3.01 (m, 1H), 2A 2.78-2.60 (m, 4H), 2.11-2.09 (m, 3H). Example 132 Compound 164

ESI-MS: 431.3 [M + H]⁺ ¹H NMR (400 MHz, DMSO-d₆) δ 13.21 (s, 1H), 12.80 (br, 1H), 9.63 (s, 1H), 9.17 (s, 1H), 8.01 (d, J = 8.0 Hz, 1H), 7.85 (s, 1H), 7.54 -7.45 (m, 1H), 7.38 (d, J = 8.2 Hz, 1H), 7.34-7.26 (m, 2H), 6.77 (s, 1H), 4.84-4.08 (m, 8H), 3.32-3.04 (m, 3H), 2.10 (s, 3H). 2A Example 133 Compound 165

ESI-MS: 434.3 [M + H]⁺ ¹H NMR (400 MHZ, DMSO-d₆) δ 13.02 (s, 1H), 7.85 (d, J = 8.0 Hz, 1H), 7.76 (s, 1H), 7.52-7.46 (m, 1H), 7.32-7.27 (m, 2H), 7.20 (d, J = 8.0 Hz, 1H), 6.73 (s, 1H), 4.31 (s, 1H), 3.82-3.69 (m, 2H), 3.58-3.48 (m, 1H), 3.40-3.30 (m, 1H), 2A 2.90-2.60 (m, 5H), 2.10 (s, 3H), 1.00 (d, J = 6.4 Hz, 3H). Example 134 Compound 166

ESI-MS: 456.2 [M + H]⁺ ¹H NMR (400 MHZ, DMSO-d₆) δ 13.01 (s, 1H), 7.87 (dd, J = 8.0, 1.5 Hz, 1H), 7.74 (d, J = 1.3 Hz, 1H), 7.60-7.52 (m, 1H), 7.23 (d, J = 8.0 Hz, 1H), 7.13 (d, J = 8.6 Hz, 1H), 7.10- 7.03 (m, 1H), 6.69 (s, 1H), 6.22 (tt, J = 55.7, 4.3 Hz, 1H), 3.78 (s, 3H), 3.76 (s, 2H), 2.91 (td, J = 15.6, 4.3 Hz, 2H), 2.84 (s, 4H). 2A Example 135 Compound 167

ESI-MS: 460.4 [M + H]⁺ ¹H NMR (400 MHZ, DMSO-d₆) δ 13.06 (s, 1H), 7.86 (dd, J = 8.0, 1.6 Hz, 1H), 7.77 (s, 1H), 7.52-7.47 (m, 1H), 7.32-7.28 (m, 2H), 7.21 (d, J = 8.0 Hz, 1H), 6.74 (s, 1H), 3.91 (dd, J = 10.8, 3.2 Hz, 2H), 3.74 (s, 2H), 3.32-3.26 (m, 2H), 2.84-2.74 (m, 2H), 2A 2.67-2.56 (m, 1H), 2.10 (s, 3H), 1.76 (d, J = 12.0 Hz, 2H), 1.56-1.46 (m, 2H) Example 136 Compound 168

ESI-MS: 473.4 [M + H]⁺ ¹H NMR (400 MHZ, DMSO-d₆) δ 13.12 (br, 1H), 7.86 (dd, J = 7.6, 1.6 Hz, 1H), 7.76 (s, 1H), 7.52-7.47 (m, 1H), 7.32-7.28 (m, 2H), 7.20 (d, J = 8.0 Hz, 1H), 6.74 (s, 1H), 3.72 (s, 2H), 2.87 (d, J = 10.4 Hz, 2H), 2.82-2.72 (m, 4H), 2.42-2.36 (m, 1H), 2.21 (s, 1H), 2.10 (s, 1H), 2.04-1.94 (m. 2H), 1.79 (d, J = 11.6 2A Hz, 2H), 1.60-1.51 (m, 2H). Example 137 Compound 169

ESI-MS: 503.4 [M + H]⁺ ¹H NMR (400 MHZ, DMSO-d₆) δ 13.12 (s, 1H), 7.94-7.88 (m, 2H), 7.51-7.48 (m, 1H), 7.32-7.28 (m, 3H), 6.77 (s, 0.4H), 6.76 (s, 0.6H), 4.81 (s, 0.8H), 4.63 (s, 1.2H), 3.79-3.74 (m, 1.2H), 3.67 (t, J = 4.0 Hz, 0.8H), 3.58-3.54 (m, 2.4H), 3.40-3.36 (m, 1.6H), 3.25-3.23 (m, 1H), 2.92 (t, J = 3.6 Hz, 1.2H), 2.80 (t, J = 3.6 Hz, 0.8H), 2.4 2A (s, 2.4H), 2.34 (s, 1.6H), 2.11 (s, 3H). Example 138 Compound 170

ESI-MS: 415.3 [M + H]⁺ ¹H NMR (400 MHZ, DMSO-d₆) δ 13.12 (s, 1H), 8.02 (d, J = 8.8 Hz, 1H), 7.90 (s, 1H), 7.86 (d, J = 7.6 Hz, 1H), 7.76 (s, 1H), 7.23 (d, J = 7.6 Hz, 1H), 6.79 (s, 1H), 3.54 (s, 2H), 2.85 (t, J = 5.2 Hz, 2H), 2.63 (t, J = 5.2 Hz, 2H), 2.36 (s, 3H), 2.17 (s, 3H). 2A Example 139 Compound 171

ESI-MS: 401.3 [M + H]⁺ ¹H NMR (400 MHZ, DMSO-d₆) δ 8.01 (d, J = 8.8 Hz, 1H), 7.89 (s, 1H), 7.85 (d, J = 7.6 Hz, 1H), 7.75 (s, 1H), 7.19 (d, J = 8.0 Hz, 1H), 6.78 (s, 1H), 3.92 (s, 2H), 3.00 (t, J = 5.6 Hz, 2H), 2.75 (t, J = 5.6 Hz, 2H), 2.17 (s, 3H). 2A Example 140 Compound 172

ESI-MS: 459.3 [M + H]⁺ ¹H NMR (400 MHZ, DMSO-d₆) δ 13.15 (s, 1H), 8.01 (d, J = 9.2 Hz, 1H), 7.92-7.87 (m, 3H), 7.30 (d, J = 8.0 Hz, 1H), 6.80 (s, 1H), 4.68-4.55 (m, 3H), 4.19-4.16 (m, 2H), 3.74-3.66 (m, 0.8H), 3.62-3.58 (m, 1.2H), 2.90-2.81 (m, 2H), 2.18 (s, 3H). 2B Example 141 Compound 173

ESI-MS: 473.3 [M + H]⁺ ¹H NMR (400 MHz, DMSO-d₆) δ 13.14 (s, 1H), 8.01 (d, J = 9.5 Hz, 1H), 7.93-7.89 (m, 3H), 7.30 (d, J = 7.9 Hz, 1H), 6.80 (s, 1H), 5.00-4.90 (m, 1H), 4.88- 4.58 (m, 3H), 4.56-4.46 (m, 1H), 3.82-3.61 (m, 2H), 2.90-2.80 (m, 2H), 2.18 (s, 3H), 1.23-1.16 (m, 3H). 2B Example 142 Compound 174

ESI-MS: 458.3 [M + H − HCl]⁺ ¹H NMR (400 MHZ, DMSO-d₆) δ 13.19 (br, 1H), 8.10 (br, 3H), 8.02 (d, J = 9.2 Hz, 1H), 7.96-7.91 (m, 3H), 7.36-7.31 (m, 1H), 6.82-6.79 (m, 1H),4.71-4.68 (m, 2H), 3.98-3.95 (m, 2H), 3.74 (t, J = 6.0 Hz, 0.9H), 3.64 (t, J = 6.0 Hz, 1.1H), 2.94 (t, J = 6.0 Hz, 1.1H), 2.84 (t, J = 6.0 Hz, 0.9H), 2.18 (s, 3H). 2B Example 143 Compound 175

ESI-MS: 472.3 [M + H − HCI]⁺ ¹H NMR (400 MHz, DMSO-d₆) δ 13.22 (br, 1H), 8.19 (br, 3H), 8.02 (d, J = 9.2 Hz, 1H), 7.96-7.90 (m, 3H), 7.34-7.31 (m, 1H), 6.82-6.79 (m, 1H), 4.89-4.38 (m, 3H), 3.92-3.76 (m, 1H), 3.74-3.58 (m, 1H), 2.96- 2.90 (m, 1H), 2.88-2.83 (m, 1H), 2.18 (s, 3H), 1.38- 1.30 (m, 3H). 2B Example 144 Compound 176

ESI-MS: 420.2 [M + H]⁺ ¹H NMR (400 MHZ, DMSO-d₆) δ 13.07 (s, 1H), 7.89 (d, J = 8.0 Hz, 1H), 7.77 (s, 1H), 7.50(td, J = 8.1,5.6 Hz, 1H), 7.34-7.27 (m, 2H), 7.24 (d, J = 8.0 Hz, 1H), 6.74 (s, 1H), 4.64 (br, 1H), 3.83 (d, J = 15.8 Hz, 1H), 3.66-3.54 (m, 2H), 3.48-3.38 (m, 1H), 2A 2.88-2.69 (m, 2H), 2.68-2.56 (m, 1H), 2.40 (s, 3H), 2.10 (s, 3H). Example 145 Compound 177

ESI-MS: 432.2 [M + H]⁺ ¹H NMR (400 MHZ, DMSO-d₆) δ 13.09 (br, 1H), 8.00-7.88 (m, 2H), 7.53-7.46 (m, 1H), 7.38-7.23 (m, 3H), 6.76 (s, 1H), 4.67 (d, J = 17.0 Hz, 1H), 4.54( t, J = 8.2 Hz, 1H), 4.40 (d, J = 17.0 Hz, 1H), 4.14 (dd, J = 8.6, 5.2 Hz, 1H), 4.08-3.92 (m, 2A 1H), 2.99 (dd, J = 16.0, 4.0 Hz, 1H), 2.81 (dd, J = 15.9, 10.9 Hz, 1H), 2.12-2.10 (m, 3H). Example 146 Compound 178

ESI-MS: 418.2 [M + H]⁺ ¹HNMR (400 MHZ, DMSO-d₆) δ 13.07 (s, 1H), 7.88 (d, J = 7.7 Hz, 1H), 7.78 (s, 1H), 7.53-7.46 (m, 1H), 7.33-7.26 (m, 2H), 7.19 (d, J = 8.0 Hz, 1H), 6.74 (s, 1H), 3.67 (br, 2H), 2.67 (br, 2H), 2.27 (br, 3H), 1.02 (s, 6H). 2A Example 147 Compound 179

ESI-MS: 420.2 [M + H]⁺ ¹HNMR (400 MHZ, DMSO-d₆) δ 13.03 (s, 1H), 7.88 (d, J = 8.0 Hz, 1H), 7.76 (s, 1H), 7.53-7.45 (m, 1H), 7.34-7.26 (m, 2H), 7.23 (d, J = 8.1 Hz, 1H), 6.74 (s,1H), 4.60-4.52 (m, 1H), 3.78 (d, J = 15.7 Hz, 1H), 3.64-3.48 (m, 2H), 3.44- 3.35 (m, 1H), 2.85-2.67 (m, 2H), 2.60-2.50 (m, 1H), 2A 2.36 (s, 3H), 2.10 (s, 3H). Example 148 Compound 180

ESI-MS: 434.2 [M + H]⁺ 2A Example 149 Compound 181

ESI-MS: 432.2 [M + H]⁺ ¹H NMR (400 MHZ, DMSO-d₆) δ 13.03 (s, 1H), 7.90-7.86 (m, 1H), 7.78 (s, 1H), 7.52-7.46 (m, 1H), 7.32-7.26 (m, 2H), 7.21 (d, J = 8.0 Hz, 1H), 6.74 (s, 1H), 3.88-3.77 (m, 3H), 3.61-3.53 (m, 1H), 3.36-3.30 (m, 1H), 3.21-3.15 (m, 1H), 2A 2.85 (d, J = 11.6 Hz, 1H), 2.66 (d, J = 12.7 Hz, 1H), 2.46- 2.40 (m, 2H), 2.32- 2.24 (m, 1H), 2.11-2.09 (m, 3H). Example 150 Compound 182

ESI-MS: 404.2 [M + H]⁺ ¹H NMR (400 MHZ, DMSO-d₆) δ 13.12 (s, 1H), 8.01-7.96 (m, 2H),7.53-7.46 (m, 1H), 7.36-7.26 (m, 2H), 6.77 (s, 1H), 4.56 (s, 2H), 3.56 (s, 2H), 2.96 (s, 3H), 2.11 (s, 3H). 2A Example 151 Compound 183

ESI-MS: 404.2 [M + H]⁺ ¹H NMR (400 MHZ, DMSO-d₆) δ 13.15 (s, 1H), 8.64 (d, J = 1.9 Hz, 1H), 8.17 (dd, J = 7.9, 1.8 Hz, 1H), 7.55-7.46 (m, 1H), 7.42 (d, J = 8.0 Hz, 1H), 7.36-7.26 (m, 2H), 6.78 (s, 1H), 3.56 (t, J = 6.6 Hz, 2H), 3.07-2.98 2A (m, 5H), 2.12 (s, 3H). Example 152 Compound 184

ESI-MS: 420.2 [M + H]⁺ ¹H NMR (400 MHZ, DMSO-d₆) δ 13.04 (s, 1H), 7.98 (d, J = 11.2 Hz, 1H), 7.86 (d, J = 7.9 Hz, 1H), 7.49 (q, J = 7.6 Hz, 1H), 7.34-7.26 (m, 2H), 7.20 (d, J = 8.0 Hz, 1H), 6.74 (s, 1H), 4.47 (br, 1H), 3.68-3.60 (m, 1H), 3.58-3.46 (m, 2H), 3.10-3.00 2A (m, 1H), 2.85-2.75 (m, 1H), 2.74-2.64 (m, 1H), 2.64-2.55 (m, 1H), 2.45 (s, 3H), 2.11-2.09 (m, 3H). Example 153 Compound 185

ESI-MS: 432.2 [M + H]⁺ ¹H NMR (400 MHZ, DMSO-d₆) δ 13.38 (s, 1H), 7.97 (d, J = 8.0 Hz, 1H), 7.88 (s, 1H), 7.54-7.46 (m,1H), 7.35-7.25 (m, 3H), 6.77 (s, 1H), 5.20- 5.06 (m, 1H), 4.85 (td, J = 8.5, 3.4 Hz, 1H), 4.20-4.16 (m, 1H), 3.89-3.71 (m, 1H), 3.31-3.21 (m, 2A 1H), 2.96-2.86 (m, 1H), 2.82-2.72 (m, 1H), 2.12-2.08 (m, 3H). Example 154 Compound 186

ESI-MS: 419.2 [M + H − HCl]⁺ 1H NMR (700 MHZ, DMSO-d₆) δ 13.29 (s, 1H), 11.76 (br, 1H), 8.58 (br, 3H), 8.15-7.95 (m, 2H), 7.53-7.38 (m, 2H), 7.33-7.23 (m, 2H), 6.79 (s, 1H), 3.90-3.60 (m, 3H), 3.30-3.00 (m, 4H), 3.00-2.70 (m, 2A 3H), 2.13-2.08 (m, 3H). Example 155 Compound 187

ESI-MS: 391.2 [M + H]⁺ ¹H NMR (700 MHz, DMSO-d₆) δ 13.22 (s, 1H), 9.04 (s, 1H), 8.05 (s, 1H), 7.52-7.48 (m, 1H), 7.32-7.28 (m, 2H), 6.80 (s, 1H), 3.57 (s, 2H), 2.93 (t, J = 5.5 Hz, 2H), 2.71 (t, J = 5.6 Hz, 2H), 2.36 (s, 3H), 2.11 (s, 3H). 2A Example 156 Compound 188

ESI-MS: 408.1[M + H]+ ¹H NMR (400 MHZ, DMSO-d₆) δ 13.20 (s, 1H), 7.66 (t, J = 7.6 Hz, 1H), 7.50- 7.44 (m, 1H), 7.29- 7.25 (m, 1H), 7.10 (d, J = 8.0 Hz, 1H), 6.77 (s, 1H), 3.53 (s, 2H), 2.86 (t, J = 5.6 Hz, 2H), 2.60 (t, J = 5.6 Hz, 2H), 2.38 (s, 3H), 2.07 (s, 3H). 2A Example 157 Compound 189

ESI-MS: 408.1 [M + H]⁺ ¹H NMR (400 MHZ, DMSO-d₆) δ 13.24 (s, 1H), 7.56 (d, J = 7.1 Hz, 1H), 7.51- 7.43 (m, 1H), 7.31-7.23 (m, 2H), 7.18 (d, J = 11.1 Hz, 1H), 6.78 (s,1H), 3.76 (s, 2H), 3.00-2.80 (m, 4H), 2.51 (s, 3H), 2.07 (s, 3H). 2A Example 158 Compound 190

ESI-MS: 424.2 [M + H]⁺ ¹H NMR (400 MHZ, DMSO-d₆) δ 13.15 (s, 1H), 7.65 (t, J = 7.6 Hz, 1H), 7.57-7.51 (m, 1H), 7.11-7.08 (m, 2H), 7.04 (t, J = 8.4 Hz, 1H), 6.71 (s, 1H), 3.76 (s, 3H), 3.52 (s, 2H), 2.86 (t, J = 5.6 Hz, 2H), 2.60 (t, J = 5.6 Hz, 2H), 2.38 (s, 3H). 2A Example 159 Compound 191

ESI-MS: 410.1[M + H]⁺ ¹H NMR (400 MHZ, DMSO-d₆) δ 13.14 (s, 1H), 7.60-7.46 (m, 2H), 7.15-7.07 (m, 2H), 7.03 (t, J = 8.8 Hz, 1H), 6.71 (s, 1H), 3.77 (s, 3H), 3.46 (s, 2H), 2.85 (t, J = 5.7 Hz, 2H), 2.58 (t, J = 5.9 Hz, 2H), 2.32 (s, 3H). 2A Example 160 Compound 193

ESI-MS: 431.3 [M + H]⁺ ¹H NMR (400 MHZ, DMSO-d₆) δ 13.22 (s, 1H), 12.92 (br, 1H), 9.71 (s, 1H), 9.19 (s, 1H), 8.02-7.97 (m, 1H), 7.95 (s, 1H), 7.53-7.46 (m, 1H), 7.34-7.26 (m, 3H), 6.77 (s, 1H), 4.76 -3.98 (m, 8H), 3.17 (br, 3H), 2.11 (s, 3H). 2A Example 161 Compound 194

ESI-MS: 445.3[M + H]⁺ ¹H NMR (700 MHZ, DMSO-d₆) δ 13.06 (br, 1H), 7.86 (d, J = 8.0 Hz, 1H), 7.83 (s, 1H), 7.53-7.45(m, 1H), 7.34-7.27 (m, 2H), 7.17 (d, J = 8.0 Hz, 1H), 6.74 (s, 1H), 3.46 (t, J = 6.4 Hz, 2H), 3.43 (s, 2H), 3.02-2.97 (m, 1H), 2.86-2.79 (m, 2A 4H), 2.50-2.48 (m, 2H), 2.23 (s, 3H), 2.10 (s, 3H). Example 162 Compound 195

ESI-MS: 460.3 [M + H]⁺ ¹H NMR (400 MHZ, DMSO-d₆) δ 13.04 (s, 1H), 7.86 (dd, J = 8.0, 1.4 Hz, 1H), 7.83-7.80 (m, 1H), 7.52-7.46 (m, 1H), 7.34-7.26 (m, 2H), 7.18 (d, J = 8.1 Hz, 1H), 6.74 (s, 1H), 3.91 (dd, J = 11.2, 2.9 Hz, 2H), 3.72 (s, 2H), 2A 3.31-3.26 (m, 2H), 2.85-2.71 (m 4H), 2.64-2.54 (m, 1H), 2.10 (s, 3H), 1.81-1.72 (m, 2H), 1.57-1.43 (m, 2H). Example 163 Compound 196

ESI-MS: 473.3[M + H]⁺ ¹H NMR (700 MHZ, DMSO-d6) δ 13.08 (s, 1H),10.01 (s, 1H), 7.92-7.79 (m, 2H), 7.55-7.44 (m, 1H), 7.34-7.25 (m, 2H), 7.22-7.14 (m, 1H), 6.74 (s, 1H), 3.73 (br, 2H), 3.46-3.34 (m, 4H), 2.89-2.76 (m, 4H), 2.61-2.57 (m, 1H), 2.49 (s, 3H), 2.10 (s, 3H), 2A 2.01 - 1.90 (m, 2H), 1.85-1.62 (m, 2H). Example 164 Compound 197

ESI-MS: 376.1 [M + H]⁺ ¹HNMR (400 MHz, DMSO-d₆) δ 13.08 (s, 1H), 8.00- 7.96 (m, 1H), 7.95 (s, 1H), 7.52-7.46 (m, 1H), 7.36 (d, J = 8.0 Hz, 1H), 7.33-7.27 (m, 2H), 6.75 (s, 1H), 3.90 (s, 2H), 3.88 (s, 2H), 2.51 (s, 3H), 2.10 (s, 3H). 2A Example 165 Compound 198

ESI-MS: 419.3 [M + H]⁺ ¹H NMR (700 MHZ, DMSO-d₆) δ 7.65-7.64 (m, 1H),7.54 (d, J = 7.7 Hz, 1H), 7.51-7.47 (m, 1H), 7.29-7.32 (m, 3H), 7.04 (dd, J = 8.4, 2.1 Hz,1H), 6.74 (s, 1H), 3.16-3.14 (m, 4H), 2.44-2.42 (m, 4H), 2.21 (s, 3H), 2.11 (s, 3H). 2A Example 166 Compound 199

ESI-MS: 435.2 [M + H]⁺ ¹H NMR (400 MHZ, DMSO-d₆) δ 7.66-7.63 (m, 1H), 7.59-7.51 (m, 2H), 7.31 (t, J = 8.0 Hz, 1H), 7.12 (d, J = 8.0 Hz, 1H), 7.08-7.01 (m, 2H), 6.68 (s, 1H), 3.79 (s, 3H), 3.15 (t, J = 4.8 Hz, 4H), 2.44 (t, J = 4.8 Hz, 4H), 2.21 (s, 3H). 2A Example 167 Compound 200

ESI-MS: 433.4 [M + H]⁺ ¹H NMR (400 MHZ, DMSO-d₆) δ 13.05 (s, 1H),7.65-7.63 (m, 1H), 7.57-7.50 (m, 2H), 7.33-7.28 (m, 3H), 7.04 (dd, J = 8.4, 2.0 Hz, 1H), 6.74 (s, 1H), 3.16-3.11 (m, 4H), 2.47-2.36 (m, 6H), 2.21 (s, 3H), 1.06 (t, J = 7.6 Hz, 3H). 2A Example 168 Compound 201

ESI-MS: 445.3 [M + H]⁺ ¹H NMR (700 MHZ, DMSO-d₆) δ 13.06 (br, 1H), 7.52-7.46 (m, 3H), 7.32-7.26 (m, 3H), 6.91 (dd, J = 8.4, 2.1 Hz, 1H), 6.75 (s, 1H), 3.38-3.34 (m, 2H), 3.19 (s, 2H), 2.85 (d, J = 10.5 Hz, 2H), 2.22 (s, 3H), 2.11 (s, 3H), 1.97-1.92 (m, 2H), 1.62-1.59 (m, 2H). 2A Example 169 Compound 202

ESI-MS: 461.2 [M + H]⁺ ¹H NMR (400 MHZ, DMSO-d₆) δ 13.00 (s, 1H), 7.59-7.50 (m, 2H), 7.47 (d, J = 7.6 Hz, 1H), 7.28 (t, J = 8.0 Hz, 1H), 7.13 (d, J = 8.4 Hz, 1H), 7.06 (t, J = 8.8 Hz, 1H), 6.92 (dd, J = 8.4, 2.1 Hz, 1H), 6.68 (s, 1H), 3.79 (s, 3H), 3.38 (d, J = 10.4 Hz, 2H), 2A 2.90 (d, J = 10.4 Hz, 2H), 2.28 (s, 3H), 2.03 - 1.93 (m, 2H), 1.65-1.63 (m, 2H). Example 170 Compound 203

ESI-MS: 486.2 [M + H]⁺ 2B Example 171 Compound 204

ESI-MS: 435.2 [M + H]⁺ ¹H NMR (400 MHZ, DMSO-d₆) δ 13.15 (s, 1H), 8.26 (s, 3H), 7.67 (s, 1H), 7.64 - 7.51 (m, 2H), 7.36 (t, J = 8.0 Hz, 1H), 7.15 - 7.03 (m, 3H), 6.71 (s, 1H), 3.79 (s, 3H), 3.71-3.62 (m, 1H), 3.43-3.27 (m, 2H), 3.12- 3.02 (m, 1H), 3.00- 2A 2.90 (m, 1H), 2.02- 1.92 (m, 1H), 1.88- 1.78 (m, 1H), 1.70-1.54 (m, 2H). Example 172 Compound 205

ESI-MS: 435.2 [M + H]⁺ ¹H NMR (400 MHZ, DMSO-d₆) 8 7.68-7.65 (m, 1H), 7.59-7.53 (m, 1H), 7.49 (d, J = 8.0 Hz, 1H), 7.31 (t, J = 8.0 Hz, 1H), 7.12 (d, J = 8.8 Hz, 1H), 7.09-7.02 (m, 2H), 6.69 (s, 1H), 3.79 (s, 3H), 3.72-3.65 (m, 2H), 2.98-2.89 (m, 1H), 2.83-2.74 (m, 2H), 1.86-1.76 (m, 2H), 1.48-1.36 (m, 2H). 2A Example 173 Compound 206

ESI-MS: 436.2 [M + H]⁺ ¹H NMR (400 MHZ, DMSO-d₆) δ 12.99 (s, 1H), 7.68-7.66 (m, 1H), 7.59-7.53 (m, 1H), 7.47 (d, J = 8.0 Hz, 1H), 7.29 (t, J = 8.0 Hz, 1H), 7.13 (d, J = 8.8 Hz, 1H), 7.09-7.01 (m, 2H), 6.69 (s, 1H), 4.66 (d, J = 4.0 Hz, 1H), 3.79 (s, 3H), 3.67-3.59 (m, 1H), 3.57- 2A 3.50 (m, 2H), 2.92-2.85 (m, 2H), 1.78-1.74 (m, 2H), 1.49-1.39 (m, 2H). Example 174 Compound 207

ESI-MS: 437.2 [M + H]⁺ ¹H NMR (400 MHZ, DMSO-d₆) δ 13.22 (br, 1H),7.50-7.40 (m, 2H), 7.31-7.14 (m, 4H), 6.78 (s, 1H), 3.05-3.00 (m, 4H), 2.49-2.44 (m, 4H), 2.22 (s, 3H), 2.08 (s, 3H). 2A Example 175 Compound 208

ESI-MS: 437.2 [M + H]⁺ ¹H NMR (400 MHZ, DMSO-d₆) δ 13.17 (br, 1H),7.50-7.43 (m, 1H), 7.39-7.34 (m, 1H), 7.30- 7.27 (m, 2H), 7.19 (t, J = 9.5 Hz, 1H), 7.10- 7.05 (m, 1H), 6.78 (s, 1H), 3.10-3.06 (m, 4H), 2.42-2.39 (m, 4H), 2.19 (s, 3H), 2.09 (s, 3H). 2A Example 176 Compound 209

ESI-MS: 453.2 [M + H]⁺ ¹H NMR (400 MHZ, DMSO-d₆) δ 13.13 (br, 1H), 7.57-7.49 (m, 1H), 7.43-7.38 (m, 1H), 7.21 (t, J = 7.9 Hz, 1H), 7.17- 7.07 (m, 2H), 7.03 (t, J = 8.8 Hz, 1H), 6.70 (s, 1H), 3.76 (s, 3H), 3.05-3.00 (m, 4H), 2.50-2.44 (m, 4H), 2.22 (s, 3H). 2A Example 177 Compound 210

ESI-MS: 453.2 [M + H]⁺ ¹H NMR (400 MHz, DMSO-d₆) δ 13.13 (br, 1H), 7.57-7.50 (m, 1H), 7.40-7.36 (m, 1H), 7.19 (t, J = 9.5 Hz, 1H), 7.13- 7.00 (m, 3H), 6.71 (s, 1H), 3.77 (s, 3H), 3.10-3.04 (m, 4H), 2.43-2.38 (m, 4H), 2.19 (s, 3H). 2A

Biological Activity Test and Results:

1. HPK1 Kinase Activity Inhibition Test

The kinase activity of HPK1 is manifested as activity of autophosphorylation and phosphorylation of downstream substrates. In the process of autophosphorylation, additional substrates are not required, and ATP is consumed to generate ADP. The amount of the product was measured by ADP-Glo reagent and luminescence method to reflect kinase activity.

Test compounds: compounds prepared in the examples of this application.

Prepare compound stock solution: dissolve the compound to be tested in 100% DMSO to make a 10 mM stock solution;

Prepare 4× Kinase Reaction Buffer:

Concentration of Final Material Stock Solution Volume Concentration Tris 1M (25×) 240 μL 40 mM MgCl₂ 1M (50×) 120 μL 20 mM BSA 7.5%(75×) 80 μL 0.1% DTT 1M(500×) 3 μL 0.5 mM  ddH₂O 5557 μL

Prepare 2×HPK1 Kinase Solution:

Concen- tration 2 × Final Final of Stock Concen- Concen- Material Solution Volume tration tration HPK1 4878 nM  1 μL 10 nM 5 nM 1 × kinase 487 μL reaction buffer solution

Prepare 4×ATP mixture:

Concen- 4 × tration Final Final of Stock Concen- Concen- Material ATP Km Solution Volume tration tration ATP 1.669 μM 1 mM (125×)  3 μL 8 μM 2 μM 4 × kinase 372 μL reaction buffer solution

Procedures:

Dilute the stock solution of the compound to be tested by 5 times with 1000 DMSO, make a 4-fold equal dilution in a 96-well dilution plate, add 1 μL of the compound to 49 L of kinase reaction buffer, and shake on a microplate shaker for 20 minutes. Transfer 2 μL of 2×HIPK1 kinase solution to 384 reaction plate, add 1 μL of the test compound to the 384 reaction plate (Greiner, 784075), centrifuge for 1 minute (1000 rpm/min), incubate at 25° C. for 10 minutes. Transfer 1 L of the 4×ATP mixture to a 384 reaction plate, centrifuge for 1 minute (1000 rpm/mm), and incubate at 25° C. for 60 minutes. In the reaction system, the final concentration of DMSO was 0.500. Transfer 4 μL of ADP-Glo to a 384 reaction plate, centrifuge for 1 minute (1000 rpm/min), and incubate at 25° C. for 40 minutes. Transfer 8 μL detection solution to a 384 reaction plate, centrifuge for 1 minute (1000 rpm/min), and incubate at 25° C. for 40 minutes. The fluorescence signal was read using a Biotek multi-function plate reader, and the +C₅₀ (half inhibitory concentration) of the compound was obtained using a four-coefficient nonlinear fitting formula.

Compounds as shown in the Examples exhibited IC50 values in the following ranges: +++=IC50≤50 nM, ++=50 nM≤IC50<500 nM, +=500 nM<IC50<2000 nM.

TABLE 1 Inhibitory effects of compounds on HPK1 kinase activity Compound IC50 Compound 1 +++ Compound 2 ++ Compound 3 +++ Compound 4 +++ Compound 5 ++ Compound 6 +++ Compound 7 ++ Compound 8 +++ Compound 9 +++ Compound 10 +++ Compound 11 ++ Compound 12 + Compound 13 ++ Compound 14 ++ Compound 15 + Compound 16 + Compound 17 + Compound 19 + Compound 20 ++ Compound 21 ++ Compound 23 +++ Compound 24 +++ Compound 25 ++ Compound 26 + Compound 27 +++ Compound 28 +++ Compound 29 +++ Compound 32 ++ Compound 33 +++ Compound 34 +++ Compound 42 +++ Compound 47 + Compound 48 ++ Compound 55 ++ Compound 58 ++ Compound 61 +++ Compound 72 ++ Compound 73 +++ Compound 74 +++ Compound 75 + Compound 76 +++ Compound 77 +++ Compound 78 ++ Compound 79 +++ Compound 80 +++ Compound 81 +++ Compound 82 +++ Compound 83 +++ Compound 84 ++ Compound 85 +++ Compound 86 +++ Compound 87 +++ Compound 88 ++ Compound 89 +++ Compound 90 +++ Compound 91 +++ Compound 92 +++ Compound 93 +++ Compound 94 +++ Compound 95 ++ Compound 96 ++ Compound 97 ++ Compound 98 +++ Compound 99 ++ Compound 100 ++ Compound 101 +++ Compound 102 ++ Compound 103 +++ Compound 104 ++ Compound 105 +++ Compound 106 +++ Compound 107 +++ Compound 108 ++ Compound 109 +++ Compound 110 ++ Compound 111 +++ Compound 112 +++ Compound 113 +++ Compound 114 +++ Compound 115 +++ Compound 116 +++ Compound 117 +++ Compound 118 +++ Compound 119 +++ Compound 120 +++ Compound 121 +++ Compound 122 +++ Compound 123 +++ Compound 124 +++ Compound 125 +++ Compound 126 +++ Compound 127 +++ Compound 128 +++ Compound 129 +++ Compound 130 +++ Compound 131 ++ Compound 132 +++ Compound 133 +++ Compound 134 +++ Compound 135 +++ Compound 136 +++ Compound 137 +++ Compound 138 +++ Compound 139 +++ Compound 140 +++ Compound 141 +++ Compound 142 +++ Compound 143 +++ Compound 144 +++ Compound 145 +++ Compound 146 +++ Compound 147 +++ Compound 148 +++ Compound 149 + Compound 150 + Compound 151 ++ Compound 152 ++ Compound 153 ++ Compound 154 ++ Compound 155 ++ Compound 156 +++ Compound 157 +++ Compound 158 ++ Compound 159 +++ Compound 160 +++ Compound 161 +++ Compound 162 +++ Compound 163 ++ Compound 164 ++ Compound 165 ++ Compound 166 ++ Compound 167 ++ Compound 168 ++ Compound 169 ++ Compound 170 +++ Compound 171 ++ Compound 172 ++ Compound 173 ++ Compound 174 ++ Compound 175 ++ Compound 176 +++ Compound 177 +++ Compound 178 ++ Compound 179 ++ Compound 180 +++ Compound 181 ++ Compound 182 ++ Compound 183 + Compound 184 ++ Compound 185 + Compound 186 + Compound 187 ++ Compound 188 ++ Compound 189 ++ Compound 190 ++ Compound 191 ++ Compound 193 +++ Compound 194 +++ Compound 195 ++ Compound 196 ++ Compound 197 +++ Compound 198 +++ Compound 199 +++ Compound 200 +++ Compound 201 +++ Compound 202 +++ Compound 203 +++ Compound 204 +++ Compound 205 +++ Compound 206 ++ Compound 207 + Compound 208 +++ Compound 209 ++ Compound 210 +++

The data in Table 1 show that the compounds of the examples of the present application have inhibitory effect on HIPK1 kinase activity.

2. Measurement of IL-2 Secretion of Jurkat Cells by ELISA

Procedures:

Human Jurkat-E6-1 cells were incubated with various concentrations of test compounds for 30 minutes in a humidified incubator at 37° C. and 500 C₀₂. Cells were transferred to cell culture plates pre-coated with anti-human CD3 antibody, then soluble anti-human CD28 antibody was added, and cells were stimulated for 24 hours at 37° C. and 5% CO₂ in a humidified incubator. The cell culture medium was collected by centrifugation, and was then transferred to a 96-well transparent microtiter plate (Thermo) pre-coated with anti-human IL-2 antibody, incubated at room temperature for 2 hours, and gently shaken, washed with washing buffer for 4 times, and then followed the ELISA MAX Deluxe Set Human IL-2 (BioLegend) kit procedure, used a microplate reader (Molecular Device, i3X) to read the GD value. The best standard curve was selected by the microplate reader application software, and the corresponding concentration was calculated according to the GD value of the standard. Results are expressed as a percentage of the amount of IL-2 secreted from compound-treated/DMSO-treated cells.

TABLE 2 Effects of compounds on secretion of IL-2 from human Jurkat cells. Percentage of the amount of Concentration of IL-2 secreted from compound the Test Compound Compound treated/DMSO-treated cells (μM) Compound 1 277% 1.0 Compound 2 238% 3.0 Compound 3 211% 1.0 Compound 5 162% 1.0 Compound 6 185% 1.0 Compound 7 314% 1.0 Compound 8 306% 0.33 Compound 9 188% 3.0 Compound 11 296% 1.0 Compound 13 315% 3.0 Compound 14 255% 3.0 Compound 16 156% 1.0 Compound 20 329% 1.0 Compound 21 258% 3.0 Compound 23 379% 0.33 Compound 25 187% 1.0 Compound 27 302% 0.33 Compound 28 302% 1.0 Compound 29 291% 1.0 Compound 33 631% 1.0 Compound 34 284% 1.0 Compound 42 365% 3.0 Compound 58 233% 3.0 Compound 61 635% 3.0 Compound 73 926% 3.0 Compound 74 411% 3.0 Compound 76 561% 3.0 Compound 77 233% 1.0 Compound 79 361% 3.0 Compound 80 191% 3.0 Compound 81 679% 3.0 Compound 82 195% 3.0 Compound 83 252% 3.0 Compound 85 239% 3.0 Compound 86 334% 3.0 Compound 87 584% 3.0 Compound 88 550% 3.0 Compound 89 689% 3.0 Compound 90 667% 3.0 Compound 92 1101%  3.0 Compound 93 210% 3.0 Compound 94 414% 3.0 Compound 98 850% 3.0 Compound 99 237% 3.0 Compound 100 284% 3.0 Compound 103 716% 3.0 Compound 105 623% 3.0 Compound 106 833% 3.0 Compound 107 599% 3.0 Compound 108 312% 3.0 Compound 109 491% 3.0 Compound 111 522% 3.0 Compound 112 703% 3.0 Compound 113 368% 3.0 Compound 114 309% 3.0 Compound 115 542% 3.0 Compound 116 193% 1.0 Compound 117 566% 3.0 Compound 118 550% 3.0 Compound 119 531% 3.0 Compound 120 482% 3.0 Compound 121 459% 3.0 Compound 122 1008%  3.0 Compound 123 1117%  3.0 Compound 124 570% 3.0 Compound 125 216% 3.0 Compound 126 428% 3.0 Compound 127 758% 3.0 Compound 128 472% 3.0 Compound 129 807% 3.0 Compound 130 454% 3.0 Compound 133 800% 3.0 Compound 134 527% 3.0 Compound 135 964% 3.0 Compound 136 702% 3.0 Compound 137 291% 3.0 Compound 138 873% 3.0 Compound 139 315% 3.0 Compound 140 436% 3.0 Compound 141 390% 3.0 Compound 142 708% 3.0 Compound 143 786% 3.0 Compound 144 716% 3.0 Compound 145 776% 3.0 Compound 146 537% 3.0 Compound 147 616% 3.0 Compound 148 531% 1.0 Compound 151 230% 3.0 Compound 154 382% 1.0 Compound 155 435% 3.0 Compound 156 849% 3.0 Compound 157 935% 3.0 Compound 159 454% 3.0 Compound 160 354% 3.0 Compound 161 393% 3.0 Compound 162 586% 3.0 Compound 163 117% 3.0 Compound 164 159% 3.0 Compound 165 181% 1.0 Compound 170 279% 1.0 Compound 171 220% 3.0 Compound 177 481% 3.0 Compound 193 169% 3.0 Compound 198 280% 3.0 Compound 199 328% 1.0 Compound 200 286% 3.0 Compound 202 539% 1.0 Compound 204 260% 3.0 Compound 210 298% 1.0

The data in Table 2 shows that, compared with Jurkat cells treated with DMSO as a blank control group, the compounds of the examples of the present application have a significant promoting effect on the secretion of cytokine IL-2 by Jurkat cells.

Unless otherwise defined, the terms used in this application are the meanings commonly understood by those skilled in the art.

The embodiments described in this application are only for exemplary purposes and are not intended to limit the protection scope of this application. Those skilled in the art can make various other substitutions, changes and improvements within the scope of this application. Therefore, this application is not limited to the above-described embodiments, but only by the claims. 

1-19. (canceled)
 20. A compound of formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, active metabolite, polymorph, isotope labeled compound, isomer or prodrug thereof,

wherein, R¹ is selected from the group consisting of: 1) hydrogen, halogen, cyano, —C(═O)NR^(a)R^(b), —OR^(a) and —NR^(a)R^(b); 2) C₁₋₆ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₃₋₈ cycloalkyl and 3- to 8-membered aliphatic heterocyclyl, unsubstituted or optionally substituted with 1, 2, 3 or 4 substituents independently selected from R¹¹; R^(a) and R^(b) are each independently selected from the group consisting of: 1) hydrogen; 2) C₁₋₆ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₃₋₆ monocyclic cycloalkyl, and 3- to 6-membered aliphatic monocyclic heterocyclyl, unsubstituted or optionally substituted with 1, 2, or 3 substituents independently selected from R¹¹; or R^(a) and R^(b) attached to the same nitrogen atom, together with the nitrogen atom, form a 3-6 membered aliphatic monocyclic heterocyclyl, unsubstituted or optionally substituted with 1, 2 or 3 substituents independently selected from R¹¹; R¹¹ is selected from the group consisting of fluorine, chlorine, cyano, C₁₋₃ alkyl and hydroxyl; Cy^(A) is selected from 6- to 10-membered aryl or 5- to 10-membered heteroaryl, unsubstituted or optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from R¹²; R¹² is selected from the group consisting of: 1) oxo, halogen, cyano, —C(═O)R^(a2), —C(═O)OR^(a2), —C(═O)NR^(a2)R^(b2), —C(═NR^(d2))NR^(a2)R^(b2), —OR^(a), —OC(═O)R^(a2), —OC(═O)OR², —OC(═O)NR^(a2)R^(b2), —SR^(a2), —S(═O)R^(e2), —S(═O)₂R^(c2), sulfonic acid group, —S(═O)NR^(a2)R^(b2), —S(═O)₂NR^(a2)R^(b2), —S(═O)(═NR^(d2))R², —NR^(a2)R^(b2), —NR^(a2)C(═O)R^(b2), —NR^(a2)C(═O)OR², —NR^(e2)C(═O)NR^(a2)R^(b2), —NR^(e2)C(═NR^(d2))NR^(a2)R^(b2), —NR^(a2)S(═O)₂R^(c2), —NR^(e2)S(═O)₂NR^(a2)R^(b2), nitro, —PR^(c2)R^(f2), —P(═O)R^(c2)R^(f2) and phosphonic acid group; 2) C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, 6- to 10-membered aryl, 5- to 10-membered heteroaryl, C₃₋₁₂ cycloalkyl and 3- to 12-membered aliphatic heterocyclyl, unsubstituted or optionally substituted with 1, 2, 3, 4, 5 or 6 substituents independently selected from R²²; 3) the two R¹² substituents attached to two adjacent ring-forming atoms on the aryl or heteroaryl group of Cy^(A), respectively, together with the two said ring-forming atoms, form a C₅₋₂ alicyclyl or a 5- to 12-membered aliphatic heterocyclyl, unsubstituted or optionally substituted by 1, 2, 3, 4, 5 or 6 substituents independently selected from R²²; R^(a2), R^(b2) and R^(e2) are each independently selected from the group consisting of: 1) hydrogen; 2) C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, phenyl, 5-6 membered heteroaryl, C₃₋₁₂ cycloalkyl and 3-12 membered aliphatic heterocyclyl, unsubstituted or optionally substituted with 1, 2, 3, 4, 5 or 6 substituents independently selected from R²²; or, R^(a2) and R^(b2) attached to the same nitrogen atom, together with the nitrogen, form a 3-12 membered aliphatic heterocyclyl, unsubstituted or optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from R²²; R^(c2) and R^(f2) are each independently selected from the group consisting of C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, phenyl, 5-6 membered heteroaryl, C₃₋₁₂ cycloalkyl and 3-12 membered aliphatic heterocyclyl, unsubstituted or optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from R²²; or, R^(c2) and R^(f2) attached to the same phosphorous atom, together with the phosphorous, form a 3-12 membered aliphatic heterocyclyl, unsubstituted or optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from R²²; R^(d2) is selected from the group consisting of: 1) hydrogen, cyano, nitro and —S(═O)₂R^(G); 2) C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, phenyl, 5-6 membered heteroaryl, C₃₋₁₂ cycloalkyl and 3-12 membered aliphatic heterocyclyl, unsubstituted or optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from R²²; R²² is selected from the group consisting of: 1) oxo, halogen, cyano, —C(═O)R^(a4), —C(═O)OR^(a4), —C(═O)NR^(a4)R^(b4), —C(═NR^(d4))NR^(a4)R^(b4), —OR^(a4), —OC(═O)R^(a4), —OC(═O)OR^(c4), —OC(═O)NR^(a4)R^(b4), —SR^(a4), —S(═O)R^(c4), —S(═O)₂R^(c4), sulphonic acid group, —S(═O)NR^(a4)R^(b4), —S(═O)₂NR^(a4)R^(b4), —S(═O)(═NR^(d4))R^(c4), —NR^(a4)R^(b4), —NR^(a4)C(═O)R^(b4), —NR^(a4)C(═O)OR⁴, —NR^(c4)C(═O)NR^(a4)R^(b)4, —NR⁴C(═NR^(d4))NR^(a4)R^(b)4, —NR^(a4)S(═O)₂R⁴, —NR^(e4)S(═O)₂NR^(a4)R^(b4) nitro, —PR^(c4)R^(f4), —P(═O)R^(c4)R^(f4), phosphonic acid group, and ═N—R^(d4); 2) C₁₋₆ alkyl, C₁₋₆ alkylene, C₂₋₆ alkenyl, C₂₋₆ alkynyl, phenyl, 5-6 membered heteroaryl, C₃₋₁₀ cycloalkyl and 3-10 membered aliphatic heterocyclyl, unsubstituted or optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from R³²; R^(a4), R^(b4) and R^(e4) are each independently selected from the group consisting of: 1) hydrogen; 2) C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, phenyl, 5-6 membered heteroaryl, C₃₋₁₀ cycloalkyl and 3-10 membered aliphatic heterocyclyl, unsubstituted or optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from R³²; or, R^(a4) and R^(b4) attached to the same nitrogen atom, together with the nitrogen, form a 3-10 membered aliphatic heterocyclyl, unsubstituted or optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from R³²; R^(c4) and R^(f4) are each independently selected from the group consisting of C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, phenyl, 5-6 membered heteroaryl, C₃₋₁₀ cycloalkyl and 3-10 membered aliphatic heterocyclyl, unsubstituted or optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from R³²; or, R^(c4) and R^(f4) attached to the same phosphorous atom, together with the phosphorous, form a 3-10 membered aliphatic heterocyclyl, unsubstituted or optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from R³²; R^(d4) is selected from the group consisting of: 1) hydrogen, cyano, nitro, and —S(═O)₂R^(G); 2) C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, phenyl, 5-6 membered heteroaryl, C₃₋₁₀ cycloalkyl and 3-10 membered aliphatic heterocyclyl, unsubstituted or optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from R³²; R³² is selected from the group consisting of: 1) oxo, halogen, cyano, —C(═O)R^(a6), —C(═O)OR^(a6), —C(═O)NR^(a6)R^(b6), —C(═NR^(d6))NR^(a6)R^(b6), —OR^(a6), —OC(═O)R^(a6), —OC(═O)OR^(c6), —OC(═O)NR^(a6)R^(b6), —SR^(a6), —S(═O)R^(c6), —S(═O)₂R⁶, sulphonic acid group, —S(═O)NR^(a6)R^(b6), —S(═O)₂NR^(a6)R^(b6), —S(═O)(═NR^(d6))R⁶, —NR^(a6)R^(b6), —NR^(a6)C(═O)R^(b6), —NR^(a6)C(═O)OR⁶, —NR^(e6)C(═O)NR^(a6)R^(b6), —NR^(e6)C(═NR^(d6))NR^(a6)R^(b6), —NR^(a6)S(═O)₂R^(c6), —NR^(e6)S(═O)₂NR^(a6)R^(b), nitro, —PR^(c6)R^(f6), —P(═O)R^(c6)R^(f6), phosphonic acid group, and ═N—R^(d6); 2) C₁₋₄ alkyl, C₁₋₄ alkylene, C₂₋₄ alkenyl, C₂₋₄ alkynyl, phenyl, 5-6 membered heteroaryl, C₃₋₆ cycloalkyl, and 3-8 membered aliphatic heterocyclyl, unsubstituted or optionally substituted with 1, 2, 3 or 4 substituents independently selected from R^(G); R^(a6), R^(b6) and R^(e6) are each independently selected from the group consisting of: 1) hydrogen; 2) C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, phenyl, 5-6 membered heteroaryl, C₃₋₈ cycloalkyl, and 3-8 membered aliphatic heterocyclyl, unsubstituted or optionally substituted with 1, 2, 3 or 4 substituents independently selected from R^(G); or, R^(a6) and R^(b6) attached to the same nitrogen atom, together with the nitrogen, form a 3-8 membered aliphatic heterocyclyl, unsubstituted or optionally substituted with 1, 2, 3 or 4 substituents independently selected from R^(G); R^(c6) and R^(f6) are each independently selected from the group consisting of C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, phenyl, 5-6 membered heteroaryl, C₃₋₈ cycloalkyl, and 3-8 membered aliphatic heterocyclyl, unsubstituted or optionally substituted with 1, 2, 3 or 4 substituents independently selected from R^(G); or, R^(c6) and R^(f6) attached to the same phosphorous atom, together with the phosphorous, form a 3-8 membered aliphatic heterocyclyl, unsubstituted or optionally substituted with 1, 2, 3 or 4 substituents independently selected from R^(G); R^(d6) is selected from the group consisting of: 1) hydrogen, cyano, nitro, and —S(═O)₂R^(G); 2) C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, phenyl, 5-6 membered heteroaryl, C₃₋₈ cycloalkyl, and 3-8 membered aliphatic heterocyclyl, unsubstituted or optionally substituted with 1, 2, 3 or 4 substituents independently selected from R^(G); Cy^(B) is selected from the group consisting of 6-10 membered aryl and 5-10 membered heteroaryl, unsubstituted or optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from R¹³; R¹³ is selected from the group consisting of: 1) oxo, halogen, cyano, —C(═O)R^(a3), —C(═O)OR^(a3), —C(═O)NR^(a3)R^(b3), —C(═NR^(d3))NR^(a3)R^(b3), —OR^(a3), —OC(═O)R^(a3), —OC(═O)OR^(c3), —OC(═O)NR^(a3)R^(b3), —SR^(a3), —S(═O)R^(c3), —S(═O)₂R^(c3), sulphonic acid group, —S(═O)NR^(a3)R^(b3), —S(═O)₂NR^(a3)R^(b3), —S(═O)(═NR^(d3))R^(c3), —NR^(a3)R^(b3), —NR^(a3)C(═O)R^(b3), —NR^(a3)C(═O)OR^(c3), —NR^(e3)C(═O)NR^(a3)R^(b3), —NR^(e3)C(═NR^(d3))NR^(a3)R^(b3), —NR^(a3)S(═O)₂R^(c3)—NR^(e3)S(═O)₂NR^(a3)R^(b3) nitro, —PR^(c3)R^(f3), —P(═O)R^(c3)R^(f3), and phosphonic acid group; 2) C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, 6-10 membered aryl, 5-10 membered heteroaryl, C₃₋₁₂ cycloalkyl, and 3-12 membered aliphatic heterocyclyl, unsubstituted or optionally substituted with 1, 2, 3, 4, 5 or 6 substituents independently selected from R²³; 3) two R¹³ substituents attached to two adjacent ring-forming atoms of the aryl or heteroaryl of Cy^(B) respectively, together with the two said ring-forming atoms, form a C₅₋₁₂ aliphatic cyclyl or a 5-12 membered aliphatic heterocyclyl, unsubstituted or optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from R²³; R^(a3), R^(b3) and R^(e3) are each independently selected from the group consisting of: 1) hydrogen; 2) C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, phenyl, 5-6 membered heteroaryl, C₃₋₁₂ cycloalkyl, and 3-12 membered aliphatic heterocyclyl, unsubstituted or optionally substituted with 1, 2, 3, 4, 5 or 6 substituents independently selected from R²³; or, R^(a3) and R^(b3) attached to the same nitrogen atom, together with the nitrogen, form a 3-12 membered aliphatic heterocyclyl, unsubstituted or optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from R²³; R^(c3) and RP are each independently selected from the group consisting of C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, phenyl, 5-6 membered heteroaryl, C₃₋₁₂ cycloalkyl, and 3-12 membered aliphatic heterocyclyl, unsubstituted or optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from R²³; or, R^(c3) and RP attached to the same phosphorous atom, together with the phosphorous atom, form a 3-12 membered aliphatic heterocyclyl, unsubstituted or optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from R²³; R^(d3) is selected from the group consisting of: 1) hydrogen, cyano, nitro, and S(═O)₂R^(G); 2) C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, phenyl, 5-6 membered heteroaryl, C₃₋₁₂ cycloalkyl, and 3-12 membered aliphatic heterocyclyl, unsubstituted or optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from R²³; R²³ is selected from the group consisting of: 1) oxo, halogen, cyano, —C(═O)R^(a5), —C(═O)OR^(a5), —C(═O)NR^(a5)R^(b5), C(═NR^(d5))NR^(a5)R^(b5), —OR^(a5), —OC(═O)R^(a5), —OC(═O)OR^(c5), —OC(═O)NR^(a5)R^(b5), —SR^(a5), —S(═O)R^(c5), —S(═O)₂R^(c5), sulphonic acid group, —S(═O)NR^(a5)R^(b5), —S(═O)₂NR^(a5)R^(b5), —S(═O)(═NR^(d5))R^(c5), —NR^(a5)R^(b5), —N^(a5)C(═O)R^(b5), —N^(a5)C(═O)OR^(c5), —NR^(e5)C(═O)NR^(a5)R^(b5), —NR^(e5)C(═NR^(d5)NR^(a5)R^(b5), —NR^(a5)S(═O)₂R^(c5), —NR^(e5)S(═O)₂NR^(a5)R^(b5) nitro, —PR^(c5)R^(f5), —P(═O)R^(c5)R^(f5), phosphonic acid group, and ═N—R^(d5); 2) C₁₋₆ alkyl, C₁₋₆ alkylene, C₂₋₆ alkenyl, C₂₋₆ alkynyl, phenyl, 5-6 membered heteroaryl, C₃₋₁₀ cycloalkyl, and 3-10 membered aliphatic heterocyclyl, unsubstituted or optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from R³³; R^(a5), R^(b5) and R^(e5) are each independently selected from the group consisting of: 1) hydrogen; 2) C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, phenyl, 5-6 membered heteroaryl, C₃₋₁₀ cycloalkyl, and 3-10 membered aliphatic heterocyclyl, unsubstituted or optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from R³³; or, R^(a5) and R^(b5) attached to the same nitrogen atom, together with the nitrogen atom, form a 3-10 membered aliphatic heterocyclyl, unsubstituted or optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from R³³; R^(c5) and R^(e5) are each independently selected from the group consisting of C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, phenyl, 5-6 membered heteroaryl, C₃₋₁₀ cycloalkyl, and 3-10 membered aliphatic heterocyclyl, unsubstituted or optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from R³³; or, R^(c5) and R^(f5) attached to the same phosphorous atom, together with the phosphorous atom, form a 3-10 membered aliphatic heterocyclyl, unsubstituted or optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from R³³; R^(d5) is selected from the group consisting of: 1) hydrogen, cyano, nitro, and —S(═O)₂R^(G); 2) C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, phenyl, 5-6 membered heteroaryl, C₃₋₁₀ cycloalkyl, and 3-10 membered aliphatic heterocyclyl, unsubstituted or optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from R³³; R³³ is selected from the group consisting of: 1) oxo, halogen, cyano, —C(═O)R^(a7), —C(═O)OR^(a7), —C(═O)NR^(a7)R^(b7), —C(═NR^(d7))NR^(a7)R^(b7), —OR^(a7), —OC(═O)R^(a7), —OC(═O)OR^(c7), —OC(═O)NR^(a7)R^(b7), —SR^(a7), —S(═O)R^(c7), —S(═O)₂R⁷, sulphonic acid group, —S(═O)NR^(a7)R^(b7), —S(═O)₂NR^(a7)R^(b7), —S(═O)(═NR^(d7))R^(c7), —N^(a7)R^(b7), —NR^(a7)(═O)R^(b7), —NR^(a7)(═O)OR^(c7), —NR^(e7)C(═O)NR^(a7)R^(b7), —NR^(e7)C(═NR^(d7)NR^(a7)R^(b7), —NR^(a7)S(═O)₂R^(c7), —NR^(e7)S(═O)₂NR^(a7)R^(b7) nitro, —PR^(c7)R^(f7), —P(═O)R^(c7)R^(f7), phosphonic acid group, and ═N—R^(d7); 2) C₁₋₄ alkyl, C₁₋₄ alkylene, C₂₋₄ alkenyl, C₂₋₄ alkynyl, phenyl, 5-6 membered heteroaryl, C₃₋₆ cycloalkyl, and 3-8 membered aliphatic heterocyclyl, unsubstituted or optionally substituted with 1, 2, 3 or 4 substituents independently selected from R^(G); R^(a7), R^(b7) and R^(e7) are each independently selected from the group consisting of: 1) hydrogen; 2) C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, phenyl, 5-6 membered heteroaryl, C₃₋₈ cycloalkyl, and 3-8 membered aliphatic heterocyclyl, unsubstituted or optionally substituted with 1, 2, 3 or 4 substituents independently selected from R^(G); or, R^(a7) and R^(b7) attached to the same nitrogen atom, together with the nitrogen atom, form a 3-8 membered aliphatic heterocyclyl, unsubstituted or optionally substituted with 1, 2, 3 or 4 substituents independently selected from R^(G); R^(c7) and R^(f7) are each independently selected from the group consisting of C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, phenyl, 5-6 membered heteroaryl, C₃₋₈ cycloalkyl, and 3-8 membered aliphatic heterocyclyl, unsubstituted or optionally substituted with 1, 2, 3 or 4 substituents independently selected from R^(G); or, R^(c7) and R^(f7) attached to the same phosphorous atom, together with the phosphorous atom, form a 3-8 membered aliphatic heterocyclyl, unsubstituted or optionally substituted with 1, 2, 3 or 4 substituents independently selected from R^(G); R^(d7) is selected from the group consisting of: 1) hydrogen, cyano, nitro, and —S(═O)₂R^(G); 2) C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, phenyl, 5-6 membered heteroaryl, C₃₋₈ cycloalkyl, and 3-8 membered aliphatic heterocyclyl, unsubstituted or optionally substituted with 1, 2, 3 or 4 substituents independently selected from R^(G); R^(G) is selected from the group consisting of: 1) halogen, oxo, cyano, carboxyl, hydroxyl, C₁₋₄ alkoxy, amino, C₁₋₄ alkylamino, nitro, C₁₋₄ alkylthio, sulphonic acid group, C₁₋₄ alkyl sulfinyl, C₁₋₄ alkyl sulfonyl, C₁₋₄ alkylaminosulfinyl, and C₁₋₄ alkylaminosulfonyl; 2) C₁₋₄ alkyl, C₁₋₄ alkylene, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₃₋₆ cycloalkyl and 3-8 membered aliphatic heterocyclyl, unsubstituted or optionally substituted with 1, 2, 3 or 4 substituents independently selected from the group consisting of oxo, halogen, hydroxyl, hydroxymethyl, carboxyl, cyano, C₁₋₃ alkoxy, amino, C₁₋₄ alkylamino, nitro, and sulphonic acid group.
 21. The compound according to claim 20, wherein, R¹ is selected from the group consisting of hydrogen, fluorine, cyano, methyl, ethyl, 1-propyl, isopropyl, cyclopropyl, methoxy, ethoxy and cyclopropyloxy; Cy^(A) is selected from the group consisting of phenyl, naphthyl and 5-10 membered heteroaryl, unsubstituted or optionally substituted with 1, 2, 3 or 4 substituents independently selected from R¹²; wherein 5-10 membered heteroaryl contains at least two ring-forming carbon atoms and 1, 2, or 3 ring-forming heteroatoms independently selected from the group consisting of N, O and S; R¹² is selected from the group consisting of: 1) oxo, halogen, cyano, —C(═O)R^(a2), —C(═O)OR^(a2), —C(═O)NR^(a2)R^(b2), —C(═NR^(d2))NR^(a2)R^(b2), —OR^(a2), —NR^(a2)R^(b2), —NR^(a2)C(═O)R^(b2), —NR^(a2)C(═O)OR^(c2), —NR^(e2)C(═O)NR^(a2)R^(b2), —NR^(e2)C(═NR^(d2))NR^(a2)R^(b2), —NR^(a2)S(═O)₂R^(e2) and —NR^(e2)S(═O)₂NR^(a2)R^(b2); 2) C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, 6-10 membered aryl, 5-10 membered heteroaryl, C₃₋₁₀ cycloalkyl, 3-10 membered aliphatic heterocyclyl, unsubstituted or optionally substituted with 1, 2, 3 or 4 substituents independently selected from R²²; 3) two R¹², together with two adjacent ring-forming atoms of the aryl or heteroaryl in Cy^(A) to which they are attached respectively, form a C₄₋₈ aliphatic cyclyl or 4-8 membered aliphatic heterocyclyl, unsubstituted or optionally substituted with 1, 2 or 3 substituents independently selected from R²²; R^(a2), R^(b2) and R^(e2) are each independently selected from the group consisting of: 1) hydrogen; 2) C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, phenyl, 5-6 membered heteroaryl, C₃₋₆ cycloalkyl and 3-6 membered aliphatic heterocyclyl, unsubstituted or optionally substituted with 1, 2 or 3 substituents independently selected from R²²; or, R^(a2) and R^(b2), together with the same N atom to which they are attached, form a 3-8 membered aliphatic heterocyclyl, unsubstituted or optionally substituted with 1, 2 or 3 substituents independently selected from R²²; R^(c2) is selected from the group consisting of C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, phenyl, 5-6 membered heteroaryl, C₃₋₆ cycloalkyl and 3-6 membered aliphatic heterocyclyl, unsubstituted or optionally substituted with 1, 2 or 3 substituents independently selected from R²²; R^(d2) is selected from the group consisting of: 1) hydrogen, cyano, nitro, and —S(═O)₂R^(G); 2) C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, phenyl, 5-6 membered heteroaryl, C₃₋₆ cycloalkyl, and 3-6 membered aliphatic heterocyclyl, unsubstituted or optionally substituted with 1, 2 or 3 substituents independently selected from R²²; R²² is selected from the group consisting of: 1) oxo, halogen, cyano, carboxyl, —C(═O)R^(a4), —C(═O)OR^(a4), —C(═O)NR^(a4)R^(b4), —C(═NR^(d4))NR^(a4)R^(b4), —OR^(a4), —S(═O)₂R^(c4), sulphonic acid group, —S(═O)₂NR^(a4)R^(b4), —S(═O)(═NR^(d4))R^(c4), —NR^(a4)R^(b4), NR^(a4)C(═O)R^(b4), NR^(e4)C(═O)NR^(a4)R^(b4), —N^(e4)C(═NR^(d4))NR^(a4)R^(b4), —NR^(a4)S(═O)₂R⁴, —N^(e4)S(═O)₂NR^(a4)R^(b4) and ═N—R^(d4); 2) C₁₋₄ alkyl, C₁₋₄ alkylene, phenyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl and 3-7 membered aliphatic heterocyclyl, unsubstituted or optionally substituted with 1, 2 or 3 substituents independently selected from R³²; R^(a4), R^(b4) and R^(e4) are each independently selected from the group consisting of: 1) hydrogen; 2) C₁₋₄ alkyl, phenyl, 5-6 membered heteraryl, C₃₋₆ cycloalkyl, and 3-6 membered aliphatic heterocyclyl, unsubstituted or optionally substituted with 1, 2 or 3 substituents independently selected from R³²; or, R^(a4) and R^(b4), together with the same N atom to which they are attached, form a 3-6 membered aliphatic heterocyclyl, unsubstituted or optionally substituted with 1, 2 or 3 substituents independently selected from R³²; R^(c4) is selected from the group consisting of C₁₋₄ alkyl, phenyl, 5-6 membered heteroaryl, C₃₋₆ cycloalkyl, and 3-6 membered aliphatic heterocyclyl, unsubstituted or optionally substituted with 1, 2 or 3 substituents independently selected from R³²; R^(d4) is selected from the group consisting of: 1) hydrogen, cyano, nitro, and —S(═O)₂R^(G); 2) C₁₋₄ alkyl, phenyl, 5-6 membered heteroaryl, C₃₋₆ cycloalkyl, and 3-6 membered aliphatic heterocyclyl, unsubstituted or optionally substituted with 1, 2 or 3 substituents independently selected from R³²; R³² is selected from the group consisting of: 1) oxo, halogen, cyano, —C(═O)R^(a6), —C(═O)OR^(a6), C(═O)NR^(a6)R^(b6), —C(═N^(d6))NR^(a6)R^(b6), —OR^(a6), —S(═O)₂R^(c6), —S(═O)₂NR^(a6)R^(b6), —S(═O)(═NR^(d6))R⁶, —NR^(a6)R^(b6), —NR^(a6)C(═O)R^(b6), —N^(e6)C(═O)NR^(a6)R^(b6), —NR^(e6)C(═NR^(d6))R^(a6)R^(b6), —NR^(a6)S(═O)₂R⁶—NR^(e6)S(═O)₂NR^(a6)R^(b6) and ═N—R^(d6); 2) C₁₋₄ alkyl, C₁₋₄ alkylene, phenyl, 5-6 membered heteroaryl, C₃₋₆ cycloalkyl, and 3-6 membered aliphatic heterocyclyl, unsubstituted or optionally substituted with 1, 2, 3 or 4 substituents independently selected from R^(G); R^(a6), R^(b6) and R^(e6) are each independently selected from the group consisting of: 1) hydrogen; 2) C₁₋₄ alkyl, phenyl, 5-6 membered heteroaryl, C₃₋₆ cycloalkyl, and 3-6 membered aliphatic heterocyclyl, unsubstituted or optionally substituted with 1, 2, or 3 substituents independently selected from R^(G); or, R^(a6) and R^(b6) attached to the same nitrogen atom, together with the nitrogen, form a 3-6 membered aliphatic heterocyclyl, unsubstituted or optionally substituted with 1, 2, or 3 substituents independently selected from R^(G); R^(c6) is independently selected from the group consisting of C₁₋₄ alkyl, phenyl, 5-6 membered heteroaryl, C₃₋₆ cycloalkyl and 3-6 membered aliphatic heterocyclyl, unsubstituted or optionally substituted with 1, 2, or 3 substituents independently selected from R^(G); R^(d6) is selected from the group consisting of: 1) hydrogen, cyano, nitro, and —S(═O)₂R^(G); 2) C₁₋₄ alkyl, phenyl, 5-6 membered heteroaryl, C₃₋₆ cycloalkyl, and 3-6 membered aliphatic heterocyclyl, unsubstituted or optionally substituted with 1, 2 or 3 substituents independently selected from R^(G); Cy^(B) is selected from the group consisting of phenyl, naphthyl and 5-10 membered heteroaryl, unsubstituted or optionally substituted with 1, 2, 3 or 4 substituents independently selected from R¹²; wherein the 5-10 membered heteroaryl contains at least one ring-forming carbon atom and 1, 2, or 3 ring-forming heteroatoms independently selected from the group consisting of N, O and S; R¹³ is selected from the group consisting of: 1) oxo, halogen, cyano, —C(═O)R^(a3), —C(═O)OR^(a3), —C(═O)NR^(a3)R^(b3), —C(═N^(d3))NR^(a3)R^(b3)—OR^(a3), —NR^(a3)R^(b3), —NR^(a3)C(═O)R^(b3), —NR^(e3)C(═O)NR^(a3)R^(b3), —NR^(e3)C(═NR^(d3))NR^(a3)R^(b3), —NR^(a3)S(═O)₂R^(c3) and —NR^(e3)S(═O)₂NR^(a3)R^(b3); 2) C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, 6-10 membered aryl, 5-10 membered heteroaryl, C₃₋₁₀ cycloalkyl, and 3-10 membered aliphatic heterocyclyl; 3) two R¹³, together with two adjacent ring-forming atoms of the aryl or heteroaryl of Cy^(B) to which they are attached respectively, form a C₄₋₆ aliphatic cyclyl or 4-8 membered aliphatic heterocyclyl, unsubstituted or optionally substituted with 1, 2 or 3 substituents independently selected from R²³; R^(a3), R^(b3) and R^(e3) are each independently selected from the group consisting of: 1) hydrogen; 2) C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, phenyl, 5-6 membered heteroaryl, C₃₋₆ cycloalkyl and 3-6 membered aliphatic heterocyclyl, unsubstituted or optionally substituted with 1, 2 or 3 substituents independently selected from R²³; or, R^(a3) and R^(b3) together with the same N atom to which they are attached form a 3-8 membered aliphatic heterocyclyl, unsubstituted or optionally substituted with 1, 2 or 3 substituents independently selected from R²³; R^(c3) is selected from the group consisting of C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, phenyl, 5-6 membered heteroaryl, C₃₋₆ cycloalkyl and 3-6 membered aliphatic heterocyclyl, unsubstituted or optionally substituted with 1, 2 or 3 substituents independently selected from R²³; R^(d3) is selected from the group consisting of: 1) hydrogen, cyano, nitro and —S(═O)₂R^(G); 2) C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, phenyl, 5-6 membered heteroaryl, C₃₋₆ cycloalkyl and 3-6 membered aliphatic heterocyclyl, unsubstituted or optionally substituted with 1, 2 or 3 substituents independently selected from R²³; R²³ is selected from the group consisting of: 1) oxo, halogen, cyano, carboxyl, —C(═O)R^(a5), —C(═O)OR^(a)S, —C(═O)NR^(a)R^(b5), —C(═NR^(d5))NR^(a5)R^(b5), —OR^(a5), —S(═O)₂R^(c5), sulphonic acid group, —S(═O)₂NR^(a5)R^(b5), S(═O)(═NR^(d5))R⁵, —NR^(a5)R^(b5), —NR^(a5)C(═O)R^(b5), —NR^(e5)C(═O)NR^(a5)R^(b5), NR^(e5)C(═N^(d5))NR^(a5)R^(b5)—NR^(a5)S(═O)₂R^(c5), —NR^(e5)S(═O)₂NR^(a5)R^(b5) and ═N—R^(d5); 2) C₁₋₆ alkyl, C₁₋₆ alkylene, phenyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl and 3-7 membered aliphatic heterocyclyl, unsubstituted or optionally substituted with 1, 2 or 3 substituents independently selected from R³³; R^(a5), R^(b5) and R^(e5) are each independently selected from the group consisting of: 1) hydrogen; 2) C₁₋₄ alkyl, phenyl, 5-6 membered heteroaryl, C₃₋₆ cycloalkyl and 3-6 membered aliphatic heterocyclyl, unsubstituted or optionally substituted with 1, 2 or 3 substituents independently selected from R³³; or, R^(a5) and R^(b5) together with the same N atom to which they are linked form a 3-6 membered aliphatic heterocyclyl, unsubstituted or optionally substituted with 1, 2 or 3 substituents independently selected from R³³; R^(c5) is selected from the group consisting of C₁₋₄ alkyl, phenyl, 5-6 membered heteroaryl, C₃₋₆ cycloalkyl and 3-6 membered aliphatic heterocyclyl, unsubstituted or optionally substituted with 1, 2 or 3 substituents independently selected from R³³; R^(d5) is selected from the group consisting of: 1) hydrogen, cyano, nitro and —S(═O)₂R^(G); 2) C₁₋₄ alkyl, phenyl, 5-6 membered heteroaryl, C₃₋₆ cycloalkyl and 3-6 membered aliphatic heterocyclyl, unsubstituted or optionally substituted with 1, 2 or 3 substituents independently selected from R³³; R³³ is selected from the group consisting of: 1) oxo, halogen, cyano, —C(═O)R^(a7), —C(═O)OR^(a7), —C(═O)NR^(a7)R^(b7), —C(═NR^(d7))NR^(a7)R^(b7), —OR^(a7), —S(═O)₂R^(c7), —S(═O)₂NR^(a7)R^(b7), —S(═O)(═NR^(d7))R^(c7), —NR^(a7)R^(b7), —NR^(a7)C(═O)R^(b7), —N^(e7)C(═O)NR^(a7)R^(b7), —NR^(e7)C(═NR^(d7))NR^(a7)R^(b7)—NR^(a7)S(═O)₂R^(c7), —NR^(e7)S(═O)₂NR^(a7)R^(b7) and ═N—R^(d7); 2) C₁₋₄ alkyl, C₁₋₄ alkylene, phenyl, 5-6 membered heteroaryl, C₃₋₆ cycloalkyl and 3-6 membered aliphatic heterocyclyl, unsubstituted or optionally substituted with 1, 2 or 3 substituents independently selected from R^(G); R^(a7), R^(b7) and R^(e7) are each independently selected from the group consisting of: 1) hydrogen; 2) C₁₋₄ alkyl, phenyl, 5-6 membered heteroaryl, C₃₋₆ cycloalkyl and 3-6 membered aliphatic heterocyclyl, unsubstituted or optionally substituted with 1, 2 or 3 substituents independently selected from R^(G); or, R^(a7) and R^(b7) together with the same N atom to which they are attached form a 3-6 membered aliphatic heterocyclyl, unsubstituted or optionally substituted with 1, 2 or 3 substituents independently selected from R^(G); R^(c7) is selected from the group consisting of C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, phenyl, 5-6 membered heteroaryl, C₃₋₆ cycloalkyl and 3-6 membered aliphatic heterocyclyl, unsubstituted or optionally substituted with 1, 2 or 3 substituents independently selected from R^(G); R^(d7) is selected from the group consisting of: 1) hydrogen, cyano, nitro and —S(═O)₂R^(G); 2) C₁₋₄ alkyl, phenyl, 5-6 membered heteroaryl, C₃₋₆ cycloalkyl and 3-6 membered aliphatic heterocyclyl, unsubstituted or optionally substituted with 1, 2 or 3 substituents independently selected from R^(G); R^(G) is selected from the group consisting of: 1) halogen, oxo, cyano, carboxyl, hydroxyl, C₁₋₄ alkoxy, amino, C₁₋₄ alkylamino, sulfonic acid group, C₁₋₄ alkylsulfonyl and C₁₋₄ alkylaminosulfonyl; 2) C₁₋₄ alkyl, C₁₋₄ alkylene, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₃₋₆ cycloalkyl and 3-8 membered aliphatic heterocyclyl, unsubstituted or optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of oxo, halogen, hydroxyl, hydroxymethyl, carboxyl, cyano, C₁₋₃ alkoxy, amino, and C₁₋₃ alkylamino; or a pharmaceutically acceptable salt, hydrate, solvate, active metabolite, polymorph, isotope labeled compound, isomer or prodrug thereof.
 22. The compound according to claim 21, wherein, R¹ is selected from the group consisting of hydrogen, fluorine, cyano, methyl and methoxy; Cy^(A) is selected from phenyl and 5 or 6 membered heteroaryl, unsubstituted or optionally substituted with 1 or 2, or 3 substituents independently selected from R¹²; wherein 5 or 6 membered heteroaryl contains 1 or 2 heteroatom(s) independently selected from the group consisting of N and S; Cy^(B) is selected from phenyl and 5 or 6 membered heteroaryl, unsubstituted or optionally substituted with 1, 2, 3 or 4 substituents independently selected from R¹³; wherein the 5 or 6 membered heteroaryl contains 1, 2, or 3 ring-forming heteroatoms independently selected from the group consisting of N and S; R¹² is selected from the group consisting of: 1) oxo, halogen, cyano, —C(═O)R^(a2), —C(═O)NR^(a2)R^(b2), —C(═NR^(d2))NR^(a2)R^(b2), —OR^(a2)—NR^(a2)R^(b2), —NR^(a2)C(═O)R^(b2), —NR^(a2)C(═O)OR^(c2), —NR^(e2)C(═O)NR^(a2)R^(b2), —NR^(e2)C(═NR^(d2))NR^(a2)R^(b2), —NR^(a2)S(═O)₂R^(c2), and —NR^(e2)S(═O)₂NR^(a2)R^(b2); 2) C₁₋₆ alkyl, phenyl, 5-6 membered heteroaryl, C₃₋₁₀ cycloalkyl and 3-10 membered aliphatic heterocyclyl, unsubstituted or optionally substituted with 1, 2, 3 or 4 substituents independently selected from R²²; 3) two R¹², together with two adjacent ring-forming atoms of the aryl or heteroaryl of Cy^(A) to which they are connected respectively, form a C₅, C₆, C₇ aliphatic monocyclyl or 5-, 6-, 7-membered aliphatic monoheterocyclyl, unsubstituted or optionally substituted with 1, 2 or 3 substituents independently selected from R²²; R¹³ is selected from the group consisting of: 1) oxo, halogen, cyano, —C(═O)R^(a3), —C(═O)NR^(a3)R^(b3), C(═NR^(d3))NR^(a3)R^(b3), —OR^(a3)—NR^(a3)R^(b3), —NR^(a3)C(═O)R^(b3), —NR^(e3)C(═O)NR^(a3)R^(b3), —NR^(e3)C(═NR^(d3))NR^(a3)R^(b3), —NR^(a3)S(═O)₂R^(c3), and —NR^(e3)S(═O)₂NR^(a3)R^(b3); 2) C₁₋₆ alkyl, phenyl, 5-6 membered heteroaryl, C₃₋₁₀ cycloalkyl and 3-10 membered aliphatic heterocyclyl, unsubstituted or optionally substituted with 1, 2, 3 or 4 substituents independently selected from R²³; 3) two R¹³, together with two adjacent ring-forming atoms of the aryl or heteroaryl of Cy^(B) to which they are connected respectively, form a C₅, C₆, C₇ aliphatic monocyclyl or 5-, 6-, 7-membered aliphatic monoheterocyclyl, unsubstituted or optionally substituted with 1, 2 or 3 substituents independently selected from R²³; or a pharmaceutically acceptable salt, hydrate, solvate, active metabolite, polymorph, isotope labeled compound, isomer or prodrug thereof.
 23. The compound according to claim 21, wherein, R¹ is selected from the group consisting of hydrogen, fluorine, cyano, methyl and methoxy; Cy^(A) is selected from the group consisting of: 1) the following structures, wherein the “

” at the end of the chemical bond in each structure means that the structures is connected to the rest of formula (I) through the bond:

2) phenyl, pyridyl, pyrimidyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, or isoxazolyl, unsubstituted or optionally substituted with 1, 2 or 3 substituents independently selected from R¹²; wherein, (a) each R¹² is independently selected from the group consisting of fluorine and chlorine; non-hydrogen R^(G1), and OR^(G1); or, (b) Cy^(A) contains one R¹², and the R¹² is selected from one of the following structures, wherein the “

” at the end of the chemical bond in each structure means that the structure is connected to the rest of formula (I) through the bond:

Cy^(A) contains two or three R¹², wherein one of R¹² is selected from the group consisting of the above structures and the others of R¹² are each independently selected from the group consisting of fluorine, chlorine, non-hydrogen R^(G1), and —OR^(G1); wherein X is selected from the group consisting of CH and N; Y is selected from the group consisting of —CH₂—, NH and O; E₁ and E₂ are each independently selected from the group consisting of —CH₂— and carbonyl, provided that E₁ and E₂ are not carbonyl simultaneously; R^(G2) is selected from the group consisting of hydrogen, —OR^(G1) and —N(R^(G1))₂; each R^(G1) is independently selected from the group consisting of: 1) hydrogen, methyl, ethyl, isopropyl, cyclopropyl, 3-oxetanyl and 3-methyl-3-azetidinyl; 2) two R^(G1) attached to the same atom, together with said atom, form a C₃₋₆ monocyclyl or 3-6 membered aliphatic monoheterocyclyl; 3) two R^(G1) attached to two different ring-forming atoms of the same monocycle are connected to form a ring structure together with part of the ring-forming atoms of said monocycle, wherein the two connected R^(G1) form a C₂, C₃ or C₄ alkylene; Cy^(B) is phenyl, pyridyl, pyrimidyl, pyridazinyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, thienyl, optionally substituted with 1, 2 or 3 substituents independently selected from R¹³; R¹³ is selected from the group consisting of: 1) oxo, halogen, cyano, —C(═O)R^(a3), —C(═O)NR^(a3)R^(b3), C(═NR^(d3))NR^(a3)R^(b3), —OR^(a3)—NR^(a3)R^(b3), —NR^(a3)C(═O)R^(b3), —NR^(e3)C(═O)NR^(a3)R^(b3), —NR^(e3)C(═NR^(d3))NR^(a3)R^(b3), —NR^(a3)S(═O)₂R^(c3), and —NR^(e3)S(═O)₂NR^(a3)R³; 2) C₁₋₆ alkyl, phenyl, 5-6 membered heteroaryl, C₃₋₆ monocyclic cycloalkyl and 3-6 membered aliphatic monoheterocyclyl, unsubstituted or optionally substituted with 1, 2, 3 or 4 substituents independently selected from R²³; 3) two R¹³, together with two adjacent ring-forming atoms of the aryl or heteroaryl of Cy^(B) to which they are connected respectively, form a C₅, C₆, C₇ aliphatic monocyclyl or 5-, 6-, 7-membered aliphatic monocyclic heterocyclyl, unsubstituted or optionally substituted with 1, 2 or 3 substituents independently selected from R²³; or a pharmaceutically acceptable salt, hydrate, solvate, active metabolite, polymorph, isotope labeled compound, isomer or prodrug thereof.
 24. The compound according to claim 20, wherein, R¹ is selected from the group consisting of hydrogen, fluorine, cyano, methyl and methoxy; Cy^(A) is phenyl, pyridyl, pyrimidyl, pyrazolyl, imidazolyl, thiazolyl or isothiazolyl, unsubstituted or optionally substituted with 1, 2 or 3 substituents independently selected from R¹², wherein 1) each R¹² is independently selected from the group consisting of: fluorine, chlorine; non-hydrogen R^(G1), and OR^(G1); or, 2) Cy^(A) contains one R¹², and the R¹² is selected from one of the following structures:

Cy^(A) contains two or three R¹², wherein one of R¹² is selected from the group consisting of the above structures and others of R¹² are each independently selected from the group consisting of fluorine, chlorine, non-hydrogen R^(G1), and —OR^(G1); each R^(G1) is independently selected from the group consisting of: 1) hydrogen, 2) methyl, ethyl, isopropyl, cyclopropyl, 3-oxetanyl and 3-methyl-3-azetidinyl; optionally substituted with hydroxyl, C₁₋₆ alkoxy or amino; Cy^(B) is selected from one of the following structures:

R^(a3) and R^(b3) are each independently selected from the group consisting of hydrogen, C₁₋₆ alkyl and C₁₋₆ cycloalkyl, or, two R^(a3) and R^(b3) attached to two adjacent ring-forming atoms respectively, together with said two ring-forming atoms form unsubstituted 5-6 membered aliphatic cyclyl or unsubstituted 5-6 membered aliphatic heterocyclyl; or a pharmaceutically acceptable salt, hydrate, solvate, active metabolite, polymorph, isotope labeled compound, isomer or prodrug thereof.
 25. The compound according to claim 20, wherein, R¹ is selected from the group consisting of hydrogen, fluorine, cyano, methyl and methoxy; Cy^(A) is phenyl, pyridyl, pyrimidyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl or a bicyclyl represented by

where a phenyl is fused with a 5-7 membered saturated aliphatic heterocyclyl, or a bicyclyl represented by

where a pyridyl is fused with a 5-7 membered saturated aliphatic heterocyclyl; wherein Z represents 1-3 heteroatoms selected from the group consisting of nitrogen and oxygen; when Z═N, N is optionally linked to Ry; Ro is selected from the group consisting of oxo, F, amino, and optionally substituted C₁₋₃ alkyl; wherein said aliphatic heterocyclyl may be fused with another 5-6 membered nitrogen-containing saturated aliphatic heterocyclyl to form a fused ring; said phenyl, pyridyl, pyrimidyl, pyrazolyl, imidazolyl, thiazolyl, and isothiazolyl is unsubstituted or optionally substituted with 1, 2 or 3 substituents independently selected from R¹², wherein, 1) when Cy^(A) contains one R¹², the R¹² is selected from one of the followings:

wherein R^(x) is selected from the group consisting of —OH, C₁₋₆ alkyl, C₁₋₆ alkoxy, —NH₂, C₁₋₆ alkylamino,

2) when Cy^(A) contains more than one R¹², the others of R¹² are each independently selected from the group consisting of fluorine, C₁₋₆ alkyl, C₁₋₆ alkoxy, and (C₁₋₆ alkylamino)methyl; Cy^(B) is selected from one of the following structures:

R^(a3) and R^(b3) are each independently selected from the group consisting of hydrogen, C₁₋₆ alkyl and C₃₋₆ cycloalkyl, or R^(a3) and R^(b3) together with N atom to which they are attached form a 4-6 membered saturated aliphatic heterocyclyl; said C₁₋₆ alkyl, C₃₋₆ cycloalkyl, and 4-6 membered saturated aliphatic heterocyclyl is unsubstituted or optionally substituted with substituent(s) selected from the group consisting of fluorine, hydroxyl, C₁₋₆ alkyl, and fluoro-substituted C₁₋₆ alkyl; R^(y) is selected from the group consisting of H, C₁₋₆ alkyl, C₁₋₆ alkyl substituted with a substituent selected from the group consisting of hydroxyl and halogen, C₃₋₆ cycloalkyl, nitrogen-containing 4-6 membered saturated aliphatic heterocyclyl, oxygen-containing 5-6 membered saturated aliphatic heterocyclyl, and —C(═O)Rs; Rs is selected from C₁₋₆ alkyl optionally substituted with substituents selected from the group consisting of hydroxyl, amino, and nitrogen-containing aliphatic heterocyclyl; or a pharmaceutically acceptable salt, hydrate, solvate, active metabolite, polymorph, isotope labeled compound, isomer or prodrug thereof.
 26. The compound according to claim 25, wherein, Cy^(A) is phenyl, pyridyl, pyrimidyl, thiazolyl or a bicyclyl represented by

 where a phenyl is fused with a 5-7 membered saturated aliphatic heterocyclyl, or a bicyclyl represented by

 where a pyridyl is fused with a 5-7 membered saturated aliphatic heterocyclyl, wherein Z represents 1-3 heteroatoms selected from the group consisting of nitrogen and oxygen; when Z═N, N is optionally linked to Ry; Ro is selected from the group consisting of oxo, F, amino, optionally substituted C₁₋₃ alkyl; wherein said saturated aliphatic heterocyclyl may be fused with another 5-6 membered nitrogen-containing saturated aliphatic heterocyclyl form a fused ring, wherein, R^(y) is selected from the group consisting of H, C₁₋₆ alkyl, C₁₋₆ alkyl substituted with the substituent consisting of hydroxyl and halogen, C₃₋₆ cycloalkyl, 4-6 membered N-containing saturated aliphatic heterocyclyl, 5-6 membered 0-containing saturated aliphatic heterocyclyl, and —C(═O)Rs, Rs is selected from C₁₋₆ alkyl optionally substituted with the group consisting of hydroxyl, amino, and N-containing aliphatic heterocyclyl; when Cy^(A) is selected from the group consisting of phenyl, pyridyl, pyrimidyl, and thiazolyl, R¹² is selected from the group consisting of

 wherein Rz is selected from the group consisting of hydrogen, optionally substituted C₁₋₆ alkyl, 4-6 membered O-containing aliphatic heterocyclyl, and —S(═O)₂—C₁₋₆ alkyl; Rp, single or multiple substituent(s), are each optionally selected from the group consisting of hydrogen, and optionally substituted C₁₋₆ alkyl; Rq is selected from the group consisting of hydroxyl, amino, optionally substituted C₁₋₃ alkyl, spiro heterocyclyl composed of two 4-5 membered nitrogen- and/or oxygen-containing rings, and 5-6 membered aliphatic heterocyclyl containing one or two heteroatoms selected from the group consisting of nitrogen and oxygen, said aliphatic heterocyclyl is optionally substituted with F, and C₁₋₃ alkyl; or a pharmaceutically acceptable salt, hydrate, solvate, active metabolite, polymorph, isotope labeled compound, isomer or prodrug thereof.
 27. The compound according to claim 26, wherein, Cy^(A) is selected from phenyl, R¹² is selected from the group consisting of

 wherein Rz is selected from the group consisting of hydrogen, optionally substituted C₁₋₆ alkyl, 4-6 membered 0-containing aliphatic heterocyclyl, and —S(═O)₂—C₁₋₆ alkyl; Rp, single or multiple substituent(s), are each optionally selected from the group consisting of hydrogen, and optionally substituted C₁₋₆ alkyl; Rq is selected from the group consisting of hydroxyl, amino, optionally substituted C₁₋₃ alkyl, spiro heterocyclyl composed of two 4-5 membered nitrogen and/or oxygen containing rings, and 5-6 membered aliphatic heterocyclyl containing one or two heteroatoms selected from the group consisting of nitrogen and oxygen, said aliphatic heterocyclyl is optionally substituted with F, and C₁₋₃ alkyl; or a pharmaceutically acceptable salt, hydrate, solvate, active metabolite, polymorph, isotope labeled compound, isomer or prodrug thereof.
 28. The compound according to claim 27, wherein, Cy^(A) is selected from the group consisting of:

wherein, W₁ is selected from CH₂ or oxygen; R^(T) is selected from hydrogen or methyl; R^(V) is selected from fluorine or methyl, the number of R^(V) is 0, 1 or 2; or a pharmaceutically acceptable salt, hydrate, solvate, active metabolite, polymorph, isotope labeled compound, isomer or prodrug thereof.
 29. The compound according to claim 28, wherein, Cy^(B) is selected from phenyl optionally substituted with a group selected from the group consisting of H, F, —CN, optionally substituted C₁₋₃ alkyl, optionally substituted C₁₋₃ alkoxy, optionally substituted C₃₋₆ cycloalkoxy and C(═O)NR^(a3)R^(b3), wherein R^(a3) and R^(b3) are each independently selected from the group consisting of hydrogen, C₁₋₆ alkyl and optionally substituted C₃₋₆ cycloalkyl, or R^(a3) and R^(b3) together with the N atom to which they attached form an optionally substituted 4-5 membered alicyclic heterocyclyl; or a pharmaceutically acceptable salt, hydrate, solvate, active metabolite, polymorph, isotope labeled compound, isomer or prodrug thereof.
 30. The compound according to claim 29, wherein, Cy^(B) is selected from the group consisting of:


31. The compound according to claim 20, wherein, R¹ is H; Cy^(A) is selected from the group consisting of: 1) phenyl, pyridyl, and pyrimidyl, unsubstituted or optionally substituted with 1, 2 or 3 substituents independently selected from R¹²; each R¹² is independently selected from the group consisting of fluorine, chlorine, non-hydrogen R^(G1), and OR^(G1); 2) phenyl, pyridyl, and pyrimidyl, optionally substituted with 1, 2 or 3 substituents independently selected from R¹²; one of R¹² is selected from the group consisting of:

 and other R¹² are each independently selected from the group consisting of: fluorine, chlorine; non-hydrogen R^(G1), and OR^(G1); 3) the following structure:

wherein the phenyl or pyridyl is unsubstituted or optionally substituted with 1 or 2 substituents independently selected from R¹²; Cy^(B) is selected from

wherein R^(a3) is selected from the group consisting of methyl, ethyl, difluoromethyl, trifluoromethyl, isopropyl and cyclopropyl; preferably selected from methyl, or ethyl; E¹ is independently selected from the group consisting of —CH₂— and oxygen; R^(G1) is selected from the group consisting of hydrogen, oxo, methyl, ethyl, isopropyl, cyclopropyl, 3-oxetanyl and 3-methyl-3-azetidinyl; R¹³ is selected from the group consisting of hydrogen, fluorine, cyano and —C(═O)—N(R^(G3))₂; preferably selected from the group consisting of hydrogen and cyano; each R^(G3) is independently selected from the group consisting of: 1) hydrogen, methyl, ethyl, isopropyl, cyclopropyl, oxetanyl, oxacyclopentyl, azetidinyl, and azacyclopentyl; 2) two R^(G3) connected to the same atom, together with said atom, form a C₃₋₆ monocyclyl or a 3-6 membered aliphatic monoheterocyclyl; 3) two R^(G3) respectively connected to two different ring-forming atoms on the same single ring are connected to form a ring structure together with part of the ring-forming atoms of said single ring, and the two connected R^(G3) form a C₂, C₃ or C₄ alkylene, or a 2-, 3- or 4-membered oxaalkylene, or a 2-, 3- or 4-membered azaalkylene; and, when R^(G3) is not hydrogen, R^(G3) is unsubstituted or independently substituted with 1, 2 or 3 substituents optionally selected from the group consisting of oxo, fluorine, hydroxyl, methoxy, amino, methylamino, dimethylamino, methyl, ethyl, and cyano; or a pharmaceutically acceptable salt, hydrate, solvate, active metabolite, polymorph, isotope labeled compound, isomer or prodrug thereof.
 32. The compound according to claim 31, wherein, when Cy^(A) is phenyl, and R¹² is heterocyclyl, R¹² is attached to para- or meta-position of the phenyl; or a pharmaceutically acceptable salt, hydrate, solvate, active metabolite, polymorph, isotope labeled compound, isomer or prodrug thereof.
 33. The compound according to claim 20, wherein the compound is selected from: Compound Structural Formula Name of Compound Compound 1

5-(2-fluoro-6-methylphenyl)-3-(4-(4- methylpiperazin-1-yl)phenyl)-1H- pyrazolo[4,3-c]pyridazin-6(5H)-one Compound 2

5-(2-methoxy-6-methylphenyl)-3-(4-(4- methylpiperazin-1-yl)phenyl)-1H- pyrazolo[4,3-c]pyridazin-6(5H)-one Compound 3

5-(2-methoxyphenyl)-3-(4-(4-methylpiperazin- 1-yl)phenyl)-1H-pyrazolo[4,3-c]pyridazin- 6(5H)-one Compound 4

5-(2,4-dimethoxyphenyl)-3-(4-(1-methyl- 1,2,3,6-tetrahydropyridin-4-yl)phenyl)-1H- pyrazolo[4,3-c]pyridazin-6(5H)-one Compound 5

5-(2-methylphenyl)-3-(4-(4-methylpiperazin- 1-yl)phenyl)-1H-pyrazolo[4,3-c]pyridazin- 6(5H)-one Compound 6

5-(2-fluorophenyl)-3-(4-(4-methylpiperazin-1- yl)phenyl)-1H-pyrazolo[4,3-c]pyridazin- 6(5H)-one Compound 7

5-(2-chlorophenyl)-3-(4-(4-methylpiperazin-1- yl)phenyl)-1H-pyrazolo[4,3-c]pyridazin- 6(5H)-one Compound 8

5-(2-ethyl-6-fluorophenyl)-3-(4-(4- methylpiperazin-1-yl)phenyl)-1H- pyrazolo[4,3-c]pyridazin-6(5H)-one Compound 9

5-(2-fluoro-6-methoxyphenyl)-3-(4-(4- methylpiperazin-1-yl)phenyl)-1H- pyrazolo[4,3-c]pyridazin-6(5H)-one Compound 10

5-(2-fluoro-6-methoxyphenyl)-3-(6-(4- methylpiperazin-1-yl)pyrid-3-y1)-1H- pyrazolo[4,3-c]pyridazin-6(5H)-one Compound 11

5-(2-fluoro-6-methylphenyl)-3-(6-(4- methylpiperazin-1-yl)pyrid-3-yl)-1H- pyrazolo[4,3-c]pyridazin-6(5H)-one Compound 12

5-(2-fluoro-6-methylphenyl)-3-(4-(4-methyl-2- oxopiperazin-1-yl)phenyl)-1H-pyrazolo[4,3- c]pyridazin-6(5H)-one Compound 13

3-(3,5-dimethyl-4-(4-methylpiperazin-1- y1)phenyl)-5-(2-fluoro-6-methylphenyl)-1H- pyrazolo[4,3-c]pyridazin-6(5H)-one Compound 14

5-(2-fluoro-6-methylphenyl)-3-(3-methoxy-4- (4-methylpiperazin-1-yl)phenyl)-1H- pyrazolo[4,3-c]pyridazin-6(5H)-one Compound 15

5-(2-fluoro-6-methylphenyl)-3-(4-((4-methyl- 2-oxo-piperazin-1-yl)methyl)phenyl)-1H- pyrazolo[4,3-c]pyridazin-6(5H)-one Compound 16

5-(2-fluoro-6-methylphenyl)-3-(2-methoxy-4- (4-methylpiperazin-1-yl)phenyl)-1H- pyrazolo[4,3-c]pyridazin-6(5H)-one Compound 17

5-(2-fluoro-6-methylphenyl)-3-(1-methyl-1H- pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridazin- 6(5H)-one Compound 18

5-(2-fluoro-6-methylphenyl)-3-(1-methyl-1H- pyrazol-3-yl)-1H-pyrazolo[4,3-c]pyridazin- 6(5H)-one Compound 19

5-(2-fluoro-6-methylphenyl)-3-(1-(1- methylpiperidin-4-yl)-1H-pyrazol-4-yl)-1H- pyrazolo[4,3-c]pyridazin-6(5H)-one Compound 20

5-(2-fluoro-6-methoxyphenyl)-3-(1-(1- methylpiperidin-4-yl)-1H-pyrazol-4-y1)-1H- pyrazolo[4,3-c]pyridazin-6(5H)-one Compound 21

5-(2-fluoro-6-methoxyphenyl)-3-(1-methyl- 1H-pyrazol-4-yl)-1H-pyrazolo[4,3- c]pyridazin-6(5H)-one Compound 22

5-(2-fluoro-6-methoxyphenyl)-3-(1-methyl- 1H-pyrazol-3-yl)-1H-pyrazolo[4,3- c]pyridazin-6(5H)-one Compound 23

5-(2-fluoro-6-methoxyphenyl)-3-(4-(1-methyl- 1,2,3,6-tetrahydropyridin-4-yl)phenyl)-1H- pyrazolo[4,3-c]pyridazin-6(5H)-one Compound 24

5-(2-fluoro-6-methoxyphenyl)-3-(4-(1- methylpiperidin-4-yl)phenyl)-1H- pyrazolo[4,3-c]pyridazin-6(5H)-one Compound 25

5-(2,4-dimethoxyphenyl)-3-(4-(4- methylpiperazin-1-yl)phenyl)-1H- pyrazolo[4,3-c]pyridazin-6(5H)-one Compound 26

5-(2,4-dimethoxyphenyl)-3-(4-(1- methylpiperidin-4-yl)phenyl)-1H- pyrazolo[4,3-c]pyridazin-6(5H)-one Compound 27

5-(2-fluoro-6-methoxyphenyl)-3-(6- morpholinopyrid-3-yl)-1H-pyrazolo[4,3- c]pyridazin-6(5H)-one Compound 28

5-(2-fluoro-6-methoxyphenyl)-3-(2-(4- methylpiperazin-1-yl)pyrimidin-5-yl)-1H- pyrazolo[4,3-c]pyridazin-6(5H)-one Compound 29

5-(2-fluoro-6-isopropylphenyl)-3-(4-(4- methylpiperazin-1-yl)phenyl)-1H- pyrazolo[4,3-c]pyridazin-6(5H)-one Compound 30

3-(4-(4-methylpiperazin-1-yl)phenyl)-5- phenyl-1H-pyrazolo[4,3-c]pyridazin-6(5H)- one Compound 31

5-(2-fluoro-6-methylpheny])-3-(2-(4- methylpiperazin-1-yl)pyrimidin-5-yl)-1H- pyrazolo[4,3-c]pyridazin-6(5H)-one Compound 32

5-(2-fluoro-6-methylphenyl)-3-(2-morpholinyl pyrimidin-5-yl)-1H-pyrazolo[4,3-c]pyridazin- 6(5H)-one Compound 33

5-(2-fluoro-6-methoxyphenyl)-3-(4-(4-methyl- 3-oxopiperazin-1-yl)phenyl)-1H-pyrazolo[4,3- c]pyridazin-6(5H)-one Compound 34

5-(2-cyclopropyl-6-fluorophenyl)-3-(4-(4- methylpiperazin-1-yl)phenyl)-1H- pyrazolo[4,3-c]pyridazin-6(5H)-one Compound 35

5-(2-fluoro-6-(trifluoromethyl)phenyl)-3-(4- (4-methylpiperazin-1-yl)phenyl)-1H- pyrazolo[4,3-c]pyridazin-6(5H)-one Compound 36

5-(2-cyclopropoxy-6-fluorophenyl)-3-(4-(4- methylpiperazin-1-yl)phenyl)-1H- pyrazolo[4,3-c]pyridazin-6(5H)-one Compound 37

5-(2-(difluoromethoxy)-6-fluorophenyl)-3-(4- (4-methylpiperazin-1-yl)phenyl)-1H- pyrazolo[4,3-c]pyridazin-6(5H)-one Compound 38

5-(5-fluoro-2,3-dihydro-1H-indan-4-yl)-3-(4- (4-methylpiperazin-1-yl)phenyl)-1H- pyrazolo[4,3-c]pyridazin-6(5H)-one Compound 39

5-(6-fluoro-2,3-dihydrobenzofuran-7-yl)-3-(4- (4-methylpiperazin-1-yl)phenyl)-1H- pyrazolo[4,3-c]pyridazin-6(5H)-one Compound 40

5-(5-fluoro-2-methylisoindolin-4-yl)-3-(4-(4- methylpiperazin-1-yl)phenyl)-1H- pyrazolo[4,3-c]pyridazin-6(5H)-one Compound 41

5-(5-fluoro-2-(2-morpholinoacetyl)isoindolin- 4-yl)-3-(4-(4-methylpiperazin-1-yl)phenyl)- 1H-pyrazolo[4,3-c]pyridazin-6(5H)-one Compound 42

3-fluoro-5-methyl-4-(3-(4-(4-methylpiperazin- 1-yl)phenyl)-6-oxo-1H-pyrazolo[4,3- c]pyridazin-5(6H)-yl)benzonitrile Compound 43

5-(2-fluoro-6-methyl-4- ((methylamino)methyl)phenyl)-3-(4-(4- methylpiperazin-1-yl)phenyl)-1H- pyrazolo[4,3-c]pyridazin-6(5H)-one Compound 44

3-fluoro-N,5-dimethyl-4-(3-(4-(4- methylpiperazin-1-yl)phenyl)-6-oxo-1H- pyrazolo[4,3-c]pyridazin-5(6H)-yl)benzamide Compound 45

5-(2-fluoro-4-(3-hydroxyl-3-methylazetidine- 1-carbonyl)-6-methylphenyl)-3-(4-(4- methylpiperazin-1-yl)phenyl)-1H- pyrazolo[4,3-c]pyridazin-6(5H)-one Compound 46

N-(2-(dimethylamino)ethyl)-3-fluoro-5- methyl-4-(3-(4-(4-methylpiperazin-1- yl)phenyl)-6-oxo-1H-pyrazolo[4,3- c]pyridazin-5(6H)-yl)benzamide Compound 47

3-(4-(4-methylpiperazin-1-yl)phenyl)-5-(4- methylpyrid-3-yl)-1H-pyrazolo[4,3- c]pyridazin-6(5H)-one Compound 48

5-(4-methoxypyrid-3-yl)-3-(4-(4- methylpiperazin-1-yl)phenyl)-1H- pyrazolo[4,3-c]pyridazin-6(5H)-one Compound 49

5-(5-amino-4-methylpyrid-3-yl)-3-(4-(4- methylpiperazin-1-yl)phenyl)-1H- pyrazolo[4,3-c]pyridazin-6(5H)-one Compound 50

5-(8-methyl-2,3-dihydro-1H-pyrido[2,3- b][1,4]oxazin-7-yl)-3-(4-(4-methylpiperazin-1- yl)phenyl)-1H-pyrazolo[4,3-c]pyridazin- 6(5H)-one Compound 51

3-(4-(4-methylpiperazin-1-yl)phenyl)-5-(4- methylpyrimidin-5-yl)-1H-pyrazolo[4,3- c]pyridazin-6(5H)-one Compound 52

5-(7-methyl-3H-imidazolo[4,5-b]pyrid-6-yl)- 3-(4-(4-methylpiperazin-1-yl)phenyl)-1H- pyrazolo[4,3-c]pyridazin-6(5H)-one Compound 53

5-(5-isopropyl-1H-pyrazol-4-yl)-3-(4-(4- methylpiperazin-1-yl)phenyl)-1H- pyrazolo[4,3-c]pyridazin-6(5H)-one Compound 54

5-(5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3- y1)-3-(4-(4-methylpiperazin-1-yl)phenyl)-1H- pyrazolo[4,3-c]pyridazin-6(5H)-one Compound 55

5-(2-fluoro-6-methylphenyl)-7-methyl-3-(4-(4- methylpiperazin-1-yl)phenyl)-1H- pyrazolo[4,3-c]pyridazin-6(5H)-one Compound 56

5-(2-fluoro-6-methylphenyl)-7-methoxy-3-(4- (4-methylpiperazin-1-yl)phenyl)-1H- pyrazolo[4,3-c]pyridazin-6(5H)-one Compound 57

5-(2-fluoro-6-methylphenyl)-3-(4-(4- methylpiperazin-1-yl)phenyl)-6-oxo-5,6- dihydro-1H-pyrazolo[4,3-c]pyridazin-7- carbonitrile Compound 58

3-(4-(4-cyclopropylpiperazin-1-yl)phenyl)-5- (2-fluoro-6-methylphenyl)-1H-pyrazolo[4,3- c]pyridazin-6(5H)-one Compound 59

5-(2-fluoro-6-methylphenyl)-3-(4-(4-(oxetan- 3-yl)piperazin-1-yl)phenyl)-1H-pyrazolo[4,3- c]pyridazin-6(5H)-one Compound 60

5-(2-fluoro-6-methylphenyl)-3-(4-(4- oxohexahydropyrrolo[1,2-a]pyrazin-2(1H)- yl)phenyl)-1H-pyrazolo[4,3-c]pyridazin- 6(5H)-one Compound 61

5-(2-fluoro-6-methylphenyl)-3-(4-(8-methyl- 3,8-diazabicyclo[3.2.1]octan-3-yl)phenyl)-1H- pyrazolo[4,3-c]pyridazin-6(5H)-one Compound 62

3-(4-(4-(2-oxa-6-azaspiro[3.3]heptan-6- yl)piperidin-1-yl)phenyl)-5-(2-fluoro-6- methylphenyl)-1H-pyrazolo[4,3-c]pyridazin- 6(5H)-one Compound 63

3-(4-(4-(ethylsulfonyl)piperazin-1-yl)phenyl)- 5-(2-fluoro-6-methylphenyl)-1H-pyrazolo[4,3- c]pyridazin-6(5H)-one Compound 64

5-(2-fluoro-6-methylphenyl)-3-(4-(2- (hydroxymethyl)morpholino)phenyl)-1H- pyrazolo[4,3-c]pyridazin-6(5H)-one Compound 65

3-(4-(1-(2-(dimethylamino)ethyl)-1H-pyrazol- 4-yl)phenyl)-5-(2-fluoro-6-methoxyphenyl)- 1H-pyrazolo[4,3-c]pyridazin-6(5H)-one Compound 66

5-(2-fluoro-6-methoxyphenyl)-3-(2-(4- methylpiperazin-1-yl)thiazol-5-yl)-1H- pyrazolo[4,3-c]pyridazin-6(5H)-one Compound 67

2-(4-(5-(2-fluoro-6-methoxyphenyl)-6-oxo- 5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3- yl)-1H-pyrazol-1-yl)propionitrile Compound 68

2-(5-(2-fluoro-6-methoxyphenyl)-6-oxo-5,6- dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl)-6- methyl-5,6-dihydro-4H-pyrazolo[1,5- d][1,4]diazepin-7(8H)-one Compound 69

3-(1-(2-hydroxyl-2-methylpropyl)-1H-pyrazol- 4-yl)-5-(4-methylpyrid-3-yl)-1H-pyrazolo[4,3- c]pyridazin-6(5H)-one Compound 70

4-(4-(5-(2-fluoro-6-methylphenyl)-6-oxo-5,6- dihydro-1H-pyrazolo[4,3-c]pyridazin-3- yl)phenyl)piperazinyl-1-carbonamide Compound 71

N-(4-(5-(2-fluoro-6-methylphenyl)-6-oxo-5,6- dihydro-1H-pyrazolo[4,3-c]pyridazin-3- yl)phenyl)-N-methyl-2-(4-methylpiperazin-1- yl)acetamide Compound 72

5-(2-fluoro-6-methoxyphenyl)-3-(2-methyl- 1,2,3,4-tetrahydroisoquinolin-6-yl)-1H- pyrazolo[4,3-c]pyridazin-6(5H)-one Compound 73

5-(2-fluoro-6-methoxyphenyl)-3-(2-methyl- 1,2,3,4-tetrahydroisoquinolin-7-yl)-1H- pyrazolo[4,3-c]pyridazin-6(5H)-one Compound 74

3-fluoro-5-methoxy-4-(3-(4-(4- methylpiperazin-1-yl)phenyl)-6-oxo-1H- pyrazolo[4,3-c]pyridazin-5(6H)-yl)benzonitrile Compound 75

5-(1,3-dihydroisobenzofuran-4-yl)-3-(4-(4- methylpiperazin-1-yl)phenyl)-1H- pyrazolo[4,3-c]pyridazin-6(5H)-one Compound 76

5-(benzo[d][1,3]dioxacyclopent-4-yl)-3-(4-(4- methylpiperazin-1-yl)phenyl)-1H- pyrazolo[4,3-c]pyridazin-6(5H)-one Compound 77

5-(2,4-difluoro-6-methoxyphenyl)-3-(4-(4- methylpiperazin-1-yl)phenyl)-1H- pyrazolo[4,3-c]pyridazin-6(5H)-one Compound 78

5-(4-chloro-2-fluoro-6-methylphenyl)-3-(4-(4- methylpiperazin-1-yl)phenyl)-1H- pyrazolo[4,3-c]pyridazin-6(5H)-one Compound 79

3-fluoro-5-methoxy-N-methyl-4-(3-(4-(4- methylpiperazin-1-yl)phenyl)-6-oxo-1H- pyrazolo[4,3-c]pyridazin-5(6H)-yl)benzamide Compound 80

3-fluoro-5-methoxy-N,N-dimethyl-4-(3-(4-(4- methylpiperazin-1-yl)phenyl)-6-oxo-1H- pyrazolo[4,3-c]pyridazin-5(6H)-yl)benzamide Compound 81

5-(2-fluoro-6-methylphenyl)-3-(4-(4-(methyl- d₃)piperazin-1-yl)phenyl)-1H-pyrazolo[4,3- c]pyridazin-6(5H)-one Compound 82

(S)-4-(3-(4-(4-(2-aminopropionyl)piperazin-1- yl)phenyl)-6-oxo-1H-pyrazolo[4,3- c]pyridazin-5(6H)-yl)-3-fluoro-5- methylbenzonitrile hydrochloride Compound 83

4-(3-(4-(4-(2-hydroxylpropionyl)piperazin-1- yl)phenyl)-6-oxo-1H-pyrazolo[4,3- c]pyridazin-5(6H)-y1)-3-fluoro-5- methylbenzonitrile Compound 84

3-(4-(4-(2,2-difluoroethyl)piperazin-1- yl)phenyl)-5-(2-fluoro-6-methylphenyl)-1H- pyrazolo[4,3-c]pyridazin-6(5H)-one Compound 85

3-fluoro-5-methyl-4-(6-oxo-3-(4-(4- (tetrahydrofuran-3-yl)piperazin-1-yl)phenyl)- 1H-pyrazolo[4,3-c]pyridazin-5(6H)- yl)benzonitrile Compound 86

3-fluoro-5-methoxy-4-(3-(4-(4-(oxetan-3- yl)piperazin-1-yl)phenyl)-6-oxo-1H- pyrazolo[4,3-c]pyridazin-5(6H)-yl)benzonitrile Compound 87

5-(2-fluoro-6-methylphenyl)-3-(4-((1S,4S)-5- methyl-2,5-diazabicyclo[2.2.1]heptan-2- yl)phenyl)-1H-pyrazolo[4,3-c]pyridazin- 6(5H)-one Compound 88

5-(2-fluoro-6-methylphenyl)-3-(4-((1R,4R)-5- methyl-2,5-diazabicyclo[2.2.1]heptan-2- yl)phenyl)-1H-pyrazolo[4,3-c]pyridazin- 6(5H)-one Compound 89

5-(2-fluoro-6-methylphenyl)-3-(4-(3,3,4- trimethylpiperazin-1-yl)phenyl)-1H- pyrazolo[4,3-c]pyridazin-6(5H)-one Compound 90

5-(2-fluoro-6-methylphenyl)-3-(4-((3S,5R)- 3,4,5-trimethylpiperazin-1-yl)phenyl)-1H- pyrazolo[4,3-c]pyridazin-6(5H)-one Compound 91

5-(2-fluoro-6-methylphenyl)-3-(4-(6-methyl- 3,6-diazabicyclo[3.1.1]heptan-3-yl)phenyl)- 1H-pyrazolo[4,3-c]pyridazin-6(5H)-one Compound 92

5-(2-fluoro-6-methoxyphenyl)-3-(4- morpholinophenyl)-1H-pyrazolo[4,3- c]pyridazin-6(5H)-one Compound 93

5-(2-fluoro-6-methylphenyl)-3-(4-(piperazin- 2-ylmethoxy)phenyl)-1H-pyrazolo[4,3- c]pyridazin-6(5H)-one Compound 94

3-(3-fluoro-4-(4-methylpiperazin-1- y1)phenyl)-5-(2-fluoro-6-methylphenyl)-1H- pyrazolo[4,3-c]pyridazin-6(5H)-one Compound 95

3-(3-((dimethylamino)methyl)-4-(4- methylpiperazin-1-yl)phenyl)-5-(2-fluoro-6- methylphenyl)-1H-pyrazolo[4,3-c]pyridazin- 6(5H)-one Compound 96

3-(3-((methylamino)methyl)-4-(4- methylpiperazin-1-yl)phenyl)-5-(2-fluoro-6- methylphenyl)-1H-pyrazolo[4,3-c]pyridazin- 6(5H)-one Compound 97

5-(2-methoxy-6-methylphenyl)-3-(6-(4- methylpiperazin-1-yl)pyrid-3-yl)-1H- pyrazolo[4,3-c]pyridazin-6(5H)-one Compound 98

5-(2-ethyl-6-fluorophenyl)-3-(6-(4- methylpiperazin-1-yl)pyrid-3-yl)-1H- pyrazolo[4,3-c]pyridazin-6(5H)-one Compound 99

3-fluoro-5-methyl-4-(3-(6-(4-methylpiperazin- 1-yl)pyrid-3-yl)-6-oxo-1H-pyrazolo[4,3- c]pyridazin-5(6H)-yl)benzonitrile Compound 100

5-(2-fluoro-6-hydroxylphenyl)-3-(6-(4- methylpiperazin-1-yl)pyrid-3-yl)-1H- pyrazolo[4,3-c]pyridazin-6(5H)-one hydrobromide Compound 101

3-(6-(4-ethylpiperazin-1-yl)pyrid-3-yl)-5-(2- fluoro-6-methylphenyl)-1H-pyrazolo[4,3- c]pyridazin-6(5H)-one Compound 102

3-(6-(4-acetylpiperazin-1-yl)pyrid-3-yl)-5-(2- fluoro-6-methylphenyl)-1H-pyrazolo[4,3- c]pyridazin-6(5H)-one Compound 103

5-(2-fluoro-6-methylphenyl)-3-(6-(4-(oxetan- 3-yl))piperazin-1-yl)pyrid-3-yl)-1H- pyrazolo[4,3-c]pyridazin-6(5H)-one Compound 104

3-(6-(1,1-dioxidothiomorpholino)pyrid-3-yl)- 5-(2-fluoro-6-methylphenyl)-1H-pyrazolo[4,3- c]pyridazin-6(5H)-one Compound 105

3-(6-(4-(ethylsulfonyl)piperazin-1-yl)pyrid-3- y1)-5-(2-fluoro-6-methylphenyl)-1H- pyrazolo[4,3-c]pyridazin-6(5H)-one Compound 106

5-(2-fluoro-6-methylphenyl)-3-(6-(4- (tetrahydrofuran-3-yl)piperazin-1-yl)pyrid-3- yl)-1H-pyrazolo[4,3-c]pyridazin-6(5H)-one Compound 107

5-(2-chloro-6-fluorophenyl)-3-(6-(4- methylpiperazin-1-yl)pyrid-3-y1)-1H- pyrazolo[4,3-c]pyridazin-6(5H)-one Compound 108

5-(4-chloro-2-fluoro-6-methylphenyl)-3-(4-(4- methylpiperazin-1-yl)pyrid-3-y1)-1H- pyrazolo[4,3-c]pyridazin-6(5H)-one Compound 109

5-(2-fluoro-6-methylphenyl)-3-(6-(8-methyl- 3,8-diazabicyclo[3.2.1]octan-3-yl)pyrid-3-yl)- 1H-pyrazolo[4,3-c]pyridazin-6(5H)-one Compound 110

5-(2-ethyl-6-fluorophenyl)-3-(2-(4- methylpiperazin-1-yl)pyrimidin-5-yl)-1H- pyrazolo[4,3-c]pyridazin-6(5H)-one Compound 111

5-(2-fluoro-6-methoxyphenyl)-3-(2- morpholinyl-pyrimidin-5-yl)-1H-pyrazolo[4,3- c]pyridazin-6(5H)-one Compound 112

5-(2-ethyl-6-fluorophenyl)-3-(4-(4-(2- hydroxyethyl)piperazin-1-yl)phenyl)-1H- pyrazolo[4,3-c]pyridazin-6(5H)-one Compound 113

5-(2-fluoro-6-methoxyphenyl)-3-(4-(4-(2- hydroxyethyl)piperazin-1-yl)phenyl)-1H- pyrazolo[4,3-c]pyridazin-6(5H)-one Compound 114

3-fluoro-4-(3-(4-(4-(2-hydroxyethyl)piperazin- 1-yl)phenyl)-6-oxo-1H-pyrazolo[4,3- c]pyridazin-5(6H)-yl)-5-methoxybenzonitrile Compound 115

5-(2-fluoro-6-methoxyphenyl)-3-(4-(4-(2- hydroxyl-2-methylpropyl)piperazin-1- yl)phenyl)-1H-pyrazolo[4,3-c]pyridazin- 6(5H)-one Compound 116

5-(2-ethyl-6-fluorophenyl)-3-(4-(4-(2- hydroxyl-2-methylpropyl)piperazin-1- yl)phenyl)-1H-pyrazolo[4,3-c]pyridazin- 6(5H)-one Compound 117

5-(2-fluoro-6-methylphenyl)-3-(4-(8-(2- hydroxyethyl)-3,8-diazabicyclo[3.2.1]octan-3- yl)phenyl)-1H-pyrazolo[4,3-c]pyridazin- 6(5H)-one Compound 118

5-(2-fluoro-6-methylphenyl)-3-(6-(4-(2- hydroxyethyl)piperazin-1-yl)pyrid-3-yl)-1H- pyrazolo[4,3-c]pyridazin-6(5H)-one Compound 119

5-(2-fluoro-6-methylphenyl)-3-(6-(4-(2- methoxyethyl)piperazin-1-yl)pyrid-3-yl)-1H- pyrazolo[4,3-c]pyridazin-6(5H)-one Compound 120

5-(2-fluoro-6-methylphenyl)-3-(4-(3- (hydroxymethyl)-4-methylpiperazin-1- yl)phenyl)-1H-pyrazolo[4,3-c]pyridazin- 6(5H)-one Compound 121

5-(2-fluoro-6-methoxyphenyl)-3-(4-(3- (hydroxymethyl)-4-methylpiperazin-1- yl)phenyl)-1H-pyrazolo[4,3-c]pyridazin- 6(5H)-one Compound 122

7-(4-(5-(2-fluoro-6-methylphenyl)-6-oxo-5,6- dihydro-1H-pyrazolo[4,3-c]pyridazin-3- yl)phenyl)tetrahydro-1H-oxazolo[3,4- a]pyrazin-3(5H)-one Compound 123

7-(4-(5-(2-fluoro-6-methoxyphenyl)-6-oxo- 5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3- yl)phenyl)tetrahydro-1H-oxazolo[3,4- a]pyrazin-3(5H)-one Compound 124

3-fluoro-5-methoxy-4-(6-oxo-3-(4-(3- oxotetrahydro-1H-oxazolo[3,4-a]pyrazin- 7(3H)-yl)phenyl)-1H-pyrazolo[4,3- c]pyridazin-5(6H)-yl)benzonitrile Compound 125

5-(2-fluoro-6-methylphenyl)-3-(4-(3-(2- hydroxylprop-2-yl)-4-methylpiperazin-1- yl)phenyl)-1H-pyrazolo[4,3-c]pyridazin- 6(5H)-one Compound 126

5-(2-fluoro-6-methoxyphenyl)-3-(4-(3-(2- hydroxylprop-2-yl)-4-methylpiperazin-1- y1)phenyl)-1H-pyrazolo[4,3-c]pyridazin- 6(5H)-one Compound 127

5-(2-fluoro-6-methoxyphenyl)-3-(4-(3-(2- methoxyprop-2-yl)-4-methylpiperazin-1- yl)phenyl)-1H-pyrazolo[4,3-c]pyridazin- 6(5H)-one Compound 128

5-(2-fluoro-6-methylphenyl)-3-(6-(3- (hydroxymethyl)-4-methylpiperazin-1- yl)pyrid-3-yl)-1H-pyrazolo[4,3-c]pyridazin- 6(5H)-one Compound 129

7-(5-(5-(2-fluoro-6-methylphenyl)-6-oxo-5,6- dihydro-1H-pyrazolo[4,3-c]pyridazin-3- yl)pyridin-2-yl)tetrahydro-1H-oxazolo[3,4- a]pyrazin-3(5H)-one Compound 130

5-(2-fluoro-6-methylphenyl)-3-(4-(2- (hydroxymethyl)-4-methylpiperazin-1- yl)phenyl)-1H-pyrazolo[4,3-c]pyridazin- 6(5H)-one Compound 131

4-(4-(5-(2-fluoro-6-methylphenyl)-6-oxo-5,6- dihydro-1H-pyrazolo[4,3-c]pyridazin-3- yl)phenyl)-1-methylpiperazin-2-carboxylic acid Compound 132

8-(4-(5-(2-fluoro-6-methoxyphenyl)-6-oxo- 5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3- yl)phenyl)-2-methylhexahydro-1H- pyrazino[1,2-a]pyrazin-4(6H)-one Compound 133

(S)-5-(2-fluoro-6-methylphenyl)-3-(4- (hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)- yl)phenyl)-1H-pyrazolo[4,3-c]pyridazin- 6(5H)-one Compound 134

(R)-5-(2-fluoro-6-methylphenyl)-3-(4- (hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)- yl)phenyl)-1H-pyrazolo[4,3-c]pyridazin- 6(5H)-one Compound 135

(S)-5-(2-fluoro-6-methoxyphenyl)-3-(4- (hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)- yl)phenyl)-1H-pyrazolo[4,3-c]pyridazin- 6(5H)-one Compound 136

(R)-5-(2-fluoro-6-methoxyphenyl)-3-(4- (hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)- yl)phenyl)-1H-pyrazolo[4,3-c]pyridazin- 6(5H)-one Compound 137

3-(4-(5,6-dihydroimidazolo[1,2-a]pyrazin- 7(8H)-yl)phenyl)-5-(2-fluoro-6- methylphenyl)-1H-pyrazolo[4,3-c]pyridazin- 6(5H)-one Compound 138

5-(2-fluoro-6-methylphenyl)-3-(4-(4- hydroxylpiperidin-1-yl)phenyl)-1H- pyrazolo[4,3-c]pyridazin-6(5H)-one Compound 139

5-(2-fluoro-6-methoxyphenyl)-3-(4-(4- hydroxylpiperidin-1-yl)phenyl)-1H- pyrazolo[4,3-c]pyridazin-6(5H)-one Compound 140

5-(2-fluoro-6-methoxyphenyl)-3-(4-(4- hydroxyl-4-methylpiperidin-1-yl)phenyl)-1H- pyrazolo[4,3-c]pyridazin-6(5H)-one Compound 141

5-(2-fluoro-6-methoxyphenyl)-3-(4-(4- methoxy-4-methylpiperidin-1-yl)phenyl)-1H- pyrazolo[4,3-c]pyridazin-6(5H)-one Compound 142

5-(2-fluoro-6-methylphenyl)-3-(4-(4- morpholinopiperidin-1-yl)phenyl)-1H- pyrazolo[4,3-c]pyridazin-6(5H)-one Compound 143

5-(2-fluoro-6-methylphenyl)-3-(4-(4-(4- methylpiperazin-1-yl)piperidin-1-yl)phenyl)- 1H-pyrazolo[4,3-c]pyridazin-6(5H)-one Compound 144

5-(2-fluoro-6-methoxyphenyl)-3-(4-(4- morpholinopiperidin-1-yl)phenyl)-1H- pyrazolo[4,3-c]pyridazin-6(5H)-one Compound 145

5-(2-fluoro-6-methoxyphenyl)-3-(4-(4-(4- methylpiperazin-1-yl)piperidin-1-yl)phenyl)- 1H-pyrazolo[4,3-c]pyridazin-6(5H)-one Compound 146

3-(4-(4-amino-4-methylpiperidin-1-yl)phenyl)- 5-(2-fluoro-6-methoxyphenyl)-1H- pyrazolo[4,3-c]pyridazin-6(5H)-one Compound 147

3-(4-(4-(dimethylamino)-4-methylpiperidin-1- yl)phenyl)-5-(2-fluoro-6-methoxyphenyl)-1H- pyrazolo[4,3-c]pyridazin-6(5H)-one Compound 148

5-(2-fluoro-6-methoxyphenyl)-3-(2- morpholinothiazol-5-y1)-1H-pyrazolo[4,3- c]pyridazin-6(5H)-one Compound 149

5-(6-methoxy-4-methylpyrid-3-yl)-3-(4-(4- methylpiperazin-1-yl)phenyl)-1H- pyrazolo[4,3-c]pyridazin-6(5H)-one Compound 150

3-(4-(1-methyl-1,2,3,6-tetrahydropyridin-4- yl)phenyl)-5-(4-methylpyrid-3-yl)-1H- pyrazolo[4,3-c]pyridazin-6(5H)-one Compound 151

5-(4-methoxypyrid-3-yl)-3-(4-(1-methyl- 1,2,3,6-tetrahydropyridin-4-yl)phenyl)-1H- pyrazolo[4,3-c]pyridazin-6(5H)-one Compound 152

5-(4-methoxypyrid-3-yl)-3-(4-(1-methyl-1H- pyrazol-4-yl)phenyl)-1H-pyrazolo[4,3- c]pyridazin-6(5H)-one Compound 153

5-(3-methoxypyrid-4-yl)-3-(4-(4- methylpiperazin-1-yl)phenyl)-1H- pyrazolo[4,3-c]pyridazin-6(5H)-one Compound 154

5-(2-fluoro-6-methoxyphenyl)-7-methyl-3-(4- (4-methylpiperazin-1-yl)phenyl)-1H- pyrazolo[4,3-c]pyridazin-6(5H)-one Compound 155

5-(2-fluoro-6-methoxyphenyl)-7-methyl-3-(4- morpholinophenyl)-1H-pyrazolo[4,3- c]pyridazin-6(5H)-one Compound 156

5-(2-fluoro-6-methylphenyl)-3-(2-methyl- 1,2,3,4-tetrahydroisoquinolin-7-yl)-1H- pyrazolo[4,3-c]pyridazin-6(5H)-one Compound 157

5-(2-fluoro-6-methylphenyl)-3-(2-(methyl-d₃)- 1,2,3,4-tetrahydroisoquinolin-7-yl)-1H- pyrazolo[4,3-c]pyridazin-6(5H)-one Compound 158

5-(2,4-difluoro-6-methoxyphenyl)-3-(2- methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)- 1H-pyrazolo[4,3-c]pyridazin-6(5H)-one Compound 159

3-fluoro-5-methoxy-4-(3-(2-methyl-1,2,3,4- tetrahydroisoquinolin-7-yl)-6-oxo-1H- pyrazolo[4,3-c]pyridazin-5(6H)-yl)benzonitrile Compound 160

5-(2-ethyl-6-fluorophenyl)-3-(2-methyl- 1,2,3,4-tetrahydroisoquinolin-7-yl)-1H- pyrazolo[4,3-c]pyridazin-6(5H)-one Compound 161

5-(2-fluoro-6-methylphenyl)-3-(1,2,3,4- tetrahydroisoquinolin-7-yl)-1H-pyrazolo[4,3- c]pyridazin-6(5H)-one hydrochloride Compound 162

5-(2-fluoro-6-methylphenyl)-3-(2-(2- hydroxyethyl)-1,2,3,4-tetrahydroisoquinolin-7- yl)-1H-pyrazolo[4,3-c]pyridazin-6(5H)-one Compound 163

3-(2-(3-aminocyclobutyl)-1,2,3,4- tetrahydroisoquinolin-7-yl)-5-(2-fluoro-6- methylpheny1)-1H-pyrazolo[4,3-c]pyridazin- 6(5H)-one hydrochloride Compound 164

3-(2-(azetidin-3-yl)-1,2,3,4- tetrahydroisoquinolin-7-yl)-5-(2-fluoro-6- methylphenyl)-1H-pyrazolo[4,3-c]pyridazin- 6(5H)-one hydrochloride Compound 165

5-(2-fluoro-6-methylphenyl)-3-(2-(1- hydroxylprop-2-yl)-1,2,3,4- tetrahydroisoquinolin-7-yl)-1H-pyrazolo[4,3- c]pyridazin-6(5H)-one Compound 166

3-(2-(2,2-difluoroethyl)-1,2,3,4- tetrahydroisoquinolin-7-yl)-5-(2-fluoro-6- methoxyphenyl)-1H-pyrazolo[4,3-c]pyridazin- 6(5H)-one Compound 167

5-(2-fluoro-6-methylphenyl)-3-(2-(tetrahydro- 2H-pyran-4-yl)-1,2,3,4-tetrahydroisoquinolin- 7-yl)-1H-pyrazolo[4,3-c]pyridazin-6(5H)-one Compound 168

5-(2-fluoro-6-methylphenyl)-3-(2-(1- methylpiperidin-4-yl)-1,2,3,4- tetrahydroisoquinolin-7-yl)-1H-pyrazolo[4,3- c]pyridazin-6(5H)-one Compound 169

5-(2-fluoro-6-methylphenyl)-3-(2-(2- morpholinoacetyl)-1,2,3,4- tetrahydroisoquinolin-7-yl)-1H-pyrazolo[4,3- c]pyridazin-6(5H)-one Compound 170

3-fluoro-5-methyl-4-(3-(2-methyl-1,2,3,4- tetrahydroisoquinolin-7-yl)-6-oxo-1H- pyrazolo[4,3-c]pyridazin-5(6H)-yl)benzonitrile Compound 171

3-fluoro-5-methyl-4-(3-(1,2,3,4- tetrahydroisoquinolin-7-yl)-6-oxo-1H- pyrazolo[4,3-c]pyridazin-5(6H)-yl)benzonitrile Compound 172

3-fluoro-4-(3-(2-(2-hydroxylacetyl)-1,2,3,4- tetrahydroisoquinolin-7-yl)-6-oxo-1H- pyrazolo[4,3-c]pyridazin-5(6H)-yl)-5- methylbenzonitrile Compound 173

3-fluoro-4-(3-(2-(2-hydroxylpropionyl)- 1,2,3,4-tetrahydroisoquinolin-7-yl)-6-oxo-1H- pyrazolo[4,3-c]pyridazin-5(6H)-yl)-5- methylbenzonitrile Compound 174

3-fluoro-4-(3-(2-(2-aminoacetyl)-1,2,3,4- tetrahydroisoquinolin-7-yl)-6-oxo-1H- pyrazolo[4,3-c]pyridazin-5(6H)-yl)-5- methylbenzonitrile hydrochloride Compound 175

(S)-3-fluoro-4-(3-(2-(2-aminopropionyl)- 1,2,3,4-tetrahydroisoquinolin-7-yl)-6-oxo-1H- pyrazolo[4,3-c]pyridazin-5(6H)-yl)-5- methylbenzonitrile hydrochloride Compound 176

(S)-5-(2-fluoro-6-methylphenyl)-3-(3- (hydroxymethyl)-2-methyl-1,2,3,4- tetrahydroisoquinolin-7-yl)-1H-pyrazolo[4,3- c]pyridazin-6(5H)-one Compound 177

(S)-7-(5-(2-fluoro-6-methylphenyl)-6-oxo-5,6- dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl)- 10,10a-dihydro-1H-oxazolo[3,4-b]isoquinolin- 3(5H)-one Compound 178

5-(2-fluoro-6-methylphenyl)-3-(2,3,3- trimethyl-1,2,3,4-tetrahydroisoquinolin-7-yl)- 1H-pyrazolo[4,3-c]pyridazin-6(5H)-one Compound 179

(R)-5-(2-fluoro-6-methylphenyl)-3-(3- (hydroxymethyl)-2-methyl-1,2,3,4- tetrahydroisoquinolin-7-yl)-1H-pyrazolo[4,3- c]pyridazin-6(5H)-one Compound 180

(S)-5-(2-fluoro-6-methylphenyl)-3-(3- (methoxymethyl)-2-methyl-1,2,3,4- tetrahydroisoquinolin-7-yl)-1H-pyrazolo[4,3- c]pyridazin-6(5H)-one Compound 181

(S)-5-(2-fluoro-6-methylphenyl)-3- (1,3,4,6,11,11a-hexahydro-[1,4]oxazino[4,3- b]isoquinolin-8-yl)-1H-pyrazolo[4,3- c]pyridazin-6(5H)-one Compound 182

7-(5-(2-fluoro-6-methylphenyl)-6-oxo-5,6- dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl)-2- methyl-1,2-dihydroisoquinolin-3(4H)-one Compound 183

7-(5-(2-fluoro-6-methylphenyl)-6-oxo-5,6- dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl)-2- methyl-3,4-dihydroisoquinolin-1(2H)-one Compound 184

5-(2-fluoro-6-methylphenyl)-3-(1- (hydroxymethyl)-2-methyl-1,2,3,4- tetrahydroisoquinolin-7-yl)-1H-pyrazolo[4,3- c]pyridazin-6(5H)-one Compound 185

9-(5-(2-fluoro-6-methylphenyl)-6-oxo-5,6- dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl)- 5,6-dihydro-1H-oxazolo[4,3-a]isoquinolin- 3(10bH)-one Compound 186

3-(1-(aminomethyl)-2-methyl-1,2,3,4- tetrahydroisoquinolin-7-yl)-5-(2-fluoro-6- methylphenyl)-1H-pyrazolo[4,3-c]pyridazin- 6(5H)-one hydrochloride Compound 187

5-(2-fluoro-6-methylphenyl)-3-(6-methyl- 5,6,7,8-tetrahydro-1,6-naphthyridin-3-yl)-1H- pyrazolo[4,3-c]pyridazin-6(5H)-one Compound 188

3-(8-fluoro-2-methyl-1,2,3,4- tetrahydroisoquinolin-7-yl)-5-(2-fluoro-6- methylphenyl)-1H-pyrazolo[4,3-c]pyridazin- 6(5H)-one Compound 189

3-(6-fluoro-2-methyl-1,2,3,4- tetrahydroisoquinolin-7-yl)-5-(2-fluoro-6- methylphenyl)-1H-pyrazolo[4,3-c]pyridazin- 6(5H)-one Compound 190

3-(8-fluoro-2-methyl-1,2,3,4- tetrahydroisoquinolin-7-yl)-5-(2-fluoro-6- methoxyphenyl)-1H-pyrazolo[4,3-c]pyridazin- 6(5H)-one Compound 191

3-(6-fluoro-2-methyl-1,2,3,4- tetrahydroisoquinolin-7-yl)-5-(2-fluoro-6- methoxyphenyl)-1H-pyrazolo[4,3-c]pyridazin- 6(5H)-one Compound 193

3-(2-(azetidin-3-yl)-1,2,3,4- tetrahydroisoquinolin-6-y1)-5-(2-fluoro-6- methylphenyl)-1H-pyrazolo[4,3-c]pyridazin- 6(5H)-one hydrochloride Compound 194

5-(2-fluoro-6-methylphenyl)-3-(2-(1- methylazetidin-3-yl)-1,2,3,4- tetrahydroisoquinolin-6-yl)-1H-pyrazolo[4,3- c]pyridazin-6(5H)-one Compound 195

5-(2-fluoro-6-methylphenyl)-3-(2-(tetrahydro- 2H-pyran-4-yl)-1,2,3,4-tetrahydroisoquinolin- 6-yl)-1H-pyrazolo[4,3-c]pyridazin-6(5H)-one Compound 196

5-(2-fluoro-6-methylphenyl)-3-(2-(1- methylpiperidin-4-yl)-1,2,3,4- tetrahydroisoquinolin-6-yl)-1H-pyrazolo[4,3- c]pyridazin-6(5H)-one hydrochloride Compound 197

5-(2-fluoro-6-methylphenyl)-3-(2- methylisoindolin-5-yl)-1H-pyrazolo[4,3- c]pyridazin-6(5H)-one Compound 198

5-(2-fluoro-6-methylphenyl)-3-(3-(4- methylpiperazin-1-yl)phenyl)-1H- pyrazolo[4,3-c]pyridazin-6(5H)-one Compound 199

5-(2-fluoro-6-methoxyphenyl)-3-(3-(4- methylpiperazin-1-yl)phenyl)-1H- pyrazolo[4,3-c]pyridazin-6(5H)-one Compound 200

5-(2-ethyl-6-fluorophenyl)-3-(3-(4- methylpiperazin-1-yl)phenyl)-1H- pyrazolo[4,3-c]pyridazin-6(5H)-one Compound 201

5-(2-fluoro-6-methylphenyl)-3-(3-(8-methyl- 3,8-diazabicyclo[3.2.1]octan-3-yl)phenyl)-1H- pyrazolo[4,3-c]pyridazin-6(5H)-one Compound 202

5-(2-fluoro-6-methoxyphenyl)-3-(3-(8-methyl- 3,8-diazabicyclo[3.2.1]octan-3-yl)phenyl)-1H- pyrazolo[4,3-c]pyridazin-6(5H)-one Compound 203

3-fluoro-5-methoxy-4-(3-(3-(8-methyl-3,8- diazabicyclo[3.2.1]octan-3-yl)phenyl)-6-oxo- 1H-pyrazolo[4,3-c]pyridazin-5(6H)- yl)benzonitrile Compound 204

3-(3-(3-aminopiperidin-1-yl)phenyl)-5-(2- fluoro-6-methoxyphenyl)-1H-pyrazolo[4,3- c]pyridazin-6(5H)-one hydrochloride Compound 205

3-(3-(4-aminopiperidin-1-yl)phenyl)-5-(2- fluoro-6-methoxyphenyl)-1H-pyrazolo[4,3- c]pyridazin-6(5H)-one Compound 206

3-(3-(4-hydroxylpiperidin-1-yl)phenyl)-5-(2- fluoro-6-methoxyphenyl)-1H-pyrazolo[4,3- c]pyridazin-6(5H)-one Compound 207

3-(2-fluoro-3-(4-methylpiperazin-1- yl)phenyl)-5-(2-fluoro-6-methylphenyl)-1H- pyrazolo[4,3-c]pyridazin-6(5H)-one Compound 208

3-(2-fluoro-5-(4-methylpiperazin-1- yl)phenyl)-5-(2-fluoro-6-methylphenyl)-1H- pyrazolo[4,3-c]pyridazin-6(5H)-one Compound 209

3-(2-fluoro-3-(4-methylpiperazin-1- yl)phenyl)-5-(2-fluoro-6-methoxyphenyl)-1H- pyrazolo[4,3-c]pyridazin-6(5H)-one Compound 210

3-(2-fluoro-5-(4-methylpiperazin-1- yl)phenyl)-5-(2-fluoro-6-methoxyphenyl)-1H- pyrazolo[4,3-c]pyridazin-6(5H)-one


34. A pharmaceutical composition comprising the compound or a pharmaceutically acceptable salt, hydrate, solvate, active metabolite, polymorph, isotope labeled compound, isomer or prodrug thereof according to claim 20 and a pharmaceutically acceptable carrier.
 35. A method of treating a disease or disorder mediated with HPK1 in a patient, comprising administering therapeutically effective amount of the compound of formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, active metabolite, polymorph, isotope labeled compound, isomer or prodrug thereof according to claim 20 to the patient.
 36. A method of preventing or treating benign or malignant tumors, myelodysplastic syndromes and diseases caused by viruses in a subject comprising administering the compound or a pharmaceutically acceptable salt, hydrate, solvate, active metabolite, polymorph, isotope labeled compound, isomer or prodrug thereof according to claim 20 to the subject.
 37. The method according to claim 36, wherein the benign or malignant tumor is selected from the group consisting of leukemia, lymphoma, multiple myeloma, lung cancer, hepatocellular carcinoma, cholangiocarcinoma, gallbladder cancer, gastric cancer, colorectal cancer, intestinal leiomyosarcoma, breast cancer, ovarian cancer, cervical cancer, endometrial cancer, vaginal cancer, malignant teratoma, pancreatic cancer, pancreatic ductal adenocarcinoma, nasopharyngeal cancer, oral cancer, laryngeal cancer, esophageal squamous cell carcinoma, thyroid cancer, kidney cancer, bladder cancer, malignant brain tumor, rhabdomyosarcoma, osteosarcoma, chondrosarcoma, osteofibrosarcoma, malignant thymoma, malignant peripheral nerve sheath tumor, prostate cancer, testicular cancer, penile cancer and other malignant tumors, as well as benign and malignant tumors of the skin.
 38. The method according to claim 36, wherein the virus is selected from the group consisting of hepatitis virus, human immunodeficiency virus, human papillomavirus, herpes simplex virus, measles virus, norovirus, Boca virus, Coxsackie virus, Ebola virus, enterovirus, lymphocytic meningitis virus, influenza virus, SARS virus and COVID-19 virus. 